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Abstract 
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally 
in 2012. Among the major challenges to global Tll control and the ultimate goal of 
TB elimination is the increasing prevalence of drug resistant strains of 
Mycobacterium tuberculosis worldwide, coupled with an extremely limited pipeline 
of novel drug development. In 2012 there were an estimated 450,000 cases of muti-
drug resistant TB (resistant to at least rifampicin and isoniazid) and 170,000 deaths 
due to multi-drug resistant (MDR) TB worldwide. The prevalence of resistance to 
isoniazid is extrememly high in some regions of the world, including Vietnam, where 
25% of new smear positive patients and 54% of retreatment patients are infected with 
strains resistant to isoniazid. Treatment outcomes are known to be worse for patients 
with undiagnosed isoniazid resistant (lNHR) TB treated with standard regimens but 
the majority of patients have successful outcomes. This thesis investigated risk factors 
for treatment failure among patients with isoniazid resistant TB in Ho Chi Minh City, 
Vietnam. 
Chapter one provides an introduction to tuberculosis and isoniazid resistant TB and 
chapter two describes the methodology of the studies decribed in the thesis. In chapter 
three, I investigate the treatment outcomes among a cohort of patients with isoniazid 
resistant tuberculosis treated according to National TB guidelines. The data show that 
unfavourable treatment outcomes are unacceptably high, at 19% among patients with 
INHR TB. 
ii 
In chapter four, I investigate three bacterial factors associated with unfavourable 
treatment outcomes among patients with isoniazid resistant TB, bacterial lineage, 
MIC to isoniazid and mutations responsible for isoniazid resistance. I show that the 
Beijing genotype is associated with young age, isoniazid resistance and multi-drug 
resistance, and unfavourable outcome. 
In chapter five, I determine the prevalence of viral hepatitis co-infection among 
patients with INHR TB. Infection with hepatitis B is 9.8% and hepatitis C 4.6% 
among patients with INHR TB and is a risk factor for the development of anti TB 
drug-induced hepatitis (A TDIH) but not for unfavourable outcome. 
In chapter six, I detennine the distribution of acetylator types for isoniazid among 
Vietnamese TB patients and show that acetylator status is not a risk factor for 
unfavourable outcome in patients with INHR TB. 
Overall, these studies show that INHR TB is a serious challenge to TB control efforts 
in Vietnam, with unacceptably high rates of treatment failure. In the final chapter, I 
discuss the implication of my findings and propose priorities for further research to 
address these issues. 
iii 
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1.1 Tuberculosis: 
1.1.1 History: 
Chapter 1 
Introduction 
Tuberculosis (TB) has been with us for thousands of years. TB is an infectious 
respiratory disease and a classic disease of poverty and as such is more common in 
underdeveloped regions of the world because of differences in culture, politics and 
socioeconomic development [1]. Historical evidence of TB has been identified via 
pathology in ancient mummified human remains and molecular techniques have been 
used to confirm the presence of Mycobacterium tuberculosis (M. lb), the bacterium 
which causes TB disease [2]. Historical evidence ofTB also comes from both primary 
and secondary accounts. 
It was long thought that humans contracted TB from infected animals, probably 
cattle, when they were domesticated about 10,000 years ago. However, this theory has 
now been disproven through phylogenetic analysis of mycobacterial species, which 
suggests bovine TB caused by Mycobacterium bovis (Mbovis) evolved from 
Mycobacterium tuberculosis and hence man probably gave TB to cattle foHowing 
domestication [3,4]. 
Evidence ofTB can be found in the Old World dating back thousands of years such as 
in Italy (5800 BC). In 400 BC, The Greek physician Hippocrates first described the 
clinical symptoms ofTB using the tenn 'phthisis'. In Asia, China has evidence ofTB 
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in a mummy dated to between 206 BC and the seventh century AD, while Japan and 
Thailand have possible evidence dated to the seventh century AD and 300 BC-300 
AD, respectively. The earliest evidence of skeletal TB in the New World may be in 
South America [5]. Pictorial evidence comes in a variety of forms including painting, 
drawings, reliefs and sculptures. Figure 1.1 shows an example of a two thousand year 
old sculptural representation of a woman with TB from Colombia. 
Figure 1-1 : Representation of a woman with pronounced gibbus (Pott's disease?). 
Momil culture, 200 BC to 100 AD, Sinu River, Colombia (reproduced from Sotomayor 
1992) [6J 
There are large bodies of written and illustrative evidence that have contributed to 
tracing the evolution and history of this infectious disease. A Chinese text (2700 BC) 
provides a description of hemoptysis and TB in the cervical lymph glands [7]. Ebers 
Papyrus (1500 BC) also describes TB of the lymph glands[8]. 
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In the sixteenth century, Fracastorius (1483-1553) wrote "De Contagione" and 
suggested that TB was due to invisible "germs". By the mid-1600s, 20% of deaths in 
England were due to TB. 
In the eighteenth century, John Bunyan referred to TB as the" Captain of all these 
men of death" [9]. By the beginning of the nineteenth century, TB was the leading 
cause of death in most European countries. 
From the beginning of the nineteenth century, many advances in diagnostics, 
treatment and bacteriology of TB were made. In 1816, Rene Laennec invented the 
stethoscope and three years later he published his book named" De l' Auscultation 
Mediate". In this book, he described his new method of diagnosis using the 
stethoscope. Sadly, he himself died of pulmonary tuberculosis in August 1826. Carlo 
Forlanini, born in 1847, developed the first specific treatment for pulmonary 
tuberculosis: artificial pneumothorax in 1906. Jean Antoine Villemin proved in 1867 
that tuberculosis was an infectious disease transmitted by contact from humans to 
animals and from one animal to another [10]. On March 24, 1882 a major 
breakthrough was achieved when Robert Koch made his famous presentation, 'Die 
Aetiologie der Tuberculosis' in which he presented demonstrations of the tubercle 
bacillus. He was awarded the Nobel Prize in Medicine or Physiology in 1905 for this 
work and World TB day is now marked on 24th March each year in honour of the 
event. In 1890 Koch isolated a substance from tubercle bacilli which he thought could 
stimulate immunity to the pathogenic bacteria and cure TB patients. He called this 
substance tuberculin. Later studies proved that Koch was unfortunately mistaken in 
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his claims for tuberculin, but it continues to be used in the tuberculin skin test for TB 
diagnosis. 
In 1895, Conrad Roentgen discovered X- rays which provided a new method of 
diagnosing TB. The theory of transmission of TB via droplet infection was 
established in 1897 [10]. By the mid -nineteenth century, the concept of the 
sanatorium with fresh air, a good healthy diet, rest and graded exercise for TB 
treatment had been established. 
Also from the late nineteenth century, many organizations were established to combat 
TB. In 1889 the Tuberculosis Association was established in the USA and in 1890s 
the League Against Tuberculosis was founded in France. One year later, the National 
Association for the Prevention of Tuberculosis and other forms of consumption was 
established in Britain[8]. In 1902, The International Union against TB was founded. It 
was set up to encourage a system of control including the notification of all cases, 
contact tracing and the provision of dispensaries and sanatoria. As the result of the 
work of these organizations and advances in understanding of the disease, coupled 
with improvements in sanitation and living standards across Europe, by the second 
half of the nineteenth century and into the twentieth, there was a marked decline in 
TB in Europe and the United States. 
At the begining of the twentieth century, the field of immunology began to develop. 
The Viennese peadiatrician, Clemens von Pirquet, had described 'serum sickness' 
using the terms allergy and allergen in 1903. Two years later he recognized that 
positive tuberculin reactions reflected latent infection with M.th and proposed a cut-
off point of 5 mm for a positive skin test. Charles Mantoux introduced the use of a 
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cannulated needle and syringe to inject tuberculin intracutaneously in 1908. Also in 
this year Calmette and Guerin began developing their TB vaccine. Florence Seibert 
developed standardized purified protein derivatives (PPO) which allowed more 
studies of tuberculin reaction sizes. In 1921, after years of attenuation by in vitro 
passage, the bacillus Calmette Guerin (BCG) BCG vaccine was introduced and 
distributed generally by 1924. From 1860 to 1945, Vietnam was under French 
colonial rule and so BCG was used extensively in Vietnam as early as the 1920s as 
part of the French health policy to fight TB. Although BCG vaccine has been used for 
a long time as a preventive measure, its protective effects have widely varied in 
evaluation, ranging from 80% to a negative effect. The reasons for this observed 
variation in protective efficiency are unknown, but several hypotheses have been 
proposed, including variations in the vaccine strains used in different regions of the 
world, variation in prevalence and exposure to environmental mycobacterial species 
and differences in the prevailing strains of M tb [11]. However, the protective effect 
of BCG vaccine against disseminated TB in children has been consistently evident 
[12]. 
The incidence of TB death has declined with improvements in living standards, 
control strategies and the development of antituberculous drug therapy. In 1944, 
Waksman introduced the antibiotic streptomycin, which was to be the first effective 
drug treatment for TB. After that, in 1945 Trudeau established the first truly 
successful sanatorium in the US for the open-air treatment of tuberculosis [10]. In the 
1950s BCG vaccination, health education and pasteurization of milk all contributed 
substantially to TB control.The introduction of streptomycin was quickly followed by 
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para-ammo salicylic acid (PAS) in 1946 by Lehmann, isoniazid in 1952 and 
rifampicin in 1963. The modern era of tuberculosis treatment and control was 
established. Treatment to cure became a realistic goal for every patient in the world 
[13]. 
As the modern era ofTB treatment began, drug resistance emerged. Monotherapy for 
TB results in the rapid selection of spontaneously occurring mutant bacilli. Resistance 
to streptomycin was shown shortly after its first use in patients [14-16]. Multi-drug 
therapy with at least three effective agents is required to prevent the selection of 
resistant strains. Inadequate therapy due to prescription or adherence, co-morbidities 
leading to poor absorption and other factors can lead to the amplification of resistance 
to more than one drug. For Mtb resistant to at least the two most potent drugs, 
isoniazid and rifampicin, treatment is more difficult and mortality rates are higher, 
therefore these strains are tenned multi-drug resistant (MDR) TB [17]. In the late 
1980s TB was thought to have been controlled and moving towards eradication in the 
developed countries but TB has since resurged with the rise of drug-resistant strains 
and the emergence of the HIV pandemic [18, 19]. 
In 1990, the Directly Observed Therapy Short-course (DOTS) strategy was developed 
by WHO and introduced to endemic countries with five essential components: (l) 
microscopic examination of sputum for acid-fast bacilli (AFB), (2) use of rifampin-
based regimens, (3) reliable supply of high-quality drugs and diagnostics, (4) 
reporting of treatment outcome and monitoring of programmes, and (5) political 
commitment from governments. 
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Initially implemented in just ten countries, by 1998, 119 countries had implemented 
the DOTS strategy [20]. In 1993, The World Health Organization declared TB a 
global emergency, estimating that one third of the world population are infected with 
Mtb. As TB case rates decreased in developed countries, funding for research and 
implementation also declined although TB remained the leading infectious disease in 
the world, mainly in underdeveloped countries. 
Together with HIV infection fanning tuberculosis, MDR TB emerged. An outbreak in 
the United States in the late 1980s and early 1990s drew attention to the problem of 
emerging drug resistance which was going undetected, untreated and transmitting 
within communities. In the USA and in the developed countries, diagnosis with 
culture and drug-susceptibility testing was available to enable treatment with 
appropriate second-line anti TB drugs but in resource-limited settings, MDR TB 
treatment was prohibitively expensive. However, in Peru, a high-burden developing 
country, the strategy of MDR TB treatment based in the community was initiated with 
good results. By the end of the 1990s, the Green Light Committee, together with the 
help of the Bill and Melinda Gates Foundation began to encourage and help Peru and 
other countries in the programmatic management of MDR TB treatment (initially 
called DOTS-Plus). 
At the millennium a set of targets for international development were agreed by 
international agencies and Non-Govermental Organizations (NGOs) known as the 
MiIIenium Development Goals (MDGs) such as reducing extreme poverty, improving 
sources of drinking water and maternal/child health [21]. For TB, The Stop TB 
Partnership has presented two specific goals: to halve TB prevalence and to halve TB 
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mortality by 2015 compared to these two levels in 1990. Recently the additional goal 
ofTB eradication by 2050 was also added (defined as a global incidence ofless than 1 
per million population). Although achieving the MDOs is challenging, especially in 
some regions like Africa and Eastern Europe, significant progress has been made. In 
2013, WHO's Stop TB Department set targets for the post-MDO era- annual deaths 
would be halved by 2025 and TB incidence would drop from 16 to 10% in the next 
ten years. TB eradication will require the development of significantly improved new 
effective drugs, diagnostics and vaccines. Today, rapid nucleic acid-based tests for 
drug-resistant TB are available and several new drugs are in the development 
pipeline, with the first new drug class being approved by the FDA and WHO for 
MDR TB in 2013 [22]. Funding and political will need to be sustained to maintain 
momentum in the drive towards TB eradication, now and in the future [23]. 
In the past, TB has increased with population size, bad sanitation, poverty, trade and 
emigration. On the other hand, TB has also declined with improvements in living 
conditions, improved nutrition, better diagnosis, health education, vaccination, 
isolation of people with TB, and curative treatment. The major challenges to TB 
control today are the HIV/AIDS pandemic, antibiotic resistance, poverty and political 
instability. 
1.1.2 Global epidemiology of tuberculosis: 
Tuberculosis is an infectious disease caused by Mtb. It is principally transmitted from 
one person to another via droplets in sputum expectorated from the respiratory tract of 
individuals with active tuberculosis disease. 
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An untreated sputum smear-positive case infects about 10 other individuals each year 
[24]. Around 5% of those infected with Mtb develop progressive primary disease in 
the 1-2 years following infection. The proportion is higher in vulnerable groups such 
as HIV infected and immunocompromised individuals, children and the elderly [25]. 
Mortality from TB is high in the absence of effective treatment. Evidence from the 
pre-chemotherapy era suggests around 60% of cases will be fatal without treatment. 
The remaining third will either remain chronically ill or recover from the disease but 
in most cases continue to harbor a latent infection. Among smear-positive patients 
receiving antituberculosis drugs, the case-fatality rate can exceed 10% within 1 year, 
due to factors such as late diagnosis, severe complications, drug resistance or drug 
reactions [5]. 
Tuberculosis is predominantly a disease of adults. Although children 0-14 years make 
up 30% of the world population, they account for only 10% (9.6%-11%) of incident 
cases with the majority of cases occurring in high TB burden countries. This data may 
be an underestimate because of many challenges and difficulties in estimation of TB 
burden in children like the lack of definite diagnosis, the presence of extra-pulmonary 
TB which requires specialist to detect, and the lower public health priority [26-28]. 
Where transmission rates are high, TB incidence peaks in young adults [29]. In 
industrialized countries, as transmission falls, the average age of TB cases increases 
[29]. The majority of indigenous TB cases in developed low-incidence countries are 
found among the elderly due to reactivation of latent infection and subsequent 
transmission within care settings. Globally, TB is more common in men than women 
in the ratio of 2: 1 and it remains a major cause of death among men in endemic 
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countries along with alcoholism and cardiovascular disease. Around two-thirds of 
cases are estimated to occur among people aged 15-59 years, the economically 
productive age-group [30]. 
The HIV pandemic has had a dramatic impact on the TB pandemic [31]. HIV 
infection, results in a gradual decline in T-cell immunity which is the crucial immune 
component in control of M.tb infection. Therefore HlV infection dramatically 
increases the risk of TB disease following primary infection and of reactivation of 
latent TB infection [32]. Other factors known to increase the risk of TB include 
diabetes, silicosis and malnutrition and exposure to smoke from smoking or biomass 
fuel [33]. An association between smoking and tuberculosis has been shown in 
numerous studies, with a strong dose-response relationship. People smoking more 
than 15 pack-years had the highest risk in one study (adjusted OR 1.90,95% CI 1.28 
to 2.81) [34]. Overcrowded living conditions, particularly in urban areas increase the 
risk of TB transmission. The chronobiological aspects related to TB such as 
seasonality, latitude, photoperiod, radiation, associated infections and circannual 
oscillations of lymphocytes activity, may be relevant in some settings but the 
relationships are not well characterized. More research is required to elucidate these 
relationships [35]. 
It has long been well-known that "TB runs in families". After infection with TB, 
individuals have differences in outcome due to variations in innate host defense 
mechanisms like immune recognition, phagocytosis, c}tokine production and effector 
mechanism in addition to environmental influences such as malnutrition. Several gene 
polymorphisms have been found to be associated with increased susceptibility and 
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severity of TB disease [36]. Further details are discussed in the TB pathogenesis 
section 1.1.4. 
As the second leading cause of death from infectious diseases worldwide (after 
HIV/AIOS), TB remains a major global health problem (figure 1.2). In 2010, there 
were an estimated 8.8 million incident cases of TB [range: 8.5-9.2 million]. The 
absolute number of TB cases as well as TB incidence rates have been falling 
gradually since 2002. There were 5.7 million notifications of new and recurrent cases 
of TB (65% of the estimated number of incident cases in 2010). Most of these cases 
were in Asia (59%) and Africa (26%). The proportion in other regions were: Eastern 
Mediterranean Region (7%), Europe (5%) and America (3%). The four countries with 
the largest incident cases were India, China, Indonesia and Pakistan. TB prevalence in 
2010 was estimated at 119 (113-135) per 100 000 population [30]. 
The majority of TB patients worldwide are now treated in programmes with OOTSI 
Stop TB Strategy with successful outcomes. At a global aggregate level, the treatment 
success rate, under WHO definitions for patients diagnosed and treated under DOTS 
was 87% among new cases of smear-positive pulmonary TB in 2009. In 2010 there 
were 1.1 million [range, 0.9-1.2 million] deaths among HIV-uninfected individuals 
with TB and approximately an additional 0.35 million [range: 0.32-0.39] deaths 
among HIV-coinfected TB patients. The Stop TB Partnership (www.stoptb.org) of the 
WHO has set targets for 2015 aiming to reduce prevalence and death rates by 50% 
compared with 1990. For 2050 the goal is to reduce the global incidence of active TB 
cases to under 1 case per 1 million population per year, the recognized definition of 
TB 'elimination' [30]. 
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WHO has also addressed the issue of co-epidemics ofTB and HIV. In 2010, globally 
34% of TB patients were tested for HIV, and about 13% of TB cases were found to 
occur among HIV- infected individuals. 80% of people with HIV were started on 
cotrimoxazole preventive therapy (CPT) and 46% on antiretroviral therapy (ART). 
WHO-initiated Global Plan targets aim that all TB patients will be tested for HIV and 
all TB patients with HIV will be treated with CPT and ART [30]. Significant progress 
has been made in integrating TB-HIV control activities in many regions but funding, 
politicial commitment and human resource training are all essential to maintain 
momentum in progress. 
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Figure 1-2 : Estimated TB incidence rate 2010 from Global Tuberculosis Control 2011, WHO[30] 
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1.1.2.1 Epidemiology of Tuberculosis in Vietnam: 
Tuberculosis control activities in Vietnam started in 1957, with separate systems in 
the North and the South. After the reunification of Vietnam in 1975, the National 
Institute for tuberculosis in Hanoi established national guidelines for tuberculosis 
control as well as for specialized clinical care for the whole country. A new national 
tuberculosis control programme (NTP) was introduced in 1986 organized according to 
principles laid down by International TB Control Association [37] . 
Tuberculosis control activities in Vietnam expanded rapidly following establishment 
of the programme. The proportion of districts covered by the NTP reached 100% by 
the year 2000 [37]. Within districts, training of communal health workers and 
provision of supplies expanded so that the proportion of communes applying NTP 
guidelines increased from 18% in 1986 to 99% in 2000. Short-course chemotherapy 
(SCC) using two months treatment with streptomycin, rifampicin, isoniazid and 
pyrazinamide, followed by six months with isoniazid and ethambutol (2SRHZ/6HE) 
was first introduced in 1989 in 12 districts of 4 provinces and was subsequently made 
available in all districts in 1999. The national notification rate for new smear-positive 
patients has fluctuated. Notification increased from 1 I per 100 000 population in 1986 
to a peak of 73 in 1998 following expansion of case detection and then began to 
decrease slightly to 69 in 2000 and 59 in 2010. Notification rates are higher in the 
South than in the North and remain low in the mountainous provinces. The proportion 
of new tuberculosis cases detected by the programme was stable, at around 60% in the 
years 1991-1995, increased to 80% in 1996, reached 86% in 1998 and declined again 
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slightly to 83% in 1999 and 81 % in 2000. Vietnam was thought to be the first high-
burden countries to reach the WHO targets of 70% case detection rate and 85% cure 
rate but despite this TB rates have not fallen significantly and are only now beginning 
to decline at approximately 1-2% per year as Vietnam develops into a middle income 
country [38]. 
Recently the case detection rate has been revised downwards to just 54%. This re-
estimation was following a prevalence' survey in 2006-2007 which showed that 
previous estimates of the case burden in Vietnam were too low, resulting in an over-
estimation of the case-detection rate. The first national survey of tuberculosis 
prevalence in Vietnam was conducted in 2006-2007 and this study was published in 
the Bulletin of the World Health Organization in 2010 [39]. The survey showed a 
weighted prevalence rate of smear-positive tuberculosis among the population aged> 
15 years of 196.8 per 100 000 population, which was 1.6 times as high as previously 
estimated by WHO. The NTP authorities suggested some additional approaches to 
TB control such as 1) introduction of active case-finding based on chest X-ray 
screening in high-risk groups, and 2) widening of the eligibility criteria for smear 
examination to other symptoms in addition to cough [39]. SCC cure rates have been 
stable at 80%-90% from 1994 to 2000 and 92% in 2009 [37]. 
Many factors have contributed to the successful implementation of tuberculosis 
control in Vietnam. Strong political commitment is the first factor and probably, the 
most important one. Tuberculosis control is a part of the Comprehensive Poverty 
Reduction and Growth strategy and contributes to the attainment of the Millennium 
Development Goals for poverty reduction in Vietnam. Tuberculosis control activities 
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at district and commune levels are fully integrated into the general health care system. 
In addition to government support, the NTP has received major sustained technical 
and financial assistance from international organizations. 
Vietnam remains among the 22 high burden countries for TB, ranking twelfth in the 
list. In 2010, TB prevalence was 334 (147-576) per 100000 population (including 
HIV infection), and the percentage of new TB cases with MDR was 2.7 (2.0-3.7) 
[30]. The NTP is facing several challenges such as a rapid increase in the proportion 
ofTB cases with lIIV co-infection, MDR and XDR TB, TB in prisons, in elderly and 
in psychiatric patients as well as combating TB in the general population. A sustained 
decline above the current rate of 1 % per year will be required to have a real impact on 
the TB epidemic in Vietnam. 
1.1.3 Mycobacterium tuberculosis: 
Mtb complex belongs to the genus Mycobacterium. Mycobacterium /eprae which 
causes leprosy is the only other major pathogen in this group. Other mycobacteria are 
variously termed the 'atypical mycobacteria', 'non-tuberculous mycobacteria' (NTM) 
or 'mycobacteria other than tuberculosis' (MaTT). NTM will be used in this thesis. 
The ADb complex includes Mtuberculosis, AI.bovis, M. ajiA icanulI1, AI. canetti, 
Mmicroti, Mcaprae and Mpinnipedi [40] (table 1.1). The cell wall of Mtb lacks a 
phospholipid outer membrane, therefore AI.tb is sometimes described as a Gram-
positive bacterium. However, Mtb stains only weakly Gram-positive because of the 
high lipid and mycolic acid components in the cell wall [41] . In smears stained with 
the acid-fast stain technique, the tubercle bacilli typically appear as straight or slightly 
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curved rods. M tb is a small, aerobic, non-motile and non-sporulated bacillium. The 
dimensions of the bacilli are I-IOllm in length (usually 3-5Ilm) and 0.2-0.6 Jlm in 
width (figure 1.3). 
Category subgroup 
Kingdom Bacteria 
Phylum Actinobacteria 
Class Actinobacteria 
Subclass Actinobacteridae 
Order Actinomycetales 
Suborder Corynebacterineae 
Family Mycobacteriaceae 
Genus Mycobacterium 
Species 
""'! tuberculosis 
lr! bovis 
M. africanum 
HAi canettii" 
M. pinnipedii 
M. microti 
M. caprae 
Table 1-1: Taxonomic classification of the agents ofTB 
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Under favourable laboratory conditions, Mtb divides every 16 to 20 hours [42]. The 
cell wall characteristic of impermeability limits nutrient uptake and so slows the 
growth rate. The long generation time results in slow in vitro culture and explains the 
sub-acute or chronic characteristic of disease. A1.tb is also able to survive very low 
temperatures. The bacilli are sensitive to heat, sunlight and ultraviolet (UV) 
irradiation. A1.tb tolerates low oxygen tension and may survive for many years in this 
condition but in a dormant state under oxygen stress[ 43] . 
Mtb has a plasma membrane, a cell-wall and an outer capsule-like layer. The 
c)'toplasmic membrane of mycobacteria contains lipopolysaccharides with functions 
including osmotic protection, traffic regulation of specific solutes and the cell house-
keeping tasks. The membrane also contains proteins with different functions such as 
sensing of the concentration of molecules in the environment, translocation of signals 
to genetic and metabolic machinery in the cytoplasm. The membrane also contains 
enzymes which are involved in metabolic processes and mediate selective passage of 
nutrients and ions. These proteins in the plasma membrane of A1.tb are potential novel 
drug targets, diagnostic probes or components ofa vaccine against tuberculosis [44]. 
The cell wall protects the cell contents and forms the structural shape of the 
bacterium. Proteins in the cell wall synthesize cell wall components and porins allow 
diffusion of aqueous solutes. Peptidoglycan forms the structure shape of the cell wall 
with covalently bound arabinogalactan, a brached polysaccharide, whose outer ends 
are esterified with mycolic acid, which is a unique high molecular weight fatty acid. 
The mycolic acids are responsible for several of the physiological aspects and 
mechanisms ofTB disease [45] . 
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The outer layer of the cell wall presents an array of free lipids, such as phthiocerol 
dimycoserosates (POMI), phenolic glycolipids (PGL), trehalose-containing 
glycolipids and sulfolipid (SL). Traversing the whole envelope, some glycolipids such 
as phosphatidyl-myo-inositol mannosides, lipomannan (LM) and lipoarabinomanan 
(LAM), are connected to the plasma membrane and extend to the exterior of the cell 
wall. LAMs are species-specific and function to modulate the host immune response 
and anti-inflammatory effects. ManLam (mannose-capped LAM) has been 
demonstrated as powerful anti-inflammatory molecules and key virulence factors 
[46]. 
The structure of Mtb gives it some characteristics such as acid fastness, extreme 
hydrophobicity, impermeability, resistance to injury and distinctive immunological 
properties. The tubercle bacillus is prototrophic and heterotrophic. 
Figure 1-3: Electron microscopy of Mycobacterium tuberculosis growing in culture from 
www.wadsworth.org 
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1.1.4 Pathogenesis of Tuberculosis: 
The clinical phenotype of tuberculosis disease results from the exposure dose and 
route and the subsequent interaction between the bacteria (Mrb) and the human host 
immune response. 
Mycobacteria are inhaled in droplet nuclei which are small enough to bypass the 
mucociliary defences of the bronchi and can pass into the terminal alveoli of the lungs 
where they encounter cells of the innate immune system, triggering a complex series 
of events with three possible outcomes. The first one is the elimination of the bacteria 
completely, the second is the containment of the infection, usually in a granuloma, for 
a prolonged period (latent TB), and the last one is the immediate progression to active 
disease with clinical manifestations. In the case of latent TB it is still unclear whether 
the bacilli are in a state of reduced metabolic activity or completely dormant in a 
spore-like form that is metabolically inactive awaiting a signal to resume division. 
However, some studies show that latent bacilli may be metabolically active because 
they remain sensitive to chemoprophylaxis [47] but the population· may not be 
homogenous and may represent a spectrum of metabolic states. 
Once a person is infected with Mrb, the chance of developing active disease is 
greatest in the first year following infection, declining exponentially thereafter [5]. 
The risk is greatest in the immunocompromised including young children, the elderly 
and advanced HIV. Children under 5 years of age represent around 50% of all 
pediatric cases. Within the first year of infection, the incidence of clinical disease is 
approximately 1.5%, and the cumulative risk during the first 5 years is estimated to be 
from 5 to 10% [5]. Post-primary TB may occur after months or years without clinical 
41 
signs following primary infection. The emergence of the disease is due to the 
reactivation of dormant bacilli which may be in response to a weakening of the 
immune system, but the factors leading to disease reactivation in the absence of overt 
immunosuppression are not well understood. Post-primary TB generally occurs in 
adults. Reinfection of a person who has had a previous primary infection may also 
lead to active TB, particularly in high-risk congregate settings, such as prisons in 
high-burden countries [48-50]. 
In the majority of individuals infected with A/tb, the immune system is able to 
contain the infection with pulmonary lesions gradually healing. For the remaining 
10% of individuals the environment is favourable for the bacilli and their 
multiplication continues resulting in a primary lesion called the Ghon focus. 
After ADb bacilli enter the lung, they interact with neutrophils which, however, are 
unable to eradicate the infection and a signaling cascade is triggered which attracts 
macrophages to the site of infection. 
Various receptors on the surface of macro phages and dendritic cells (DCs) are able to 
recognize Mtb, including toll-like receptors (TLR), complement receptors, mannose 
receptors, and scanvenger receptors. These receptors recognize various components of 
Mtb [51] and trigger pro-inflamatory signalling which activates other macrophages to 
ingest and digest the invading Mtb in addition to recruiting T -lymphocytes to the 
infected area. The macrophages present the A/tb antigens on their surface in 
association with HLA Class II antigens. If the bacilli successfully evade the initial 
intracellular destruction via phagosome-lysosome fusion and production of reactive 
oxygen and nitrogen species, the bacteria will be able to multiply and the 
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macrophages will be disrupted [52]. Elimination of A1.lb infection is thought to be 
highly dependent on the interaction between macrophages and lymphocytes. Dendritic 
cells transport antigens from phagocytosed bacterial cells at the primary Ghon 
complex to the proximal draining Iynph nodes, where they express presentation 
molecules in high density to activate na'ive T-Iymphocytes, such as major 
histocompatibility complex (MHC-I or II) , as well as co-stimulatory molecules, such 
as IL-I2, IL-IS, or IL-23 [53]. At this stage, the bacilli may disseminate from the 
primary complex via a transient bacteraemia leading to the development of disease at 
sites outside the lungs, most commonly in the cervical lymph nodes but any organ of 
the body may be affected. CD4+ T -lymphocytes are known to be crucial in the control 
of Mtb infection, as evidenced by the dramatic increase in susceptibility to TB among 
people with advanced HIV infection. Activated T lymphocytes appear rapidly after 
infection and recognize Mlb antigens. 
CD4+ lymphocytes may develop into either Thl or Th2 cells with different patterns 
of cytokine secretion and the Th Iffh2 balance is important in determining the 
outcome of infection. CD4 T cells provide the crucial protective effect by the 
production of gamma interferon (INF- y). The role of other T-cell subtypes like CDS 
T cells is incompletely understood, but the Th Iffh2 balance must favour TH I for 
protective efficacy at this stage [54, 55] . 
Two or three weeks after infection, T-cell immunity develops with the presence of 
antigen-specific T lymphocytes. These T lymphocytes will proliferate and activate 
macrophages to kill mycobacteria [53]. Central solid necrosis may inhibit the bacilli 
at this stage resulting in a dormant infection. Disease may progress directly after 
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primary infection or, within 2 - 3 years, disease (post primary TB) develops due to 
immune failure. The final outcome of TB infection depends on the balance between 
growth and killing of ~M.tb, on tissue necrosis, and fibrosis or regeneration. 
1.1.5 Pathology of Tuberculosis 
TB is one of the granulomatous inflammatory conditions (figure 1.4). The basic 
inflammatory response to infection by Mtb is the formation ofa granuloma that is the 
pathologic hallmark of TB. A granuloma comprises a microscopic aggregation of 
activated macrophages (epithelioid) surrounded by lymphocytes. There are many 
types of cells which participate in the formation of a granuloma such as epithelioid 
cells, Langhans giant cell or foreign body giant cells, lymphocytes, polymorphs, 
plasma cells, eosinophils and fibroblasts. Granuloma formation is a complex 
procedure involving many various cells and immune effectors like chemokines and 
cytokines [56]. Granuloma formation is a part of adaptive immunity, however, innate 
immune cells are significantly involved. 
The macrophages activate and develop into epithelioid cells with abundant pale-pink 
cytoplasms, indistinct borders, and vesicular nucleoli [57]. This type of cell has a 
secretory function to enhance the microbiocidal properties and induce necrosis of lung 
tissue. Epithelioid cells may fuse to form Langhans giant cells which have various 
configurations and can be at the periphery or anywhere in a granuloma [57]. 
The granuloma provides the environment in which the activated macrophages can 
inhibit the growth of Mtb. Bacteria can become dormant when they are in a 
granuloma and this situation is called latent TB. However, when immunity fails or 
M.tb replicates, reactivation ofTB occurs. If the macrophages undergo apoptosis, this 
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leads to caseous necrosis which is described as firm, pale, crumbly and yellowish 
tissue like soft white cheese and leads to the spread of TB infection. The 
development of caseous necrosis in a TB granuloma correlates with pathogenic 
dysregulation of lipid metabolism [57]. According to Elkington and more recent 
studies, Mtb drives the expression of matrix metalloproteinease-l (MMP-l) which 
can degrade type I collagen and drives the destruction of pulmonary tissue in TB [58]. 
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Figure 1-4: Definition of the stages of human TB lung granuloma 
Reproduced from Kim et al. EMBO Mol Med. 2010 [57] 
A,B. nascent granuloma (A) (x40) and nascent granuloma (B) (x 100) 
C,D. caseous granuloma (C) (xIOO) and caseous granuloma (0) (x40) 
E,F. fibrocaseous granulomas (x40), and 
a,H. resolved granulomas (x40) 
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1.1.6 Host genetic susceptibility to TB 
It has long been recognized that certain ethnicities or families appear to have a high 
level of susceptibility to TB and it was at one time widely thought to be a heritable 
condition. The genetic basis of this susceptibility has been traced to polymorphism in 
many genes and TB susceptibility is now known to be polygenic. One of the first host 
susceptibility genes for TB was first identified in mice. This gene was initially called 
Beg then renamed Natural Resistance-Associated Macrophage protein-1 (NRAMP1) 
and finally termed SLC11A1, the gene which encodes the protein, although it is still 
often referred to as NRAMP [59, 60]. Many other genes, including those for vitamin 
o receptors and the components of IFN-y signaling pathways have also been 
identified as having a role in susceptibility to tuberculosis, although the complexities 
of the polygenic interactions resulting in susceptibility to active disease have yet to be 
unravelled [61]. Genome Wide Association Studies (GW AS) has been applied to 
many infectious diseases including TB but the complexities of polygenic 
susceptibility have yet to be fully elucidated [62,63]. GWAS have been conducted on 
the Vietnamese population, and the results may suggest pathways and genetic factors 
leading to increased risks of TB in this population. Vietnam has participated in the 
1,000 genomes project (www.l OOOgenomes.org) which aims to map human genetic 
polymorphism across ethnicities and strengthen host genetic disease susceptibility 
research. 
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1.2 Pulmonary Tuberculosis: 
1.2.1 Symptoms and Signs: 
Primary Tuberculosis (TB) can be detected at the asymptomatic stage but in high-
burden settings this rarely occurs, while in developed countries diagnosis is often 
made by Chest X-ray (CXR) during health-screening or contact tracing. A history of 
TB contact is the single most important factor in non-endemic settings and the 
conversion of the tuberculin test from negative to positive is an evidence for primary 
TB, although this is rarely documented outside developed countries. The patient may 
present with symptoms of upper respiratory tract infection such as cough, malaise but 
weight loss is uncommon. Enlargement of the lymph node may cause complex 
obstruction resulting in collapse of the peripheral lung leading to pneumonia with 
symptoms of cough, fever and shortness of breath. Pennanent damage to the lung may 
occur resulting in bronchiectasis. From primary infection, a number of manifestations 
of extrapulmonary TB may occur such as TB pleural effusion (after 6-12 months), 
miliary or meningeal TB disease (within 6-12 months). Dissemination to other distant 
sites like bone or genitourinary tract may also occur during bacteraemic 'seeding'. 
Two common manisfestations of primary TB are erythema nodosum and phlyctenular 
conjunctivitis. Erythema nodosum appears as reddened or brown swellings that 
usually have a dimension of 3-18mm. They are on the extensor surfaces of the limb, 
most commonly on the shins and sometimes on the upper limbs (figure 1.5). 
Arthralgia occurs in more than 50% of patients. It is caused by perivascular 
inflammation of the arteries and veins within the dennis. High circulating levels of 
immune complexes are probably responsible for this manifestation. Differential 
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diagnoses are sarcoidosis, streptococcal throat infection or inflammatory bowel 
disease. It may be idiopathic in 70% of cases. Erythema nodosum caused by TB 
usually occurs 3-8 weeks after TB infection. Lesions usually resolve with TB 
treatment although some discoloration of the skin may remain permanently [64]. 
Phlyctenular conjunctivitis is uncommon and it may occur in children usually within 
12 months of primary infection. Lesions appear as small grey or yellow nodules on 
the conjunctiva near the limbus with dilated vessels radiating outwards. It may have 
symptoms like irritation, pain, lacrimation and photophobia. Lesions can appear and 
disappear spontaneously. Treatment of TB and local therapy such as atropine and 
hydrocortisone drops for relieving inflammation are the rule for resolution. 
Figure 1-5 : Erythema nodosum. 
Reproduced from http://www.patient.co.ukldoctor/erythema-nodosum. 
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Individuals with post-primary TB may be asymptomatic and be detected only by 
screening or on routine chest radiography. The commonest symptoms of TB are 
cough and prolonged sputum production (> 2 weeks). Other lung symptoms which 
may occur are haemoptysis, breathlessness, chest pain and constitutional symptoms 
such as malaise, tiredness, fever, weight loss, night sweats, pallor and anorexia. 
Clubbing may be present in extensive or long-standing disease. Respiratory signs 
may be absent, especially in the early stages. There may be evidence of consolidation, 
reduced breath sounds and crackles. Wheezes may be present if obstruction is present. 
Amphoric breathing may be heard. In chronic disease, the trachea and mediastinum 
may be deviated toward the side of disease. 
1.2.2 Diagnosis of tuberculosis 
The diagnostic approach for possible tuberculosis includes a detailed medical history, 
clinical examination, and if available, radiological, microbiological, immunological, 
molecular and histological examination. Definitive diagnosis of pulmonary TB 
requires the identification of Af.tb in culture of sputum samples. According to WHO 
guidelines, if suspicion of pulmonary TB is high despite culture and smear for Mlb 
being negative, six sputum samples and two different chest radiographs over a period 
of 2 weeks should be performed to confirm the diagnosis of sputum-negative 
pulmonary TB [65]. In practice, ruling out TB is difficult and resource intensive in 
these circumstances, mycobacterial culture may not be available and many clinicians 
will initiate treatment rather than leave a potential TB case untreated. 
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American Thoracic Society CATS) definitions for classification of suspected TB cases 
are as follows: 
No TB exposure and no TB infection : patient has no history of exposure to TB 
subject and has a negative reaction to the tuberculin test. 
TB exposure and no evidence ofTB infection: patient has a history ofTB exposure 
but has a negative reaction to the tuberculin skin test. 
Latent TB, no TB disease: patient has a positive reaction to the tuberculin skin test 
but has no clinical, bacteriological or radiographic evidence of active TB. 
Clinically active TB: patient must have clinical, bacteriological andlor radiographic 
evidence of current tuberculosis [66]. 
1.2.3 Differential diagnosis 
There are many diseases that need to be considered in the differential diagnosis of 
pulmonary TB. A list of potential diseases for differential diagnosis is summarized in 
table 1.2: 
51 
Table 1-2 : Differential diagnosis (from Clinical Tuberculosis) [5] 
* Usually unilateral cavitation. Often occurs in the presence of other pulmonary 
diseases such as bronchiectasis or chronic obstructive pulmonary disease 
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Routine blood tests including total blood cell count, liver function tests (alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase and total 
bilirubin), kidney function tests (urea and creatinine), blood glucose, electrolytes and 
uric acid, should be obtained before TB treatment. It is recommended all patients with 
TB are tested for HIV infection and HIVfTB service integration has been scaled up in 
recent years in many countries but the goal of universal coverage is yet to be achieved 
[67]. 
1.2.4 Smear microscopy 
Sputum samples should be examined for acid fast bacilli using smear microscopy[68]. 
The high lipid content of the cell wall of mycobacteria renders them resistant to 
decolorisation by acid-alcohol after primary staining with basic fuchsin and hence 
acid-alcohol fast bacilli can be visualized with high specificity. Ziehl-Neelsen staining 
is the most widely used technique [69]. The sputum specimen should be first 
concentrated by centrifugation or filtration to improve the sensitivity of the test, but 
the majority of smears performed worldwide are direct smears (unconcentrated 
sputum) due to resource limitations. Alternative, simplified concentration methods, 
such as by magnetic beads, have been developed but none is yet in wide-spread use 
[70-73]. The specimen is spread onto a microscope slide then heat-fixed, stained with 
the primary stain (usually carbol fuschin), heated to enhance penetration of the dye 
into the bacilli, decolorized with acid-alcohol solution and finally counterstained with 
a dye such as methylene blue in order to obtain better differentiation between the acid 
fast baciIli and the background. A modification of Ziehl-Neelsen stain known as the 
Kinyoun stain, allows cold acid-fast staining. Fluorescent staining, usually with 
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auramine 0 as the primary stain, allows more rapid reading of slides but can result in 
reduced specificity due to the difficulty of differentiating mycobacteria from artefacts 
[74]. Fluorescence microscopy has been widely used in developed countries but 
positive slides require restaining with the ZN technique to confirm the presence of 
acid-fast bacilli. Recently improved fluorescence microscopes using an ultra-bright 
light-emitting diode have been developed and evaluated by the Foundation for 
Innovative New Diagnostics (FIND; www.finddiagnostics.org) and are now 
recommended for implementation [75]. 
1.2.5 Sputum culture 
Sputum samples should be cultured for isolation of bacilli for further identification 
and drug susceptibility testing wherever possible. Due to the lack of culture 
laboratories, this is usually only possible at major TB referral centres outside 
developed countries. Culture of Mrb may be performed with solid or liquid culture 
media. Solid culture generally uses the egg-based Lowenstein-Jensen or Ogawa 
media, or agar-based Middlebrook 7H \0 or 7H II [76]. Liquid culture techniques 
include the commercial automated Bactec Mycobacteria Growth Indicator Tube 
(MGIT) system (Becton Dickinson, USA). M. tb produce non-pigmented colonies 
with a rough and dry appearance ressembling breadcrumbs on egg- based media but 
on agar-based media, the colonies appear flatter [77] (figure 1.6). The false-positive 
rate for conventional culture is generally below 5% in a good laboratory, but may 
occur due to clerical errors or laboratory cross-contamination. Time for results of 
conventional culture and drug susceptibility testing (DST) are extremely slow on solid 
media, taking 4-6 weeks for initial isolation and a further 4 weeks for DST. Liquid 
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culture techniques are faster and more sensitive, and DST may be inoculated directly. 
Cultures may become positive within one week on the MOlT system, but generally 
take between 2-3 weeks [78]. 
Figure 1-6 : Colonies of ftlycobacterium tuberculosis on Lowenstein Jensen media 
http://commons.wikimedia.org/wikilFile:M-tuberculosis-on-Lowenstein-
Jensen.jpg 
During the last two decades, several liquid culture-based methods for cultivation and 
DST of Mtb have been introduced, the most widely used is the MOlT automated 
system for liquid culture. In this method, a fluorescent quenching-based oxygen 
sensor is embedded at the bottom of the tube containing an enriched Middlebrook 
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7H9 broth. The growing mycobacteria consume the dissolved oxygen which generates 
orange fluorescence when illuminated with an UV lamp. The BACTEC MGIT960 
system, that performs incubation and reading of the tubes continuously inside the 
machine, uses a predefined algorithm to interpret the fluorescent signal and to report 
the results as positive or negative. The time for detection of Mtb from sputum 
samples in MGIT is about 14 days but the contamination rate can be high (2-10%). 
The sensitivity and specificity for the BACTEC MGIT960 method are very high 
81.5% and 99.6% according to a meta-analysis [78]. 
The isolation of Mtb needs to be confirmed with biochemical tests when performing 
culture and DST. Characteristics of Mtb are slow growth, non-pigmented colonies, 
positive niacin test. Aftb is inhibited by p-nitrobenzoic acid and displays nitratase 
activity, with susceptibility to pyrazinamide, growth on thiophene carboxylic acid 
hydrazide (TCH), absence of catalase production at 68°C and absence of iron uptake 
[76, 77] (table 1.3). 
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Test M.tuberculosis M.Bovis M.bovis BeG M.africallum M.microti M.callettii 
Morphology rough rough rough rough rough smooth 
Preferred carbon glycerol pyruvate pyruvate glycerol glycerol glycerol 
source 
Pyrazimidase + 
- -
+ + + 
Niacin + - - +/- + -
Nitratase + 
- -
+/-
-
+ 
Urease +/-
-
+ +/- +/- + 
Susceptibility to Tell R s s S S R 
02 requirement aerobic Micro- Micro- Micro-aerophilic Micro- Unknown 
L- .. ___ 
.. aerophilic aerophilic __ aerophilic 
R = resistant, S= susceptible, TCH= Thiophene-2-carboxylic acid hydrazide 
Table 1-3: Colony morphological and biochemical characteristics of species in the Mycobacterium tuberculosis complex [80] 
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1.2.6 Drug susceptibility testing 
Drug-susceptibility testing (DST) of M tb can be determined by observation of 
growth or inhibition of growth in a medium containing antituberculous drugs [79]. 
Conventional methods using egg- or agar-based media are still commonly used and 
considered the gold standard. In order to reduce the extremely long turnaround times 
of conventional methodologies, automated liquid culture methods have been 
developed. Initially, these used radiometric detection as in the BACTEC 460 system 
but later systems use fluorometric quenching for detection and are therefore safer. As 
for Mtb culture, the most widely used automated system is now the MGIT960 system 
(Becton Dickinson, USA). The average sensitivities reported by WHO for detection 
of resistance to INH, RiF, SM, and EMB were 98.7%, 97.2%, 90.8% and 89.3% 
respectively. The sensitivities to detect susceptibility to INH, RiF, SM and EMB were 
98.5%, 96.8%, 93.9% and 94%, respectively [80]. WHO reference standards for the 
minimum inhibitory concentration (MIC) of antituberculous drugs using the 
proportion method on LJ medium are O.2llg/ml -161lg/ml for INH, 4llg/ml for SM, 
40Ilg/ml for RiF and 2llg/ml for EMB [81]. 
Microscopic Observation Drug Susceptibility (MODS) is a novel technique for the 
detection of tuberculosis and multidrug-resistant tuberculosis [82]. It is based on three 
principles: 1) Mtb grows faster in liquid medium, 2) Mtb with cord formation can be 
visualized microscopically at an early stage (figure 1.7) and 3) the incorporation of 
drugs permits the rapid and direct drug-susceptibility testing. The MODS assay uses 
enriched Middlebrook 7H-9 liquid medium. In the MODS assay, samples are 
inoculated into drug-free (control) and wells containing the drug of interest. The 
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MODS assay is a rapid test [82]. MODS sensitivity and specificity for detection ofTB 
in a recent meta-analysis of 21 eligible studies were 96% [95%CI 94-98] and 96% 
[95%CI 89-100], respectively. The MODS assay is more sensitive than smear 
microscopy with a median time to detection of 9 days [83]. The sensitivity and 
specificity for detection of rifampicin resistance pooled estimates are 98.0% [95% CI 
94.5-99.3] and 99.4% [95% CI 95.7-99.9%], respectively. Isoniazid resistance is 
detected with 97.7% [94.4-99.1 %] sensitivity and 95.8% [88.1- 98.6%] specificity 
with a 0.1 ~g/ml cut-off [84]. However, the cording feature of M.tb growth in MODS 
wells is not sufficiently specific to accurately discriminate Mtb from NTM and a 
recent modification has added P-nitrobenzoic acid (PNB) to one growth well to enable 
specific identification of .M.tb [85, 86]. Challenges for this assay are supply of 
reagents and meticulous technique during inoculation and plate handling to prevent 
contamination and potential biohazards related to M.tb growing in liquid culture [62]. 
The MODS assay can be used for diagnosis of extrapulmonary tuberculosis with 
appropriate sample processing [87, 88] . 
Other non-commercial phenotypic OST tests include the nitrate reductase assay 
(NRA) and colorimetric redox indicator (CRI) [89-91] 
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Figure 1-7 : M. tuberculosis characteristic cording in MODS plate at x400 
magnification with inverted microscope (courtesy Dr Dang Thi Minh Ha) [92] 
1.2.7 Mycobacteriophage assays 
Mycobacteriophage based assays using mycobacteriophages to identify M.tb from 
biological specimens requiring only two days to give result and allowing rapid testing 
for susceptibility to rifampicin showed early promise in small research evaluations but 
have low specificity in scale up and are not recommended [84, 93]. 
Mycobacteriophage based assays for ALtb are unlikely to be valuable and FIND has 
now discontinued further development of these assays. 
1.2.8 Nucleic acid amplification tests 
Nucleic acid amplification tests (NAA T) have been developed In many different 
formats for diagnosing TB. 
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Two line probe assays (LPA) are commercially available for detection of resistance to 
RiF or INH, the INNO-LIPA Rlf.TB (Innogenetics, Belgium) and the Genotype 
MTBDR-Plus (Hain Lifesciences, Germany). These assays identify mutations in the 
rpoB gene for RiF resistance and the katG gene or inhA gene, for INH resistance, 
through amplification and reverse hybridisation. The advantages of the LPA include 
relatively short turn-around time ranging from 1 to 2 days and the fact that they can be 
applied directly on smear positive sputum. A meta-analysis concluded that the 
MTBDR-Plus assay has a high sensitivity (98.1%, [95% CI: 95.9-99.1]) and 
specificity (98.7%, [95%CI: 97.3 -99.4]) for rifampicin resistance. However, the 
sensitivity for INH resistance is modest and variable (84.3%, [95% CI :76.6-89.8]) 
with high specificity (99.5%, [95% CI 97.5%-99.9%]) [94]. Therefore LPA can be 
used to detect resistance to RIF and INH but cannot be used to rule it out. Following 
large-scale demonstration projects in high-burden settings, line probe assays were 
recommended by WHO for use on smear positive sputum but are not recommended as 
a complete replacement for conventional culture and drug-susceptibility testing [95]. 
The Xpert MTBIRIF test (Cepheid, USA), endorsed by the WHO in 2010, is an 
automated molecular test for detection of Mtb and resistance to RiF (figure 1.8). A 
Cochrane review of 15 studies with a total of 7,517 participants concluded Xpert has a 
pooled sensitivity of88% (95% CI 83% to 92%) and pooled specificity of98% (95% 
CI 97% to 99%) when used as an initial test replacing smear microscopy [96, 97]. 
Compared with phenotypic drug-susceptibility testing, for rifampicin resistance 
detection (11 studies, 2340 participants), Xpert achieved a pooled sensitivity of 94% 
(95% CI 87% to 97%) and pooled specificity of 98% (95% CI 97% to 99%). In TB 
61 
patients with HIV co-infection, the sensitivity of smear microscopy for the diagnosis 
of TB is very low but GeneXpert sensitivity is relatively unaffected by HIV co-
infection, so the use of XpertMTB/RIF has the potential to increase the detection of 
TB among HIV -infected individuals. The cost of the test is still high compared to 
smear microscopy but less costly than culture and drug-susceptibility testing. 
However, FIND has negotiated cost reductions for use in low-and middle- income 
countries with the cost for the GeneXpert 4-module instrument of US $17,500 and the 
cost per cartridge of $10 [98]. The test gives a result in 2 hours from inoculation of 
the cartridge [97]. 
Figure 1-8 : Assay procedure for the MTBIRIF test 
Reproduced from: 
http://www.finddiagnostics.org!export/sites/defaultlprogramsItb/images/xpert/xpert_m 
tb-rif-.procedureJPG 
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1.2.9 Sputum induction 
Apart from sputum examination using microscopy and culture to diagnose pulmonary 
TB, sputum induction can be used to improve sample collection and test sensitivity. 
According to a meta-analysis study from Hepple et ai., the overall success of sputum 
induction was high from 76.4% (95% CI 68.5-83.2) to 100% (95% CI 98.5-100) and 
side effects were mild and rare. The researchers concluded that this technique 
increases TB case detection, and should be used for patients who cannot expectorate 
spontaneously, or whose sputums are negative on smear [99]. However, sputum 
induction carries increased risk to the clinical staff and other patients and appropriate 
precautions should be implemented. 
1.2.10 Immunological tests 
A method that has been used widely for diagnosis of tuberculous infection is the 
tuberculin skin test (TST). This test is not effective in diagnosis of active TB disease 
rather than infection, particularly in low- and middle-income countries where there is 
a high prevalence of Mtb infection and the BCG vaccination is frequently 
administered as the TST is confounded by prior BeG vaccination. Some countries, 
such as the USA, have historically not used universal BeG vaccination in order to 
preserve the diagnostic utility of TST. TST uses tuberculin that is obtained from a 
sterilized and concentrated M tb culture filtrate. In 1934, Seibert prepared a purified 
protein derivative (PPD) called tuberculin [100]. In 1951, PPD was adopted and used 
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by the WHO [101]. Nowadays, PPO-RT23 is most widely used worldwide. 
Tuberculin should be stored at 4°C to SoC. 
The tuberculin test involves the administration of tuberculin via the intradermal route 
(this test is called intradermal reaction: lOR) (figure 1.9). When tuberculin penetrates 
the skin, phagocytosis of the material produces an inflammatory reaction. In non-
sensitised subjects, this reaction disappears rapidly, however in subjects with 
sensitization of prior mycobacterial infection, this reaction intensifies. The T 
lymphocytes that were previously sensitized with Mtb antigen secrete lymphokines 
generating lymphomonocytic perivascular infiltration. The host response to the 
tuberculin starts within 5 to 6 hours, peaking after 48 to 72 hours and persisting for 
several days. This phenomenon represents a cell-mediated delayed immune 
hypersensitivity reaction. The reading of result should be obtained 48 to 72 hours after 
performing the test by measuring along the transverse diameter of induration in 
millimetres. The interpretation of positive or negative results of TST depends on 
different clinical situations of patients, including BCG vaccination status, HIV status 
and age. It is therefore relatively subjective in interpretation [101]. 
Following Mtb infection, between 2 and 12 weeks are required for the sensitized T 
Lymphocytes to be able to recognize tuberculin. False-positive tuberculin test can be 
due to mUltiple reasons. The most important is infection involving environmental 
mycobacteria or due to BCG vaccination. Alternative PPO preparations are available 
to assist in the differentiation ofNTM infection but are not widely used [102, 103]. 
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Figure 1-9 : Photograph showing administration of the tuberculin skin tcst. 
Reproduced from: A tuberculosis guide for specialist physicians [104]. 
Interferon-y release assays (IGRA) measure Interferon-gamma (IFN-y) response to 
A1.tb antigens. ESAT-6 and CFP-lO are specific to Mlb whereas PPD will be 
confounded by BCG vaccination. There are two major commercial IGRA tests 
available, QantiFERON-Gold (QFT-G, Qiagen, Netherlands) which measures the 
concentration of interferon- y using ELISA, and T-SPOT.TS (Oxford Immunotec, 
UK) which counts the number of cells that release interferon-y manifested as spots. 
The QFT-G test is available as an "in-tube" version (QFT-G-IT) which includes 
antigen TB7.7 together with ESAT-6 and CFP-10 [105]. The specificity ofIGRA is 
high and thought to be superior to that of TST whereas the sensitivity is variable 
between studies. It is extremely difficult to evaluate the specificity of IGRAs as no 
suitable gold standard exists and long-term cohort follow-up studies are costly. It has 
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been difficult to establish cut-off values for differentiating between active and latent 
infection and in 2011 WHO issued a negative advisory that lGRA should not be used 
for the diagnosis of active TB in high-burden settings [105]. 
lGRAs including QFT and T-SPOT are considered to be more accurate tests 
compared to TST for latent TB and both are widely used for identifying recent 
contacts with L TB I in low-burden settings [106]. 
Other commercial serodiagnostic tests for TB currently marketed are not accurate and 
WHO issued an unprecedented negative advisory against the use of such tests in 2010 
following extensive evaluation [107]. 
1.2.11 Biomarkers 
Many biomarkers have been studied in TB infection and disease but only two 
biomarkers- C-reactive protein (CRP) and procalcitonin (PCT) are of clinical value. 
CRP is an acute phase protein produced by the liver in response to inflammation that 
binds to phosphocholine on the surface of dead or dying cells to promote 
phagocytosis. Serum CRP levels increase in the advanced stages of TB and decrease 
with treatment. PCT is a peptide precursor of the hormone calcitonin that is involved 
in calcium homeostasis. PCT increases in bacterial inflammation and is not elevated 
in pulmonary TB so it can be used to differentiate between TB and pneumonia [108]. 
Until now, accurate rapid point-of-care diagnostic tests have not been developed and 
novel biomarker discovery remains challenging. Many promising biomarkers have 
been investigated but more trials according to international research standards need to 
be conducted [109]. 
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1.2.12 Radiological imaging 
Chest X-ray (CXR) is the most useful tool for diagnosis of lung infections but is 
highly dependent on the skill and experience of the reader. Although certain features 
such as hilar lymphadenopathy can be highly suggestive of TB, CXR can neither 
confirm nor rule-out a diagnosis ofTB [110]. 
In primary TB, infiltrates or consolidations visible on CXR may affect any lung 
segment but the middle and lower lobes are characteristic of T8. Consolidations are 
generally dense and homogenous in appearance. The most characteristic radiological 
feature in primary TB is image of lymphadenopathy. Lymph node involvement is 
generally unilateral with the hilar and paratracheal regions most often affected [110]. 
In post-primary TB, chest radiography often reveals patchy infiltrates or poorly 
defined segmental consolidation. These pulmonary abnormalities are usually located 
in more than one segment or lobe and the apical and posterior segments of the upper 
lobes, or the superior segment of the lower lobe are most commonly affected. Single 
or multiple cavitations with thick walls and irregular margins are the hallmark of this 
form. There may be a small quantity of fluid in the cavitation manifesting as an air-
fluid level. Nodular opacities are another common feature. Only approximately five 
percent of patients will have a tuberculoma visible on CXR. 
Computerized Tomography Scan (CT scan) of the lung can be used to enhance 
detection of TB in patients with a normal or inconclusive CXR. Chest CT scan is 
useful to describe lesions and their positions. Moreover, CT scan can detect 
complications and lesions in pleura and mediastinum [110]. 
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In primary TB, chest CT is consistently shown to be more sensitive than plain CXR 
films for the detection of lung lesions and enlarged lymph nodes. In post-primary TB, 
radiologic findings in CT are the "tree-in-bud" (nodular opacities), centrilobular small 
nodules, patchy or lobular areas of consolidation and cavitation. In miliary TB, the 
'scattered millet' appearance is seen from numerous nodules scattered throughout 
both lungs 1-3 mm in diameter. Generally, differences between drug sensitive and 
drug resistant TB on radiological imaging can be attributed to differences in disease 
progression. 
Recently, positron emission tomography has been investigated as a non-invasive 
method to monitor disease activity and responses to antituberculosis therapy but this 
is not feasible on a large-scale and is likely to be limited to monitoring disease 
progression in intractable cases [111, 112]. 
1.2.13 Bronchoscopy 
Fiberoptic bronchoscopy is used in suspected TB cases which are sputum smear 
negative to obtain bronchial washing/aspirate samples to confirm the presence of 
mycobacteria or obtain a differential diagnosis. Bronchial brushing and 
bronchoalveolar lavage fluid, in postbronchoscopy sputum and biopsy samples may 
also be examined by smear, culture and nucleic acid amplification for mycobacteria. 
The most common bronchoscopic findings of TB are congestion, swelling, 
hyperaemia, whitish plaques of variable size, ulceration, erosion and granulation. The 
segmental opening may be narrowed and slightly defonned [113]. 
1.2.14 Genotyping of ~/.tb 
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Recently, progress has been made in understanding the basic biology of M.tb. The 
field of mycobacterial genetics, the development of the field of molecular 
epidemiology and the sequencing of the entire M.tb genome have been key factors. 
IS6110 restriction fragment length polymorphism (RFLP) typing allowed 
investigators to analyze clinical isolates to study transmission of tuberculosis in 
communities, leading to a clearer understanding ofTB transmission [114]. In 1998, 
the complete DNA sequence of Mtb (strain H37RV) was reported, which raised 
hopes of insights into disease pathogenesis [lIS]. Comparative genomics of 
mycobacteria have made it possible to construct evolutionary trees which elucidate 
the phylogenetic evolution of human disease [4, 116]. In addition, genomics has been 
used to compare virulent to avirulent M.tb strains, as well as immunogenic from 
nonimmunogenic strains. These insights from genomics may help to develop 
effective tuberculous vaccines in the future since the immune correlates of protection 
against TB remain unknown [117]. 
Mtb from different lineages may have different clinical phenotypic properties but the 
evidence is often conflicting and so the correlation of genotype and phenotype has 
remained elusive [118]. In one study from Gambia, researchers found that 
transmission of Aftb to contacts was similar among Aftb strains from different 
lineages. However, progression to active TB within a 2-year follow-up period varied 
by lineage; 5.6% ofthose exposed to East-Asian lineage, 1.2%-3.9% exposed to Euro-
American lineage and only 1% of people exposed to West African lineages [119]. 
IS6110 Restriction Fragment Length Polymorphism (lS6J 1 0 RFLP) is a genotyping 
technique for Mtb which can be used to obtain "fingerprints" for different isolates of 
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Af.tb dependent upon the location and number of IS6110 insertions. The 
mycobacterial insertion sequence IS6110 has been shown to be present in multiple 
copies in the chromosome of some strains of Mtb. In RFLP analysis the Mtb 
chromosomal DNA is digested by a restriction enzyme and the resulting DNA 
fragments are separated according to their length by gel electrophoresis. The insertion 
sites of IS611 0 are then detected by hybridization to an IS 6110 specific probe. 
IS6110 RFLP fingerprinting of Mtb was the standard identification method in studies 
on transmission of tuberculosis in the 1990's [120]. It has now been largely 
superseded by other, simpler techniques. 
Variable-Number Tandem Repeat-Mycobacterium Interspersed Repetitive Units 
(VNTR-MIRU) is the Af.tb specific name of a multiple locus VNTR analysis-based 
typing scheme. MIRU VNTR has become an alternative method as it allows high-
throughput, discriminatory and reproducible analysis of clinical isolates resulting in a 
more reliable and faster method for transmission analysis [121, 122]. 
Spoligotyping is based on polymorphisms in the "Direct Repeat" (DR) region, of 
Mycobacterium tuberculosis complex bacteria [123, 124]. The DR region consists of 
a non-variable repeated sequence of 36 base-pairs length which is interspersed with 
variable spacer regions, each of which are between 35 to 41 base pairs in length. One 
DR and its neighbouring non-repetitive spacer is called" Direct Variant Repeat" 
(DVR). Deleted sequences of DNA within the DR region result in variations in the 
presence or absence of the variable spacers between strains of Mtb. The presence of 
spacers is detected by peR amplification targeted to the non-variable repeat sequence. 
The resulting amplicons are then hybridised to probes specific for each variable 
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spacer sequence on a membrane and the presence or absence of spacers recorded as a 
binary code. The short sequence amplification required for spoligotyping make it a 
relatively robust technique which can be applied directly to smear positive clinical 
samples. Many studies have evaluated the clinical usefulness of spoligotyping for 
simultaneous detection and typing of Mtb strains [125]. Spoligotyping can be a useful 
method for rapid outbreak identification in low incidence such as in nosocomial 
outbreaks or in the management of transmission of multidrug-resistant tuberculosis 
[126, 127]. 
Large sequence polymorphisms (LSPs) can define the six principal lineages of the 
Mtb complex including Euro-American, East-Asian, Indo-Oceanic, East-African-
Indian (E~I) and the West-African lineages 1 and. 2. The robustness ofLSPs has been 
validated by multi locus DNA sequence analysis. Spoligotype families are sub-
lineages within the main lineages defined by LSPs [128]. 
1.2.15 Treatment 
There are believed to be four hypothetical populations of },ltb that may exist in 
patients with TB including actively growing organisms, slow intermittently growing 
organisms, organism surviving under microanaerobic conditions in a low pH 
environment, and completely dormant organisms surviving under anaerobic 
conditions. There are also three mechanisms of major activities of anti-tuberculosis 
drugs: (I) Drugs which have ability to kill actively growing bacilli rapidly such as 
INH, RiF and SM (bactericidal); (2) Drugs with the ability to kill the semi-dormant 
organisms such as RiF and PZA (sterilizing); and (3) Drugs which have ability to 
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prevent the emergence of bacillary resistance including INH, RiF, SM, EMB and PZA 
(bacteriostatic ). 
The goals for TB treatment are to cure the individual patient and to minimize the 
transmission of Mtb to other persons. The prinicipal recommended regimen for drug 
sensitive TB in newly diagnosed patients is a two month 'intensive phase' of 
treatment with INH, RiF, EMB and PZA followed by a four month 'continuation 
phase' of RiF and INH (2HRZE/4HR) [129]. Alternative treatment regimens are 
recommended in cases of known or suspected drug resistance, severe forms ofTB and 
other special situations. Although no longer recommended by WHO, several NTPs 
still use an eight month treatment regimen (2HRZE/6HE or 2HRSZ/6HE). The 6-
month regimen (2RHZE/4RH) was significantly superior to the 8-month regimen 
(2RHZE/6HE) in a multi-country RCT conducted by the IUATLD RCT . A 7-month 
continuation phase regimen is recommended for patients with cavitary pulmonary TB, 
positive sputum culture at completion of initial phase, and lack of PZA in the initial 
phase. In populations with known or suspected high levels of bacillary resistance to 
INH, WHO has suggested that RiF, INH and EMB should be used rather than RiF and 
INH in the continuation phase, but there is no evidence for the efficacy of this 
regimen and the recommendation is based on expert opinion only [129]. The twice-
weekly regimens should not be used because of the risk of treatment failure when 
missed doses occur. For treatment of relapse cases with smear positivity or 
retreatment after interruption, the 8-month regimen of 2SRHZE/RHZE/SR3H3E3 is 
recommended. However, this regimen is controversial because it 'adds a single drug 
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to a failing regimen' and has been shown in several studies to have poor efficacy 
[129]. 
In 1993, WHO announced the DOTS (directly observed treatment short course) 
strategy comprising 5 key components consisting of (1) a network of trained health-
care or community workers to administer DOT, (2) properly equipped laboratories 
with trained personnel to perform sputum microscopy for TB diagnosis, (3) a reliable 
supply of high-quality drugs, (4) an accurate record keeping and cohort analysis 
system for monitoring case-findings and outcomes and (5) sustained political 
commitment and funding [130]. 
The bactericidal and sterilizing activities of rifampicin as well as their dose and 
concentration dependence have been demonstrated in many studies [131]. Higher 
doses than the 600mg standard TB dose of rifampicin have been studied for diseases 
including brucellosis without detection of significant increase in severe adverse events 
and many now advocate that a higher standard dose should be trialled for pulmonary 
TB [132]. Mild hepatotoxicity occured more frequently among patients who received 
high-dose rifampicin in one study although no patients developed serious 
hepatotoxicity [133]. The safety and tolerability of high-dose rifampicin needs to be 
assessed meticulously. A systematic review showed high dose of RiF resulted in 
improvement of culture conversion rates. However, side effects such as flu-like 
syndrome were seen when using RiF intermittently [134]. A phase II clinical trial is 
planned but not yet recruiting to compare the pharmacokinetics and 
pharmacodynamics of daily doses of 1200 mg and 900 mg of rifampicin with the 
standard dose (600mg) during the intensive phase of treatment with a view to the 
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potential of high dose RiF to shorten TB treatment (ClinicaITrials.gov Identifier: 
NCT01408914) [135]. 
It is recommended that all patients with tuberculosis should be given counselling for 
HIV and tested due to the high susceptibility of HIV-infected individuals to TB 
disease [67]. Patients also should be tested for hepatitis Band C virus infection using 
serological tests if they have risk factors such as injecting drug use, birth in Asia or 
Africa, and HIV infection. Routine blood tests are also recommended to establish 
liver function and the risk of adverse drug reactions such as baseline measurements of 
serum amino transferases (aspartate aminotransferase AST, alaninne aminotransferase 
ALT), bilirubin, alkaline phosphatase, serum creatinine and a platelet count. Testing 
of visual acuity and red-green color discrimination should be obtained when EMB is 
to be used as a baseline for ocular toxicity monitoring. 
During pulmonary TB treatment, ideally a sputum specimen for microscopic 
examination and culture should be checked at a minimum of monthly intervals until 
two consecutive specimens are negative on culture [136]. In practice, monthly culture 
is not feasible in high-burden settings and most TB patients never receive a culture 
test. Treatment is monitored via sputum smear microscopy alone. Patients should be 
clinically evaluated at least monthly to identify any adverse effects of the anti-
tuberculosis medications and to assess adherence. 
Bacteria may continue to be expectorated several months into treatment and dead 
bacilli will give positive smear results. Treatment failure is defined by WHO as a 
positive Mlb culture or AFB smear after at least 5 months of treatment (table 1.4). In 
high-burden settings due to the lack of resources for culture, most failure cases are 
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identified by smear positivity at 5 months of treatment or later. Relapse is defined as 
recurrent tuberculosis at any time after completion of treatment with apparent cure at 
treatment completion of the previous episode of TB. Cases classified as relapse may 
be cases of reinfection as the necessary genotyping to define relapse is normally only 
performed in a research context. 
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a These definitions apply to pulmonary smear-positive and smear-negative patients, 
and to patients with extrapulmonary disease. Outcomes in these patients need to be 
evaluated separately. 
b The sputum examination may not have been done or the results may not be 
available. 
C For smear- or culture-positive patients only 
Table 1-4: Definitions oftreatment outcomes 
From: Treatment of tuberculosis, 4th Edition,WHO (2009) (129] 
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The use of anti-TB drugs in fixed-dose combination (FOe) tablets comprising 2, 3 or 
even 4 drugs can be convenient for prescription and adherence. The use of FOe 
reduces medication error, simplifies drug procurement and supply, and decreases the 
risk of development of drug resistance and increases treatment adherence. However, 
FOe drugs may still be taken irregularly and so the need for treatment supervision 
remains. Many studies have shown that there are no significant differences between 
FOe and single tablets regarding treatment outcome using measures such as sputum 
conversion rate and relapse, and no increased incidence of adverse events [13 7]. The 
major multicountries trial conducted by the IUATLO and known as 'study e' 
published in 2011, showed non inferiority of FOe and that use of FOe had potential 
advantages compared to a regimen of separately given drugs [138]. In contrast, one 
study, conducted in Singapore, found a higher relapse rate at 2 and 5 years after 
treatment completion in patients who received FOe tablets compared with those who 
received single tablets [139]. Patients were followed for 18 months and it is therefore 
possible performace of FDe regimens was overestimated due to occurrence of 
undetected late relapse. 
possible reasons for treatment failure include non-adherence, drug resistance and 
malabsorption of anti-TB drugs. Social exclusion including homelessness, alcohol or 
substance abuse, behavioural problems, mental retardation and lack of social or 
family support are risk factors for non-adherence to the TB treatment [140]. 
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1.2.16 Surgery 
Adjunctive surgery for pulmonary TB improves the chance of cure in some patients 
with drug-resistance. Three basic criteria for surgery are anti-TB drug resistance with 
a high probability of failure or relapse with medical therapy only, localized TB 
lesions, and after lung resection sufficient drug activity for TB medical therapy. 
Chemotherapy should be given 3 months before surgery [112]. 
1.2.17 Adjunctive therapies 
In case of severe respiratory insufficiency, central nervous system and pericardial 
involvement, corticosteroids can be used to modulate the immune response which is 
thought to be responsible for much of the tissue damage and ensuing complications 
[141-143]. In cases of tuberculous meningitis, adjunctive corticosteroids are 
recommended in all cases as meta-analysis of available trial data has demonstrated 
their efficacy in reducing mortality and neurological sequelae [144]. There is 
insuffient data to prove a beneficial effect of steroids in cases of HI V-associated TBM 
and no trials establishing optimum formulation, dosage and duration. A recent 
systematic review suggested a mortality benefit for steroids across all forms of TB, 
including pulmonary, but more data is required from high quality randomized 
controlled trials to confirm this [145]. 
Immunotherapy such as cytokine supplementation and Mycobacterium vaccae have 
been tried and some approaches have shown moderate benefit in cavity resolution and 
sputum sterilization but have not been sufficiently effective to be adopted as routine 
measures [146-148]. In early studies Vitamin D showed potential in TB treatment by 
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enhancing mycobacterial killing by macophages but clinical trial data has shown 
conflicting results of vitamin D supplementation on outcomes [149-151]. 
1.2.18 Paradoxical response 
Paradoxical reaction is a condition in which patients have a temporary exacerbation of 
symptoms, signs and radiographic manifestations of TB after TB treatment and is 
particularly common in cases of HIV co-infection, when it is known as immune 
reconstitution inflammatory syndrome (IRIS) [152]. Manifestations may include high 
fever, new or exacerbated lymphadenopathy, central nervous system lesions, 
expanded pulmonary parenchymal infiltration, and pleural effusion. Other 
differentials should be ruled out such as treatment failure before diagnosis of 
paradoxical reaction. Changes in IB treatment regimen are questioned in paradoxical 
reaction. In cases which the clinical situation is severe, corticosteroids should be used 
at a dose of about 1 mg/kg and gradually reduced after 1 to 2 weeks [153]. 
1.2.19 Treatment for special situations 
Renal insufficiency and end-stage renal disease: RiF and INH are metabolized by 
the liver so the dosing of these two drugs is not changed. PZA is also metabolized by 
the liver but its metabolites may accumulate with renal insufficiency. EMB is 80% 
cleared by the kidney so it is accumulated in renal failure. A longer interval between 
doses of PZA and EMB is recommended, for example, three times a week. In patients 
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on hemodialysis, drugs should be given after this procedure to avoid removal of the 
drugs [129]. 
Hepatic disease: regimens with fewer potentially hepatotoxic agents should be 
recommended, such as regimens without INH, regimens without PZA, regimens with 
only one potentially hepatotoxic drug, and regimens with no potentially hepatotoxic 
drugs at all [129]. 
Pregnancy and breastfeeding: Streptomycin is contraindicated in pregnancy but 
RiF, lNH and EMB may be used. There is insufficient data on the use of PZA during 
pregnancy and the US guidelines do not recommend its use, while WHO and 
IUA TLD do. The degree of advancement of disease should be taken into account 
when deciding to initiate treatment. There is no evidence that breastfeeding while 
taking first line TB medications is harmful to the infant [129]. 
Tuberculosis and diabetes mellitus: a link between tuberculosis and diabetes has 
been suspected for a long time. The dramatic increases in adult diabetes incidence in 
the last few decades have focused attention on the link between diabetes and 
susceptibility to TB [154]. In addition, TB may exacerbate glycaemic control 
dysfunction in diabetic individuals [155, 156]. Diabetic patients, who need more than 
40 units of insulin per day, or whose haemoglobin Al c concentration is greater than 
7%, are more likely to develop tuberculosis according to a cohort study of over 
40,000 individuals from Hong Kong [157]. Diabetes may also influence the 
radiographic clinical presentation of TB, a large proportion of diabetic patients with 
tuberculosis had lower-lung involvement, multi lobar infiltration and mUltiple cavities 
in one series [158]. Impaired immunity in diabetic patients may lead to increased 
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bacterial burden, slower bacterial clearance on treatment and higher rates of failure 
and relapse. Diabetes can alter oral absorption, decrease protein binding of drugs and 
lead to renal insufficiency which can substantially alter the pharmacokinetics of 
antituberculosis drugs, which may be partially responsible for the increased treatment 
failure. For example, in a small study from Indonesia, diabetic TB patients had 
rifampicin serum concentrations 53% lower than those of non-diabetic TB patients 
[159]. In treatment ofTB patients with diabetes, therapeutic drug monitoring has been 
suggested but is not currently practical outside a research setting [155]. 
Tuberculosis and tobacco: Smoking is a major risk factor for tuberculosis. Passive 
exposure to tobacco and other forms of smoke also carries an increased risk [160]. 
Smokers are more likely to have cough, dyspnoea, appearances of lesions on upper 
zones on chest radiography, cavity and miliary appearance, and positive sputum 
culture, probably as a consequence of the pre-existing lung-damage [161]. In studies 
investigating the influence of smoking on time to sputum culture conversion, findings 
have been conflicting and may be confounded by the level and duration of smoking 
history (pack-years). Exposure to tobacco smoke influences treatment outcome. 
Smoking has been significantly associated with default and failure of treatment, but 
was not with death, compared to non-smokers. A case-control study of 111 cases and 
333 controls from India showed an association between tobacco smoking and 
pulmonary tuberculosis with OR of3.8 [95% CI 2.0-7.0] [162]. TB Patients need and 
should receive counselling and assistance for smoking cessation and these 
interventions are becoming more widely promoted in high-TB incidence countries, 
but are still extremely limited [162]. 
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1.2.20 Complications ofTB 
Without treatment of TB, the disease will usually progress and eventually result in 
death. In addition, TB disease can spread to other parts of the body through 
bacteriaemic seeding. The most common acute complications are lung damage, adult 
respiratory distress syndrome, pleural effusion, pneumothorax, empyema, 
bronchiectasis, haemoptysis, TB meningitis, miliary TB, joint and bone TB, TB 
peritonitis, TB pericarditis, TB lymphadenitis, bowel TB, fallopian TB and 
tuberculoma. Immune reconstitution inflammatory syndrome (IRIS) is a common but 
poorly defined complication of HIV-associated TB once ARV treatment is initiated. 
The late complications are aspergilloma, bronchogenic carcinoma, tracheobronchial 
stenosis and bronchiectasis. TB can cause vascular lesions including pulmonary and 
bronchial arteritis, thrombosis, bronchial artery dilatation and Rasmussen aneurysm. 
Mediastinal lesions such as lymph node calcification, oesophago-mediastinal fistula 
and oesophago-bronchial fistula are also seen in TB complications. A rare 
complication of pulmonary TB is deep vein thrombosis (DVT) [163]. 
1.3 Drug-Resistant Pulmonary Tuberculosis 
1.3.1 Epidemiology 
Drug resistant strains of tuberculosis are increasing in prevalence globally and 
represent one of the major threats to TB eradication due to the lack of novel second-
line agents [164]. Although drug resistance was identified immediately following the 
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clinical application of streptomycin, the early implementation of multi-drug therapy 
for TB has actually preserved the limited number of truly effective first-line drugs 
remarkably well. However, multiple new drug classes are now urgently needed to 
allow effective eradication of drug-resistant fonns ofTB. 
In 2008, an estimated 3.6% of all TB cases were muItidrug resistant TB (MDR-TB, 
resistant to at least INH and RiF), numbering between 390,000 - 510,000 cases 
wordwide, of which 150,000 resulted in death [164]. Fifty percent of MDR-TB cases 
occurred in China and India. Twelve countries have reported proportions ofMDR-TB 
of 6% or more among new TB cases and five of these countries reported rates of 50% 
or more among previously treated cases. Extensively drug-resistant TB (XDR-TB) 
was defined by WHO in 2006 as MDR Mlb additionally resistant to a 
fluoroquiniolone and an injectable second-line agent. Worldwide, 5.4% of MDR-TB 
cases were estimated to be extensively drug resistant TB (XDR-TB). By 2010, 58 
countries had reported at least one case ofXDR-TB [164]. 
The total number of estimated MDR-TB cases in Vietnam ranks the third highest in 
the Western Pacific region. There were an estimated 4,047 new cases (95% CI, 2341 
to 6056) and 2,374 previously treated cases (95% CI, 1378 to 3535) of MDR-TB 
(www.who.int/tb/data, September 2013). The prevalence of MDR-TB was 2.7% 
(95%CI, 2% to 3.6%) in new TB cases and 19.3% (95CI, 14.2% to 25.4%) in 
retreatment cases. Vietnam has developed the programmatic management of drug-
resistant TB (PMDT) from 2009 in five cities and provinces including Ho Chi Minh 
City and Hanoi [165]. FQs are widely used for treating respiratory infections, 
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therefore the prevalence of FQs resistant M.tb is substantial in some regions, but is not 
yet high in Vietnam according to the limited available data. 
1.3.2 Classification and definition 
TB is classified as Orug- resistant TB (OR-TB) if the infecting isolate of M.tb grows 
in vitro in the presence of one or more antituberculosis drugs. Some general tem1S for 
drug resistant bacteria have unique and specific definitions in the context of drug 
resistant TB and are listed below for clarity. 
Mono-resistant TB is resistant to a single antituberculous drug. 
Poly-resistant TB is resistant to more than one antituberculous drug, but not resistant 
to both isoniazid (lNH) and rifampicin (RiF). 
Multi-drug resistant TB (MDR TB) is resistant to at least RiF and INH. 
Extensively drug-resistant TB (XDR TB) is defined as MOR-TB with additional 
resistance to a fluoroquinolone (FQs) and at least one of second-line injectable drugs 
(kanamycin (Ka), amikacin (Am) or capreomycin (Cm)). 
Totally drug-resistant TB (TDR) is not recognized as a definition by the WHO but 
has been used to describe strains that are resistant to all first and second-line drug 
classes (for example, aminoglycosides, cyclic polypeptides, fluoroquiolones, 
thioamides, serine analogues and salicylic acid derivates). Lack of standardization of 
laboratory tests for resistance to second-line agents make reports of TOR TB 
unreliable. The control, prevention and treatment of such deadly bacilli challenges 
TB programmes worldwide [166]. 
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1.3.3 Mechanism of drug resistance in )'1.tb 
After the introduction of anti-TB drugs, M.tb strains with resistance may be selected. 
Resistance in Mtb is due to spontaneous chromosome mutations at a frequency of 
between 106 to 108 replications, depending on the drug, and therefore resistant 
organisms will be present in the absence of drug pressure. Af.lb does not acquire 
resistance through DNA transfer or plasmid acquisition [167]. In theory, a drug 
resistant population will not emerge if at least three effective drugs are used. Irregular 
drug supply, inappropriate prescription and poor adherence are errors leading to 
clinically drug-resistant TB. The transmission of resistant Af.lb strains from an index 
patient to others aggravates the problem. 
1.3.3.1 Isoniazid resistance mechanism 
INH has the highest early bactericidal activity (EBA) of all antituberculous drugs, 
however it is only active against growing tubercle bacilli, but not active against non-
replicating or anaerobic tubercle bacilli. INH is a prodrug which is activated by the 
catalase-peroxidase enzyme (katG) encoded by the /wIG gene [168]. The primary 
target of INH inhibition is the inhA enzyme (enoyl-acyl carrier protein reductase) 
involved in elongation of fatty acids in mycolic acid synthesis [169]. Recent studies 
showed that INH-NAD(P) adducts react with other protein targets besides inhA such 
as DfrA (an NADPH-dependent dihydrofolate reductase involved in DNA synthesis) 
[170]. The MIC of INH is 0.02-0.2 ~g/m1. In vitro, resistance to INH occurs at a 
frequency of I in 105-6 bacilli. INH-resistant clinical isolates of A11b may lose the 
catalase peroxidase enzyme, conferring complete resistance due to the need for the 
kalG gene product to activate the pro-drug, but at considerable fitness cost [171]. 
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KalG S315T is the most common INH resistance mutation. The prevalence of the 
mutation among INH resistant strains varies between 50-95% geographically for 
unknown reasons [172]. Mutations at other sites in KalG can also confer resistance to 
INH. Mutation at codon 463 was initially thought to be resistance associated, but has 
now been shown to be a phylogenetic mutation [173, 174]. Resistance to INH also 
commonly occurs by mutation in the promoter region of mabAlinhA or, more rarely, 
by mutations at the inhA active site, lowering the InhA affinity to the INH-NAD 
adduct (low-level resistance MICs=0.2-1 ~g Iml) . Mutation in inhA can confer cross-
resistance to ethionamide (ETH) [169]. Ninety percent of INH- resistant isolates in 
Vietnam have at least one mutation in the kalG or inhA promoter gene regions [175]. 
Mutation in the promoter region of ahpC, encoding an alkylhydroperoxide reductase, 
increases expression of the enzyme and compensates for the lack of catalase-
peroxidase. About 10-25% of low level INH-resistant strains have no known 
resistance mutations. Mutation in mshA encoding an enzyme of mycothiol 
biosynthesis has shown INH and ETH resistance in vitro [176]. 
Mutations in kalG confer higher levels of resistance, generally >5~g/ml, than 
mutations in the inhA promoter or aphC genes (1-2~g/ml, or 2:5 times the MIC). [3, 
177, 178]. Mutation in the inhA promoter region, usually C-15T, confers low level 
INH resistance due to overexpression of inhA. In addition, mutations in the inhA 
structural gene result in an increased dissociation constant for the inhA-NADH-
complex [179, 180]. Mutation in inhA can confer cross-resistance to ethionamide 
(ETH) [169]. Mutation in mshA encoding an enzyme of mycothiol biosynthesis has 
also shown INH and ETH resistance in vitro [176]. 
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The role of ahpC (alkyl hydroperoxidase reductase) is to detoxify organic peroxides 
and mutations are thought to lead to overexpression which compensates for the loss of 
catalase peroxidase activity [181,182]. 
Mutations with changes in the genes, kasA (B-ketoacyl ACP synthase) and ndh 
(NADH dehydrogenase) have also been observed in INH resistant isolates but a meta-
analysis failed to confirm a role in clinical INH resistance [172, 183-185]. 
Mtb, in common with other bacteria, uses efflux pumps to expel harmful substances 
from their cytoplasm. INH efflux is thought to occur via a reserpine-inhibitable pump 
encoded by a three-gene Af.tb operon, iniABC [186], but other as yet uncharacterised 
mechanisms are also likely to exist since 10-20% of phenotypically INH resistant 
isolates have no known mechanism of resistance. Recently, some new mutations 
potentially linked to INH resistance have been described in mabA, Thr4I1e, from 5 patients 
with different strains whose sputum cultures remained postitive after standard TB treatment 
[187]. The identification of efflux pumps may lead to a new way to enhance 
antituberculosis therapy, through inhibition of this mechanism [188] and it is likely 
that whole genome sequencing of resistant isolates will give further insights into INH 
resistance mechanisms in the next few years [189-191]. 
1.3.3.2 Rifampicin resistance mechanism 
RiF is a bactericidal antibiotic that is active against both growing and stationary phase 
Mtb baciIli. Strains with MICs <1 Jlg/ml in liquid or agar medium or MICs < 40 
Jlg/ml in Lowenstein-Jensen medium are considered RiF-susceptible. RiF interferes 
with RNA synthesis by binding to the p subunit of the RNA polymerase at the 
catalytic center resulting in blockage of the elongation of the RNA chain. 
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Spontaneous resistance to RiF occurs at a frequency of 1 in 107 to 108 bacilli via 
mutations in a defined 81 base pair (bp) region of the rpoB gene. Mutations at codons 
531,526 and 516, occur in 96% of RiF-resistant M.tb [192] and generally result in 
high level resistance (MIC > 32~g/ml) and cross-resistance to all rifamycins. Specific 
mutations in codons 511, 516, 518 and 522 are related to lower-level resistance to RiF 
and rifapentine but susceptibility to rifabutin and rifalazil [193]. 
1.3.3.3 Pyrazinamide resistance mechanism 
PZA is an important drug because it kills persistent bacilli in acidic pH environments 
and plays a crucial role in shortening TB treatment [194]. PZA is not active against 
}.-f.bovis [195]. The MIC ranges from 6.25-50 ~g/ml. PZA is a prodrug that requires 
conversion to its active form pyrazinoic acid (POA) by the 
pyrazinamidase/nicotinamidase enzyme encoded by the pncA gene of }.-f.tb [196]. 
The target of PZA is related to membrane energy metabolism [197]. POA reaches the 
cell surface through passive diffusion and a defective efflux. The acid pH facilitates 
the formation of uncharged protonated POA and PZA can permeate through the 
membrane to accumulate and disrupt the membrane of Mtb. PZA-resistant M.tb 
strains with pncA mutations, lose pyrazinamidase/nicotinamidase activity [198]. 
Resistance testing to PZA in vitro is unreliable due to the need for an acid 
environment and reports of the prevalence of pncA mutations among resistant strains 
vary widely [199, 200]. It is unclear if this is due to variations in the phenotypic DST 
accuracy or due to other factors, but it is apparent that other undiscovered or poorly 
characterized mechanisms of resistance exist [201]. 
1.3.3.4 Ethambutol resistance mechanism 
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EMB is a bacteriostatic agent that is active for growing bacilli with MICs of 0.5-2 
Jlg/ml. EMB interferes with the biosynthesis of arabinogalactan in the cell wall via 
arabinosyl transferase, an enzyme encoded by embB [202]. Strains resistant to EMB 
have MICs > 7.5 Jlg/ml. In vitro, spontaneous EMB resistance occurs at a frequency 
of 1 in 105 bacilli. The most frequently occurring EMB resistance mutation is at codon 
306 of the embB gene. Approximately 65% of EMB-resistant strains have embB 
mutations [203]. 
1.3.3.5 Mechanism of aminoglycoside resistance 
SM is an aminoglycoside antibiotic that is active against various bacterial species 
including actively growing Mtb with MICs of 2-4 Jlg/mL SM inhibits protein 
synthesis by binding to the 30S subunit of ribosomes causing misreading of the 
mRNA message during translation. The site of action of SM is the 30S subunit of the 
ribosome at the ribosomal protein S 12 and the 16S rRNA [204]. Mutations in the S 12 
protein are encoded by rpsL gene and 16S rRNA encoded by rrs gene [205]. A 
mutation in gidB encoding a conserved 7-methylguanosine methyltransferase specific 
for 16S rRNA causes low level SM resistance [206]. 
The second-line tuberculosis drugs, kanamycin (KM) and amikacin (AMK), also 
belong to the aminoglycoside class and inhibit protein synthesis through modification 
of ribosomal structures at the 16S rRNA [207]. Mutations at 16S rRNA (rrs) position 
1400 are related to high-level resistance to KM and AMK [208]. Capreomycin (CPM) 
is a polypeptide antibiotic. A gene called tlyA encoding rRNA methyltransferase is 
involved in resistance to CPM [209]. Cross-resistance can occur between KM, AMK 
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and CPM and depends on the resistance mechanism of an individual strain. SM-
resistant strains are often susceptible to KM and AMK [210, 211]. 
1.3.3.6 Fluoroqinolone resistance mechanisms 
Fluoroquinolones (FQs) inhibit DNA gyrase (topoisomerase II) and topoisomerase 
IV, resulting in microbial death [212]. A1.1b does not have homologs of to poi some rase 
IV. DNA gyrase is an A2B2 protein. The A subunit carries the breakage-reunion active 
site and the B subunit promotes adenosine triphosphate hydrolysis. A and B subunits 
are encoded by gyrA and gyrB, respectively [213]. The quinolone-resistance-
determining regions (QRDR) of gyrA (320bp) and gyrB (375pb) are the most 
important locations in FQ resistance. GyrB mutations are of much rarer occurrence 
and confer lower-level resistance than gyrA mutations [212]. The WHO definition of 
FQ resistance in Mtb is MIC of ofloxacin ~ 2 Jlg/ml [214]. Other underlying 
mechanisms for mycobacterial resistance to FQs have been suggested such as 
decreased cell wall permeability to drug, drug efflux pumps, drug sequestration and 
drug inactivation [212,215,216]. A new proposed mechanism of quinolone resistance 
is related to MfpA which is a member of the pentapeptide repeat family of proteins 
from Mlb, whose expression causes resistance to FQs [217]. 
1.3.3.7 Resistance mechanisms of other second line agents 
Ethionamide/prothionamide and thioamides: ETH is a derivative of isonicotinic acid 
and bactericidal with MICs of 0.5-2 Jlg/ml in liquid medium, 2.5-10 Jlg/ml in 7Hll 
agar and 5-20 Jlg/ml in LJ medium. ETH is a prodrug that is activated by ElaA/ElhA 
(monooxygenase) and inhibits the same targets as INH through the mycolic acid 
synthesis pathway coded by inhA. Mutations in the drug-activating enzyme 
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EtaAlEthA cause resistance to ETH and other thionamides [218]. Mutations in inhA 
confer resistance to both INH and ETH. Due to the relative rarity of resistant strains 
and the lack of standardization and reproducibility of DST for the second-line agents, 
the resistance mechanisms are poorly characterized. 
It is of vital importance that the mechanisms of resistance in Mtb to all drugs are fully 
elucidated to facilitate rapid diagnosis, drug class preservation, and the development 
of novel compounds. This is particularly important for the first line agents. Whole 
genome sequencing efforts are revealing further mechanisms of resistance but 
environmentally induced mechanisms will require in vitro characterization [189-191, 
219]. 
1.3.4 Treatment of drug resistant tuberculosis 
1.3.4.1 Treatment of MDR TB 
MDR TB is a treatable disease under ideal conditions. In practice, only one in ten 
patients have access to treatment and the cure rates vary widely from 25% to 82% 
[79]. Adherence to treatment is an essential element for success. MDR patient cohorts 
can vary widely in resistance patterns with some regions having rare second-line 
resistance or exposure to second line drugs and other regions, such as the fonner 
Soviet states, having wide-scale resistance to multiple second-line drugs among MDR 
cases [79]. Treatment success is highly dependent on the extent of resistance to 
additional drugs. The absence of second- line drugs in previous regimens is strongly 
associated with a successful outcome of MDR-TB treatment [220]. Withdrawal of 
drugs due to adverse effects has been found to be related with poor treatment 
outcomes, due to the potential for further amplification of drug resistance. HIV 
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infection is also a strong risk factor for relapse. Among MDR TB patients in a cohort 
study in the US the overall relapse rate was 2.06 per 100 persons-years for HIY-
infected patients compared with 0.52 for non-tHY -infected patients [221]. According 
to a systematic review and meta-analysis, overall the successful outcome rate for 
MDR treatment cohorts which have been reported is 62% [95% CI: 57-67] while 13% 
defaulted, 11 % died, and 2% were transferred out [220]. Factors related to poor 
outcomes were male gender, alcohol abuse, low BMI, smear positivity at diagnosis, 
fluoroquinolone resistance and the presence of an XDR resistant pattern. Surgical 
intervention, no previous treatment and fluoroquinolone usage were factors associated 
with good outcome. Three categories of treatment regimen for MDR TB include 
standardized regimen, empirical regimen and individualized regimen. In standardized 
regimens, DST data from representative patient populations are used to design 
regimens in the absence of individual DST. Empirical treatment regimens are 
designed based on the TB treatment history of the individual patient and DST data 
from the representative patient population. Individualized treatment regimens are 
guided by the treatment history of the patient and individual DST results. It is 
important to consider the treatment history of a patient even when full DST results are 
available because DST can be unreliable, particularly for second-line agents, and may 
take many months to obtain, during which time the DST profile of the in vivo strain 
may have evolved. 
Anti-TB drugs are divided into 2 principal categories: first- and second-line drugs 
(table 1.5). Researchers also classify agents into 5 groups based on efficacy, 
experience of drug usage and drug class. 
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Group 1: first-line oral agents including Isoniazid (INH), Rifampicin (RiF), 
Ethambutol (EM B), Pyrazinamide (PZA) and Rifabutin (Rfb). 
Group 2: injectable agents such as kanamycin (KM), amikacin (AMK), 
Capreomycin (CPM) and streptomycin (SM). 
Group 3: Fluoroquinolones (FQs) . 
Group 4: oral bacteriostatic second-line agents such as ethionamide (ETH), 
prothionamide (Pto), cycloserine (Cs), terizidone (Trd) and p-aminosalicylic acid 
(PAS). 
Group 5: Agents with unproven efficacy and/or high toxicity such as c10fazimine 
(Cfz), Iinezolid (Lzd), amoxicillinlclavulanate (AmxlClv), thioacetazone (Thz), 
Imipenem/cilastin (lpm/Cln), high-dose Isoniazid and clarithromycin (Clr). 
The basic principles for designing a MDR treatment regimen are : (I) the regimen 
should be based on the history of drugs that patients are known to have taken; (2) 
based on the prevalence of resistance to individual drugs in the population from which 
the patient originates; (3) At least four drugs should be included to which the isolate is 
thought to be susceptible; (4) PZA, EMB and a quinolone should be given once a 
day, in contrast, ETH, Cs, PAS are given in split doses; (5) the drug dosage should be 
detennined by body weight; (6) treatment of adverse drug effects should be 
immediate and adequate; (7) an injectable drug should be used for at least six months; 
(8) the minimum length of treatment should be 18 months after culture conversion; 
(9) drugs are administered as directly observed therapy; (10) DST does not predict 
with 100% certainty the effectiveness or ineffectiveness of a drug; (11) PZA can be 
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used for the entire treatment and (12) early DR-TB detection and treatment are 
important factors. 
Duration of treatment for MDR-TB is currently a minimum of 18 months after 
negative culture conversion. Extension of therapy to 24 months may be indicated in 
chronic cases with extensive pulmonary damage. 
In Bangalesh, a 9-12 month regimen (4 months gatifloxacin, c1ofazimine, ethambutol, 
pyrazinamide, prothionamide, kanamycin and high-dose isoniazid! 5 months 
gatifloxacin, clofazimine, ethambutol and pyrazinamide) gave a relapse-free cure of 
87.9% (95% CI, 82.7-91.6) among 206 patients in a cohort analysis [222]. A RCT 
entitled Standardized Treatment Regimen of Anti-TB drugs for patients with Multi 
drug-resistant TB (STREAM) has been developed to test this regimen used in the 
Bangladesh study. The trial has a non-inferiority design to compare the Bangladesh 
regimen with the standard 18-month minimum WHO treatment regimen (Clinical 
Trial number: ISRCTN78372190). Vietnam is one of the countries participating in 
this trial. The clinical trials uses moxifloxacin in place of gatifloxacin due to the lack 
of a GMP source for gatifloxacin. 
Due to the desperate need for improved, less toxic and shorter treatment regimens for 
MDR TB several countries have expressed an intention to implement the 'Bangladesh 
regimen' and WHO has therefore adopted a policy of offering technical advice on 
implementation and evaluation [223]. 
1.3.4.2 Novel TB drugs for MDR TB 
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In 2013 the diarylquinolone R20791 0 (bedaquiline also known as TMC 207 or J) was 
approved by the FDA and WHO as the first new drug class for the treatment of MDR 
TB [22]. Bedaquiline was shown in a phase 2 randomised controlled trial to reduce 
the time to sputum culture conversion (hazard ratio, 11.8; 95% CI: 2.3 to 61.3; 
p=0.003), and increase the proportion of patients with sputum culture conversion 
(48% vs. 9%), with no increase in mild and moderate adverse events except nausea 
occurred significantly more frequently among patients with Bedaquiline (26% vs. 4%, 
p=0.04) compared to placebo group [224]. Bedaquiline has also been tested in 
combination therapy which showed that it was well tolerated with safe treatment 
outcomes [225]. Five conditions necessary for WHO-supported use of bed aquiline are 
specified: effective treatment and monitoring, proper patient inclusion, informed 
consent, adherence to WHO recommendations and active pharmacovigilance and 
management of adverse events. The WHO guideline for interim use of bedaquiline 
emphasizes the need for further phase III evaluation ofthis drug [226]. 
Several new drugs for tuberculosis have been discovered and used off-label for MDR 
treatment moxifloxacin (M) and linezolid (Lzd). Rifapentine in the rifamycin class is 
also FDA approved for TB treatment. Further novel agents are at the preclinical and 
clinical trial stage (Figure 1.1 0), including the nitroimidazoles (PA 824 and 
delanamid/OPC 67683) (www.newtbdrugs.org). 
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Figure 1-10: TB drug pipeline 2013 
Reproduced from Zumla et al. Nature Reviews Drug Discovery 2013 [227). 
1.3.4.3 Regimens for drug-resistant TB 
Regimens for the treatment of DR-TB are based on expert opinion, rather than 
evidence from randomized controlled trials. Recent meta-analyses of data from RCTs 
96 
have provided some evidence to guide treatment of DR-TB. TNH-monoresistant TB 
has a good outcome if identified before the emergence of further resistance Short-
course chemotherapy can achieve around 98% cure with less than 5% relapse when 4 
drugs (RHZE/S) are used throughout the 6 months of treatment [228]. If the regimen 
is reduced to two drugs in the continuation phase after two months (RH), the relapse 
rate after 6 months rises to 10% [229]. Some researchers have advised alternative 
regimens such as RE or REZ for more prolonged durations. The best treatment for 
INH mono-resistant TB programmatically is still unclear. 
RiF-monoresistant TB has a much more ominous prognosis. Some researchers have 
previously recommended a regimen with HZE for 18-24 months [230] but the 
addition of a fluoroquinolone to the regimen to complement INH in place of RiF is 
likely to be a more effective regimen [231]. RiF monoresistance is rare, but is more 
common among HIV -infected individuals, which complicates treatment. Research is 
required to determine the optimum regimen in these cases but, due to the rarity of the 
condition, it is likely that treatment regimens will continue to be guided by caution to 
prevent the development ofMDR TB for the foreseeable future. 
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1.3.4.4 Surgery for MDR TB 
Surgery may be considered in intractable cases ofMOR TB to improve the efficacy of 
drug therapy but it is not curative and the threshold for surgical intervention varies 
widely between centres [232]. At least two months of drug therapy should be given 
before surgery to decrease the bacterial load with an additional 12-24 months of 
chemotherapy following surgery. Surgery is more effective in cases where the disease 
is limited to a single lung or lung lobe. 
1.3.4.5 Treatment of DR-TB in special conditions and situations 
Co-morbidities including diabetes mellitus, liver disorders, renal insufficiency, 
seizure and psychiatric disorders, complicate the treatment of drug-resistant TB and 
must be given consideration in the choice of drugs and monitoring of adverse events 
[65]. 
Pregnancy is not a contra-indication to treatment but injectable agents are not 
recommended. Lactating mothers should be given infant formula and attempts be 
made to limit exposure of any children in smear positive cases [65]. 
1.3.4.6 Monitoring progress of treatment of drug resistant TB: adverse effects 
Second-line drugs have a higher range and frequency of adverse effects than the first-
line antituberculosis drugs [65]. If adverse effects are mild and not dangerous, the 
treatment regimen should be continued with the help of ancillary drugs. Reducing 
dosages of the offending drugs is another method for managing adverse effects [233]. 
In principle, dosage should not be reduced below the level expected to produce 
adequate serum levels for TB treatment, however in practice this is difficult to 
determine, especially for the second line drugs. Sometimes, cycloserine and 
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ethionamide are completely tolerated at a lower dose. Pyridoxine should be given to 
any patient receiving cycloserine to prevent neurological adverse effects with a dose 
of 50 mg for every 250 mg of cycloserine prescribed. Psychosocial support is a 
component of the management of adverse effects [65,234]. 
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AUC = area under curve; MIC = minimum inhibitory concentration; EBA = early bactericidal activity; cfu = colony forming units; ? = uncertain; 
PAS = para-aminosalicylic acid. 
Table 1-5: Pharmacokinetic characteristics of current anti-tuberculosis drugs 
Reproduced from Mitchison et al. IJTLD 2012 [235] 
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1.4 INH Resistant Pulmonary Tuberculosis 
1.4.1 Chemical characteristics of Isoniazid 
Isoniazid was first synthesized in 1912 and first used clinically in 1952. The 
molecular formula is: C6H7N30 with a molecular weight of 137,14. 
Generic names for isoniazid are isonicotinic acid hydrazide; isonicotinylhydrazine; 
isonicotinylhydrazine. 
1.4.2 Mechanism of action 
INH is a bactericidal agent against organisms of the genus Mycobacterium including 
Mtuberculosis. It has the highest early bactericidal activity (EBA) of the TB drugs 
and is responsible for the rapid decrease in bacterial load in the first week of treatment 
[236-239]. INH is bactericidal to rapidly-dividing Mtb bacilli but bacteristatic to 
replicating bacilli [240]. 
INH is a prod rug activated by the catalase-peroxidase haemoprotein product of katG 
and is transformed into iso-nicotinic acid, which has a similar structure to nicotinic 
acid, an important precusor of nicotinamide adenine dinucleotide (NAD). The 
accumulation of iso-nicotinic acid leads to the generation of iso-NAD instead of 
NAD which then blocks multiple enzyme systems as a non-functional co-factor [180]. 
Isoniazid acts in multiple pathways, principally to inhibit mycolic acid biosynthesis. 
Isoniazid also induces an activation of the mycobacterial NADase and leads to a 
diminution of the intracellular NAD concentration. 
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INH also inhibits inhA, a nicotinamide adenine dinucleotide (NADH)-specific enoyl-
acyl carrier protein (ACP) involved in fatty acid synthesis. 
1.4.3 Pharmacokinetics and Pharmacodynamics of isoniazid 
1.4.3.1 Absorption 
Isoniazid is a highly reactive water soluble drug absorbed from a limited area of the 
small intestine. INH should not be given with food because this significantly reduces 
its bioavailability. A high carbohydrate diet, high gastric pH and altered hepatic and 
gastric blood-flow may also decrease bioavailability of isoniazid [241]. . 
Peak plasma concentrations are reached after 1-2 hours after ingestion and the median 
peak plasma concentration approximately 3Jlg/ml. It is lower in children than adults 
due to faster elimination, with the same mg/kg dosage [242-244]. The WHO treatment 
guidelines for pediatric TB have recently been revised to reflect this [245]. . 
INH is distributed in all body fluids including cerebrospinal, pleural and ascitic fluids; 
and in tissues, organs and excreta. 
1.4.3.2 Metabolism 
INH is acetylated to N-acetylisoniazid (NAT), then biotransformed to isonicotinic 
acid and monoacetyl-hydrazine. An individual may be fast (FF), intermediate (FS) or 
slow acetylator (SS), depending on polymorph isms in the N-acetyl-transferase-2 
genotype (NA T2) . Slow acetylators are characterized by a relative lack of hepatic N-
acetyltransferase. A pharmacokinetic study showed that 88% of the variability in INH 
serum clearance is affected by NAT2 gene *4 (NAT2*4) alleles. Ethnicity, gender 
and body weight contribute relatively little to the variability [246]. In addition to 
102 
affecting the pharmokinetics of serum INH concentrations, differences in INH 
metabolism also generate different concentrations of toxic metabolites and may 
impact the rate of adverse reactions. Some researchers suggest that the rapid 
acetylators should take larger doses of INH than slow acetylators, who are at higher 
risk of adverse reactions such as peripheral neuritis, and hepatic toxicity [247]. 
The distribution of acetylator types varies across different ethnicities: in most Asian 
ethnicities the majority are fast acetylators, while among Caucasians the ratio is 
reversed [248]. NAT2 genotyping could become a useful alternative to therapeutic 
drug monitoring for INH [249]. 
According to a study conducted in Warsaw, with a 300mg dose of INH 38.6% of fast 
acetylators did not achieve a concentration of 1 JlgI ml in plasma three hours after 
ingestion of the drug. In contrast, 29.7% of slow acetylators maintained 
concentrations of INH 2 Jlg/ml in plasma six hours after ingestion [250] . 
1.4.3.3 Excretion of INH 
INH is primarily excreted through the kidney. Other routes are breast milk, saliva, 
sputum and faeces. About 50% to 70% ofa 5mg/kg oral INH dose is excreted in urine 
within 24 hours as metabolites, varying by acetylator type [251]. 
1.4.3.4 Drug-drug interactions ofINH 
Known drug interactions for INH are attributable to its interaction with the 
cytochrome P450 system, especially CYP2E 1. INH shows a biphasic inhibition-
induction so it increases serum concentrations of some drugs such as phenytoin and 
carbamazepine. INH increases the effects of warfarin and theophylline, and inhibits 
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metabolism of benzodiazepines, monoamine oxidase and histaminases [252]. There 
are no known interactions with antiretroviral agents for HIY [67]. 
1.4.4 Toxicity of INH 
1.4.4.1 Hepatitis 
INH usage is associated with a risk of developing severe, potentially fatal hepatitis. 
The risk of hepatotoxicity increases with age, it is rare in persons under 20 but up to 
2.3% in those who are over 50 years of age and daily alcohol consumption [253]. 
Acetyl hydrazine, which is released from acetylated INH, may be one of the toxic 
metabolites responsible for hepatitis with higher concentrations reached in slow 
acetylators. The symptoms of hepatitis are anorexia, nausea, vomiting, fatigue, 
malaise and weakness. Between 10-20% patients using INH have mild and transient 
elevation of serum transaminase levels which is not a contraindication to continued 
use [254]. 
1.4.4.2 Central Nervous System 
Potential neurotoxic adverse reactions are convulsions, toxic encephalopathy, optic 
neuritis, optic atrophy, memory impairment and toxic psychosis. These side effects 
are not common in TB treatment but may occur in cases of overdose [255]. 
Use of JNH can produce peripheral neuropathy but this can be prevented by 
concurrent administration of pyridoxine. Peripheral neuropathy is a dose-dependent 
adverse reaction that occurs in less than 0.2% of patients at dosages of 3-5 mg/kg/day 
and more commonly in patients with malnutrition, diabetes, HIY infection, renal 
failure, alcoholism, pregnancy or lactation. Pyridoxine should be given at a dosage of 
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5-10 mg! day for prevention and at 250mg/day for treatment of isoniazid-induced 
neuropathy [256, 257]. 
1.4.4.3 Other adverse events associated with INH 
Potential gastrointestinal adverse effects include nausea, vomiting and epigastric 
distress. Rare haematological adverse effects include agranulocytosis, haemolysis, 
aplastic anaemia, thrombocytopaenia and eosinophilia. 
Endocrine and metabolic effects which can occur but are also rare are pellagra 
hyperglycaemia, acidosis and gynecomastia. 
Hypersensitivity reactions occur in relatively rare cases «1% of patients) and 
manifest as fever, skin rashes, lymphadenopathy and vasculitis [258]. 
Development of antinuclear antibodies occurs in 1 of 5 patients receiving isoniazid. 
INH should not be used in patients who develop clinical lupus erythematosus (less 
than 1%). 
1.4.5 The early bactericidal activity (EBA) ofINH 
EBA is defined as the fall in counts/ml sputum/day during the first 2 days of 
treatment. INH at a 300 mg dose has the highest EBA of any antituberculous agent. 
The bactericidal activity of INH is dose- related. The N-acetyl-transferase-2 genotype 
(NA T2) also influences the EBA of INH; faster INH acetylators have been found to 
have a lower EBA [131]. 
1.4.6 Treatment oflNH resistant pulmonary TB 
Resistance to INH is the most common form of drug resistance and the prevalence of 
INH resistance (alone or in combination with other drugs) in newly pulmonary TB 
105 
was estimated at 10.3% in the world in 2008 [259]. INH resistance is defined as low 
level resistance and high level resistance if there is over 1 % growth of Mtb in the 
presence of 0.2 Ilg/ml and 1 Ilg/ml, respectively. INH resistance is a key precursor in 
the development ofMOR-TB. The efficacy and optimal duration of treatment for INH 
resistant new pulmonary TB patients have long been discussed. Treatment failure, 
relapse and acquired resistance to other first-line drugs such as RiF may occur. There 
is no evidence from definitive randomized controlled trial to determine the best 
treatment for various patterns of drug resistance [260] . 
Several studies have demonstrated that there is an association between the kalG 
S315T mutation and high-level INH resistance, and an association between inhA 
mutation and low-level INH resistance [3, 172, 177, 178]. A US study concluded that 
there was no association between INH resistance mutation and clinical presentation 
but this is not surprising and the impact on treatment outcomes has not been 
established [261]. A study in Korea evaluated alternative treatment regimens for INH-
resistant pulmonary TB such as 2RHZEIlORE, 2RHZE17RE and 2RHZE/4REZ. They 
concluded that the overall success rates were 90% for 2RHEZII ORE, 92% for 
2RHEZ/4REZ and 100% for 2RHEZ17RE. However, this study was too small to draw 
robust conclusions (n=39 patients) [262] and efficacy under study conditions is likely 
to vary substantially from effectiveness under programmatic conditions. From a study 
conducted by Ormerol et aI, a regimen of 2RZE17RE may be possible for the 
treatment of isoniazid-resistant organism if given under close supervision [263]. In 
another study in Southeast Texas, severallNH-resistant treatment regimens were also 
compared. They concluded that treatment durations should be over 7 months, and 
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twice-weekly treatment regimens were associated with relapse, whereas thrice-weekly 
and daily treatments performed similarly [264]. According to WHO, regimens that are 
suggested for INH resistant pulmonary TB (+1- SM resistance) consist of RiF, PZA 
and EMB for a minimum duration of treatment of 6-9 months. They advise that a 
fluoroquinolone may be added to the regimen to strengthen it for patients with 
extensive disease [260] . Thus, there is no clear evidence of the optimal regimen for 
INH-resistant TB and adequately powered randomized controlled trials are needed. 
1.5 Anti-TB drug-induced hepatotoxicity 
The most frequent adverse reactions to TB treatment are hepatotoxicity, skin 
reactions, and gastrointestinal and neurological disorders [265]. Anti-TB drug-
induced liver injury (DILl) or anti-TB drug-induced hepatotoxicity (ATDlH) is a 
significant problem which causes substantial morbidity, and mortality of 6%-12% if 
TB drugs are continued after the onset of symptoms [233]. Asymptomatic 
transaminase increases are common during TB treatment but hepatotoxicity can cause 
death if it is not recognized early. Adverse effects in general, and A TDIH in 
particular, will diminish treatment effectiveness because of nonadherence, and they 
may eventually contribute to treatment failure, relapse or drug-resistance if poorly 
managed. Isoniazid, rifampicin and pyrazinamide, which are metabolized by the liver, 
are potentially hepatotoxic drugs. 
1.5.1 Functions of the liver 
The liver has a central role in drug metabolism and detoxification. After drugs are 
ingested, the splanchnic circulation carries them directly into the liver. Metabolic 
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enzymes convert them through three pathways. Most anti-TB drugs require 
biotransformation with phase 1 and phase 2 enzymes in order to become water-
soluble compounds. The phase 1 pathway makes use of enzymes for oxidation, 
reduction and hydrolysis of the cytochrome P450 class. The Phase 2 pathway includes 
glucuronidation, sulfation, deacetylation and deamination which forms compounds 
ready for excretion. In the phase 3 pathway, the cellular transporter proteins excrete 
these compounds into bile or the systemic circulation. Activity of these pathways is 
influenced by both endogenous and exogenous factors, including circadian rhythms, 
hormones, cytokines, morbidities, genetic factors, general health and nutrition status 
of an individual and presence and dose of chemicals. 
In phase 1, oxidation or demethylation that occurs with the aid of cytochrome P450 
(CYP450) enzymes which usually produces toxic intennediates. In phase 2, a large 
water-soluble compound that transformed by glucuronidation or sulfation results in 
eliminated non-toxic metabolites. Glutathione, an enzyme in second phase, is 
responsible for detoxification, for example, enzyme glutathione S-transferase can bind 
to toxic compounds. Transporters, such as P-glycoprotein, nuclear receptors and 
pregnane X-receptor, also play a critical role in the orderly elimination of drugs 
during phase 3 metabolism. 
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Figure 1-11: Six mechanisms of liver injury 
Reproduced from Lee, NEJM 2003 [266]. 
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1.5.2 Definition of Antituberculous drug-induced hepatotoxicity 
ATDIH is a clinical diagnosis of exclusion because histological samples of the liver 
are usually not obtained. Acute viral hepatitis should be considered as a differential 
diagnosis. The signs and symptoms of A TDIH are jaundice, abdominal pain, nausea, 
vomiting, asthenia, encephalopathy and fulminant hepatic failure. A TDIH ranges 
from nonspecific transaminase increase to fuminant hepatic failure. A TDIH is 
potentially fatal if not detected and managed appropriately [267]. The time of onset to 
acute liver injury is usually within one month of initiating antituberculous drugs but 
may occur later. Many definitions of A TDIH have been used in the literature but a 
consensus definition has not been reached leading to subjectivity in diagnosis and 
treatment. A common definition is an increase in serum alanine aminotransaminase 
(AL T) greater than three times the upper limit of normal (ULN) with symptoms of 
hepatitis, or five times without symptoms; and/or an increase in serum total bilirubin 
over 1.5mg/dl (l mg/dl x 17.1 = llmolll) and this is the definition used in this thesis. A 
recent consensus statement on management of HIV ITB also includes total serum 
bilirubin over 40 llmol/l as a criteria for ATDIH [268]. For patients with increase of 
liver function tests CAL T) before TB treatment, the elevation of ALT greater than 1.5 
times the baseline ALT should be considered as ATDIH. An increase in serum ALT 
(SOPT: serum glutamate pyruvate transaminase) is more specific than an increase in 
AST (SOOT: serum glutamic oxaloacetic transaminase) for hepatocellular injury, 
because abnormalities in muscle, heart or kidney also show an increase in AST [269]. 
ALT and AST levels rise following exercise, haemolysis or muscle injury and tend to 
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be higher in men, especially in persons with high body mass index. Children and the 
elderly tend to have lower transaminase concentrations. AST is higher than AL T in 
alcohol-related transaminase elevation. 
Increase in alkaline phosphate and/or bilirubin, with little or no increase in AL T, 
suggests cholestasis. An increase in serum y-glutamyl transpeptidase can differentiate 
liver-related AP increase from other organ-related AP increases. Jaundice is usually 
detected when serum bilirubin exceeds 3.0 mg/dl (nonnal total bilirubin is from 0.3 to 
1.9 mg/dl) (Jlmol/L x 0.0585 = mg/dl). 
Rechallenge with the suspected agents with AL T elevation more than two times of 
ULN and a fall in AL T with discontinuation of suspected agents may strongly support 
the diagnosis. Time interval from initiation of anti-TB drugs to occurrence of A TDIH 
is considered as the latency period, which usually ranges from 6 to 102 days (mean: 
17.35 +/- 18.67 days). The time interval between stopping INH, RiF and PZA and 
achieving normal liver function tests is considered as the normalization period, which 
usually ranges from 4-58 days (mean: 18.71 +/- 11.36 days) [270]. 
1.5.3 Incidence 
The incidence of A TDIH during TB treatment has been reported at between 2% and 
28%. The incidence varies between different world regions. Asian countries, 
especially underdeveloped regions where factors such as liver disease, malnutrition 
and advanced TB disease play a role, are reported to have the highest rates of 
incidence of ATDIH [271]. From four Indian studies, the risk of ATDIH was 11.5% 
in India compared to 4.3% in Western countries [272]. Transaminase elevations are 
reported in 0.3% of all patients treated with isoniazid monotherapy [273]. In a trial of 
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a novel rifampicin and pyrazinamide prophylactic regimen for latent TB, 
hepatotoxicity occurred in 5.3% of patients [274]. When pyrazinamide was 
introduced in the 1950s, a high incidence of A TDIH was reported. This appears to be 
associated with the high dosage ofPZA used in earlier studies of 40-70 mg/kg [275], 
however, PZA is responsible for more hepatotoxicity than INH and RIF in current 
regimens. 
1.5.4 Pathological features 
INH-induced hepatotoxicity manifests as hepatocellular steatosis and necrosis, and 
toxic isoniazid metabolites bind to cell macromolecules. Hydrazine, which is the toxic 
metabolite of INH, causes steatosis, hepatocyte vacuolation and glutathione depletion. 
Lipid vacuoles and mitochrondrial swelling are found in periportal and midzonal 
hepatocytes. 
Hyperbilirubinemia is a common manifestation due to interference with bilirubin 
excretion. Centrilobular necrosis is a lesion caused by RiF, possibly associated with 
cholestasis. Lesions range from spotty to diffuse necrosis to cholestasis [276]. 
In patients who have died ofRiF- and PZA-induced hepatotoxicity, lesions are found, 
such as bridging necrosis, lymphocytic infiltration, focal cholestasis, increased 
fibrosis and micronodular cirrhosis [66]. 
1.5.5 Mechanism of toxicity 
ATDIH may result from three main mechanisms: (I) from a metabolite to cause 
direct toxicity, and/or (2) from an immunological response affecting hepatocytes, 
biliary epithelial cells, and/or (3) from idiosyncratic reactions, which are independent 
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of dosage, to affect liver vasculature [233]. Idiosyncratic reactions comprising most 
types of A TDIH may result in hepatocellular injury and/or cholestasis. In 
hypersensitivity reactions, haptens are produced by immunogenic drugs or their 
metabolites are free or bound to hepatic proteins. The processes including antibody-
dependent cytotoxic, T-cell and eosinophilic hypersensitivity responses, may be 
evoked. Tumor necrosis factor-a, interleukin (IL)-12 and IFN- yare released and 
promote hepatocellular programmed cell death (apoptosis), an effect opposed by IL-
14, IL-lO, IL-13 and monocyte chemotatic protein-I. Idiosyncratic reactions may 
recur within days to weeks after re-exposure. 
The exact mechanism of A TDIH is unknown if it is due to idiosyncratic reaction, it 
can affect any organ system. Figure 1.11 shows six possible mechanisms of liver 
injury. 
1.5.5.1 Isoniazid 
Acetylation is the main metabolic pathway of INH metabolism. INH (isonicotinic 
acid hydrazide) is acetylated by the hepatic enzyme N-acetyltransferase 2 (NAT-2) 
into acetylisoniazid, which is then hydrolyzed into acetylhydrazine and isonicotinic 
acid. Acetylhydrazine is either hydrolyzed into hydrazine or acetylated into 
diacetylhydazine and is subsequently oxidized into hepatotoxic intennediates by 
cytochrome P450 2E I (CYP2E I). A small part of INH is directly hydrolyzed into 
isonicotinic acid and hydrazine [277]. 
Previously, it was thought that acetylhydrazine was the toxic metabolite of INH but 
recently, researchers have suggested that hydrazine, not INH and acetylhydrazine, is 
more likely to be the cause of INH-induced hepatotoxicity [277]. Several hydrazine 
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metabolites, such as acetylhydrazine, hydrazones and nitrogen gas, have been 
identified. The major route of hydrazine metabolism is oxidation. In hydrazine 
reactions; nitrogen, diimide and powerful diazene reducing agents; are intermediates. 
One study on rat liver microsomes showed that nitrogen-centered radicals, which 
formed during oxidative hydrazine metabolism, probably are involved in the 
hepatotoxic process [278]. 
Cytochrome P450 2E 1 (CYP 2E 1) is involved in ATDlH because it is associated with 
the metabolism of several carcinogens and drugs, and it may be related with 
susceptibility to alcoholic liver disease and many types of cancers such as 
hepatocellular carcinoma. Three genotypes of CYP 2E 1 are c lIc 1, c 1 Ic2 and c2/c2. 
The CYP 2E 1 c lIel genotype is related to high CYP 2E 1 activity and may produce 
many hepatotoxins. Animal studies showed that isoniazid and hydrazine induce CYP 
2El activity and INH inhibited effects on CYPIA2, 2A6,2C19 and 3A4 activity. 
CYPIA2 is involved in hydrazine detoxification. CYP2EI is related to the severity of 
ATOIH [279]. 
Oxidative stress, which results from an imbalance between oxidants and antioxidants 
involving A TOIH, is still a topic for debate. Non-enzymatic and enzymatic systems 
(e.g. glutathione conjugation) are associated with the detoxification of reactive 
oxygen species. Reduced glutathione levels, activity of glutathione-S transferase, 
catalase and superoxide dismutase after the administration of INH and hydrazine, 
show that oxidative stress is involved in INH-induced hepatitis. N-acetylcysteine (a 
sulfhydryl-containing compound) has a hepatoprotective effect. Futhermore, TB 
patients with A TOIH have lower plasma levels of glutathione and higher 
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malondialdehyde, which is an oxidative stress parameter. Induced glutathione 
depletion is not directly involved in INH-induced hepatitis. One study from China 
showed that the glutathione S-transferase mu I (GSTM 1) Rsal null genotype tended 
to increase susceptibility to A TDIH but the association with A TDIB was not 
significant [280]. 
1.5.5.2 Rifampicin 
RiF is a potent inducer of cytochrome P450. The major pathway of RiF metabolism is 
desacetylation into desacetylrifampicin and hydrolysis will produce a 3-formyl 
rifampicin. The mechanism of RiF-induced hepatitis is unknown. The combination of 
RIF and INB has been associated with an increased risk of hepatotoxicity because RiF 
induces isoniazid hydrolase which increases hydrazine production, especially in slow 
acetylators [281] (figure 1.12). ATDIB of RiF has been detected in patients with 
underlying liver diseases. RiF is implicated in cholestatic A TDIH [282]. 
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Figure 1-12: Rifampicin induction of the hydrolysis pathway of isoniazid 
metabolism into the hepatotoxic metabolite hydrazine. 
Reproduced from Askgaard et al. Thorax 1995 [281] 
1.5.5.3 Pyrazinamide 
PZA (pyrazoic acid amide) is converted into pyrazinoic acid CPA) and then is 
oxidized to 5-hydroxypyrazinoic acid by xanthine oxidase. A report of a cell- line, 
animal and clinical trial from Taiwan confirmed that 5-hydroxypyrazinoic acid (5-
OH-PA) was responsible for PZA-induced hepatitis [283]. The mechanism of PZA-
induced hepatotoxicity is unknown, but it is possibly due to direct toxicity. A study 
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from Taiwan showed that slow acetylators developed A TDIH more frequently in 
anti-TB treatment with first-line (INH+RiF+PZA+EMB) drugs, specially in a regimen 
in which PZA is administered at the same time as INH, RiF and EMS [279]. The 
mechanism of hepatotoxicity of PZA is both dose-dependent (5% for a dosage of 20-
30 mglkg per day and 10% for a dosage of 40-70 mg/kg per day) [284] and 
idiosyncratic. In a cohort and case-control analysis, researchers found that adding 
PZA to INH and RiF would increase the risk of ATDIH appreciably [285]. 
1.5.5.4 Other drugs 
ATDIH occurs in about 2% of patients treated with ethionamide or prothionamide, 
and in 0.3% with PAS. Cycloserine does not appear to be associated with ATDIH 
[65]. 
1.5.6 Risk factors for anti-tuberculous drug induced hepatotoxicity 
Many risk factors for A TDIH have been reported. Older patients are at higher risk of 
hepatotoxic reactions due to the decreased clearance of drugs metabolized by CYP450 
enzymes and changes associated with ageing in liver blood flow, liver size, drug 
binding. Heptotoxicity of antituberculous drugs is 4 times higher in patients over 35 
years of age [286]. 
The risk of hepatotoxicity may be higher in women due to higher CYP 3A activity but 
studies have reported conflicting findings [287]. According to one study from Taiwan, 
abnormal baseline transaminase levels are an independent risk factor for A TDIH 
[288]. 
Extensive TB disease may be another risk factor for ATDIH. Minimal disease is 
defined as TB lesions that involve only one lobe or there is no cavitary lesion on chest 
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radiography. Extensive disease is defined as TB lesions that occupy more than two 
lobes, or in both lungs, or have cavitary or miliary images on chest X ray film. 
Patients with HIV have altered activities in the oxidative pathway so they are more 
likely to have ATOIH. HIV patients require concomitant use of anti-TB drugs and 
anti-retroviral (ARV) drugs which also have hepatotoxic effects. The use of anti fugal 
drugs (for example, fluconazole) is also a risk factor for ATDIH. 
Several studies show that hepatitis Band C coinfection increase the risk of A TOIH. In 
general, patients with pre-existent liver disease (liver cirrhosis, fatty liver or diffuse 
hepatic pathology) are at risk of hepatotoxicity [289]. In Taiwan, high initial 
HBV /HCV viral load was a significant predictor of ATOU-I [290]. From a study in 
Korea, researchers found that A TO IH occurred more frequently in Hev -seropositive 
patients during TB treatment [291]. However, using regimens containing RiF, INH, 
EMB and lor PZA after recovery from ATOIH, could be safe and successful [291]. 
Co infection with hepatitis C and HIV elevates the risk of A TOIH. Acute viral 
hepatitis is a confounding factor in patients with ATDIH. ALT, AST, bilirubin levels 
are significantly higher in patients with acute viral hepatitis, compared with patients 
with ATOIH and time taken for normalization of liver functions was significantly 
longer in patients with acute viral hepatitis compared with patients with ATOUI. 
The presence of HLA-OQB 1 *020 and the absence of HLA-OQA 1 *0 I 02 were 
independent risk factors for ATOIH with OR of 1.9 and 4.0, respectively in North 
Indian patients [292]. 
In some studies but not in others, slow acetylator genotype is a risk factor for A TOIH. 
In one study from Turkey, researchers found that slow acetylators (76.7%) have 
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higher risk of developing hepatotoxicity than intermediate (13.3%) and fast 
acetylators (10%) with statistically significant difference (p<O.OOI). They concluded 
that analysis of NA T2 polymorphism could be used before treatment in hospital to 
determine which patients are at risk of developing ATDIH [293] . 
The cytochrome P450 2EI (homozygous wild type) and the glutathione S-transferase 
(homozygous null genotype) are related to ATDIH. Genetic polymorphisms in the 
pregnane X-receptor (PXR) have a role in CYP3A4 expression and in theory, they are 
involved in susceptibility to ATDIH. 
Alcoholism is related to a higher risk of ATOIH because of enzyme induction. Daily 
TB treatment also increases the risk of ATOIH compared with thrice-weekly 
treatment but also increases the impact of intermittent non-adherence and the risk of 
treatment failure. Although some studies showed that alcohol use was a significant 
predictor of ATOIH, others found no association, although definitions of excessive 
alcohol consumption vary between studies [233]. 
Malnutrition or hypoalbuminemia (serum albumin levels of less than 3.5 mg/dl) is a 
risk factor for A TDIH. Patients with low albumin «3.5 mg/dl) have been reported to 
have three times higher risk of A TDIH [294]. Body mass index (BMI= body weight 
(kg) / (height (m))2) of 20kg/m2 or less is an independent predictor of ATDIH, 
probably due to the depletion of glutathione stores and impaired drug metabolism by 
the liver [295]. 
1.5.7 Management 
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The management of A TO IH is shown in figure 1.13. In the cases of moderate or 
severe drug-induced hepatotoxicity, treatment should be interrupted and after hepatitis 
has resolved, treatment should be reintroduced. Guidelines differ on the pattern of 
reintroduction and in practice many clinicians follow protocols derived from 
individual experience and the clinical history of the patient. British Thoracic Society 
(BTS) and American Thoracic Society (A TS) guidelines recommend reintroducing 
drugs sequentially while the Task Force of the European Respiratory Society 
recommends restarting all drugs simultaneously [296]. According to a study, 
researchers found that the recurrence rate of A TOIH was not significantly different 
between the 3 different reintroduction regimens [292] . 
The majority of patients have successful reintrodution of anti-TB drugs and tolerate 
reintroduction of INH, RiF and PZA. Another study showed that the risk of 
developing ATOIH after reintroducing all anti-TB drugs (RiF,INH,PZA) was 24% 
[270]. However, reintroducing INH, RiF and PZA after normalization of liver 
function tests should be approached with caution in patients with more severe 
ATDIH. After reintroduction of TB drugs, regular monitoring of liver function tests 
such as serum AL T, AST, and bilirubin levels should be done every week for the first 
month, every 2 weeks in the second month, and at the end of the third month. After 
the third month, laboratory testing should be performed when indicated. 
Regimen selection for patients with A TDIH: In regimens without PZA, RiF, INH 
and EMB might be used for 9 months until OST of the Af.lb isolate is completed. 
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In patients with cirrhosis, RiF and EMB and quinolones (Ievofloxacin, ofloxacin and 
gatifloxacin) or cycloserine should be used for 12-18 months. For patients with 
encephalopathic liver disease, the regimen consists of EMB, fluoroquinolone, 
cycloserine and capreomycin (or aminoglycoside) for 18 and 24 months. In one study 
from the USA, the researchers investigated the regimen of ethambutol, ofloxacin and 
streptomycin (EOS) for the first three months and nine months in continuation phase 
in patients with liver injury (3SEO/9EO) and they concluded that in the patients with 
severe liver disease, this regimen was well-tolerated and effective in 85% of patients 
[297]. Potential side effects with fluoroquinolone are nausea and vomiting, severe 
anaemia, conjunctivitis, pruritic rash, convulsions, arthralgia, vision change and 
giddiness [298]. 
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Figure 1-13: Monitoring for hepatotoxicity during treatment ofTB disease 
Reproduced from Saukkonen et ale AJRCC2006 [233]). 
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1.6 Hepatitis B, C and Pulmonary Tuberculosis 
1.6.1 Hepatitis B virus infection and pulmonary tuberculosis 
Hepatitis B virus (HBV) belongs to the family of hepadnaviruses with a relaxed 
circular, double stranded DNA genome of approximately 3,200 base pairs [299]. 
Hepatitis B virus (HBV) infection is a major health problem and one of the most 
important infectious diseases in the world. It is estimated that about 2 billion people 
are infected, with over 350 million chronic cases and 1-2 million deaths per year. In 
Asia, the prevalence of chronic HBV infection is over 8% (300]. 
HBV is transmitted by perinatal, percutaneous and sexual exposure, or by person to 
person contact through open cuts and sores, transfusion, nosocomial infection and 
organ transplantation. HBV infection is more common in certain groups such as 
injecting drug users, persons with multiple sex partners, men who have sex with men, 
and workers who are exposed occupationally to contaminated blood and blood 
products [301]. Carriers of HBV are at higher risk of developing cirrhosis, hepatic 
decompensation and hepatocellular carcinoma [302]. Surface antigen (HBsAg) is 
detectable in the serum between 30 and 60 days post-infection. Anti-HBV surface 
antigen antibodies may develop after resolving infection or following vaccination and 
therefore a positive antibody test does not define infection. Anti-HBc antibodies 
develop in all HBV infections and persist indefinitely. 
In the acute phase following infection the incubation period lasts from one to four 
months with a serum sickness-like syndrome manifesting with fever, skin rash, 
arthralgia and arthritis. The symptoms of hepatitis are right upper quadrant 
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discomfort, nausea, jaundice and other unspecific constitutional symptoms. Alanine 
and aspartate aminotransferase concentration levels may rise to 1000-2000 lUlL. 
Fulminant hepatic failure occurs in approximately 0.1-0.5% of patients [303]. 
Hepatitis B prevalence is highest in sub-Saharan Africa and East Asia and the rate of 
HBV chronicity of the adult population of these regions is between around 5%-10% 
according to WHO data. Most patients with chronic hepatitis B are clinically 
asymptomatic, with normal physical examination but some have symptoms of fatigue. 
If symptoms are present they may include stigmata of chronic liver disease, 
splenomegaly, spider angiomata, caput medusae, palmar erythema, testicular atrophy, 
gynaecomastia, jaundice, ascites, peripheral oedema and encephalopathy with 
decompensated cirrhosis. AST and AL T enzymes show mild to moderate elevation. 
The HBV virus may be in either a high replicative state or low/non-replicative state 
during chronic infection [301]. A high replicative state results in active liver disease, 
in which elevated serum ALT, HBV DNA and HBeAg are present. For the low or 
non-replicative phase, ALT may be normal, HBeAg is not detectable but anti-HBeAg 
antibody is present. 
Inactive HBsAg carrier state is defined as (1) positive for HBsAg, (2) negative for 
hepatitis B e antigen (HBeAg) and positive for the antibody to HBeAg, (3) <105 
copies per ml serum HBV DNA, and (4) normal pretreatment aspartate 
aminotransferase (AST)I alanine aminotransferase (AL T) levels. Chronic hepatitis B 
is diagnosed according to the following criteria : (l) positive for HBsAg, (2) > 105 
copies per ml of serum HBV DNA and/or elevated AST/ALT levels before 
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undergoing antituberculosis treatment. Acute hepatitis B is diagnosed by testing for 
antibody to hepatitis B core antigen JgM (anti-HBc JgM) positivity [304]. 
Pulmonary tuberculosis patients with HBV are more likely to be sensitive to 
hepatotoxic anti TB drugs such as RiF, INH and PZA because of pre-existing hepatic 
damage, and their liver functions improve more slowly [303]. 
Patients with HBV infection have consistently been shown to have a higher rate 
hepatotoxicity on TB treatment, although the differences do not always reach 
statistical significance, probably due to study size. According to a study, in Brazil 
HBV infection showed considerably high relative risk (RR=2.91) although not 
statistically significant for anti -TB drugs induced hepatotoxicity. Using a scoring 
system and drawing a monograph, the study also shows how to estimate survival 
probabilities and median times to hepatotoxicity event for each patient [305]. In 
another study conducted in China in 2005, it was shown that the rate of 
hepatotoxicity in TB patients with HBV infection during TB treatment was higher 
than that in patients without HBV (59% vs 24%) [306]. Another study from Korea 
also showed that drug- induced hepatotoxicity occurred more frequently in HBsAg 
carriers than in control patients (8% vs 4%), although this was not a statistically 
significant discrepancy. However, the study showed HBsAg carriers with TB could 
follow standard regimens using RiF, INH, PZA and EMB by monthly liver function 
testing [307]. HBV coinfection in patients with HIV and TB is a risk factor for the 
development of severe hepatotoxicity, in which case highly active antiretroviral 
therapy (HAART) [308] and anti-TB drugs need to be stopped. In patients who are 
hepatitis B carriers receiving TB drugs, most liver dysfunction episodes are often 
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preceded by an increase in HBY -DNA levels and as a result, it may be better to 
consider the use of antiviral drugs such as lamuvidine to bring these levels down 
[309]. With these patients, regular liver function and drug monitoring are essential to 
detect asymptomatic cases before they evolve because early drug modification or 
withdrawal may prevent further liver damage and mortality. 
1.6.2 Hepatitis C virus (HCY) infection and pulmonary tuberculosis 
HCY, a member of the Flaviviridae family, is a small-enveloped virus with one 
single-stranded positive-sense RNA molecule of 9.6kb [310]. HCY is a major cause 
of progressive liver disease [311]. There are an estimated 170 million cases 
worldwide of which 80% are chronic. The complications ofHCY infection are severe 
liver fibrosis and cirrhosis. 30%-50% of individuals with cirrhosis will develop 
hepatocellular carcinoma [312, 313]. Transmission usually occurs via sexual 
intercourse with HCY-infected individuals or shared needles. A systematic review 
showed that less than 1% of subjects who are exposed to HCY through contaminated 
needle stick injury develop acute HCY infection [312]. The level of HCY viremia 
can influence the risk of infection. Specific HLA types of children can influence the 
risk of acquiring infection from infected mothers [312]. 
Common symptoms of hepatitis C are fatigue, muscle ache, loss of appetite or nausea. 
It is estimated that only one out of four individuals infected with HCY is aware of the 
disease, so HCY diagnostics should be performed in all patients with increased 
aminotransferase levels [314]. HCY RNA measurement can discriminate between 
chronic hepatitis C and resolved HCY infection. Acute hepatitis C is a condition in 
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which both anti HCY antibodies and HCY RNA are positive but this may also occur 
in cases of acutely exacerbated chronic hepatitis C. 
A study from Taiwan showed that HCY co-infection was an independent risk factor 
for hepatitis during anti-tuberculosis treatment and heaptotoxicity exacerbation was 
associated with slower recovery from hepatitis [315]. According to Ungo et al., 30% 
of HCY -infected patients developed hepatotoxicity compared to II % of non-HCY-
infected patients during antituberculosis treatment. This study also showed that 
transaminases in HCY may be normal, or wax and wane over time in a "sine wave" 
pattern [316]. K won et at. also found liver enzyme levels were more often elevated 
during TB treatment in HCY-positive patients (41%) than in control subjects (20%), 
and hepatotoxicity occurred more frequently in HCY-infected patients (13%) 
compared to controls (4%). However, they also concluded that the reintroduction of 
TB therapy with RiF, INH, PZA and EMB could be safe and successful even in 
patients with HCY infection, but monthly liver function tests should be performed 
[291]. 
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AIMS OF THE THESIS 
1) Detennine the rate of unfavourable outcome for patients with INHR TB on 
standardised treatment outcomes. 
2) Investigate bacterial factors associated with treatment failure for patients with 
INHRTB. 
3) Detennine the prevalence of hepatitis B/C infection and the incidence of 
antituberculous drug induced hepatitis among TB patients in Ho Chi Minh 
City. 
4) Investigate the impact of host factors, acetylator status and viral hepatitis 
coinfection on treatment outcome for patients with INHR TB. 
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Chapter 2 
Methods 
2.1 Study design 
2.1.1 Setting 
Ph am Ngoc Thach Hospital is responsible for TB control in HCM City and the 
southern provinces. It is a tertiary referral hospital and also functions as a primary TB 
hospital serving the local community, with around 750 staff and over 800 beds. In 
2012, the hospital served 23,342 in-patients and 270,035 patients in total. 
In Ho Chi Minh city, there are 24 District TB Units (DTU) namely districts 1,2,3,4, 
5, 6, 7, 8, 9, 10, 11, 12, Binh Chanh, Binh Tan, Binh Thanh, Can Gio, Cu Chi, Go 
Yap, Hoc Mon, Nha Be, Phu Nhuan, Tan Binh, Tan Phu and Thu Duc (15 urban 
districts and 9 rural districts). DTUs take responsibility for the diagnosis and 
management of TB patients. The number of staff at each DTU is dependent on the 
patient numbers but may include doctors, nurses, technicians and social workers. 
Diagnosis of TB at DTUs is a passive process. When patients have symptoms 
suggestive of TB, they self-present at the DTU for sputum examination and chest X 
ray. DTUs also have facilities for acid fast bacilli (AFB) direct smear. If a DTU is 
located within a hospital, the other laboratory tests are available. However, culture 
and DST are not available in any DTU. Sputum samples are transferred to PNT 
Hospital for testing if needed. In case there are any difficult cases in diagnosis, 
treatment and management such as how to handle side effects, staff at DTUs will seek 
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advice from P T Hospi tal doctors. Patients Ill ay se lf-present at P T Il osp ital for 
diagnos is and initiati on of treatrnen t but are generall y referred to their hOlll e DTUs fa r 
con tinued management once stab le. 
District 6 DTU 
A14/1 Ba Hom 
Ward 13 
District 5 DTU 
Pham Ngoc Thach Hospital 
120 Hung Vuong 
Ward 12 
Phu Nhuan DTU 
Ho Chi Minh City 
Binh Thanh DTU 
104/8 Dinh Bo Unh 
Ward 24 
Distric t 1 DTU 
23 1 Tran Hung Dao 
Co Giang Ward 
District 4 DTU 
396/27 Nguyen Tat Thanh 
Ward 18 
Figure 2-1 :Ma p showing geogra phic location of pa r ticipa tin g districts in H o C hi 
M inh C ity 
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2.1.1.1 Participating sites 
Four DTUs (district 6,4, Binh Thanh and Phu Nhuan) and the out-patient department 
at PNT Hospital were initially chosen for participation in the study based on staff 
resources and patient burden (figure 2.1). Recruitment at these sites commenced in 
December 2008. After one year of recruitment, the number of INH resistant 
pulmonary TB patients fell short of the expected target. In October 2009, four 
additional DTUs (district 1, 3, 8 and Tan Binh) were invited to join the study and 
recruitment at these sites began in December 2009. The study completed recruitment 
at all sites in June 2011. District 3 was withdrawn from the study in early 2010 due to 
low recruitment (9 patients). 
In summary, eight units participated in the INH study namely PNT Hospital out-
patient department, district 6,4,1,8, Phu Nhuan, Binh Thanh and Tan Binh. Table 2-1 
shows the number of health staff in DTUs participating in the study. 
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District Doctor Nurse Nurse LAB Others Total New smear positive 
assistant technician pulmonary TBcasesl year 
District 2 1 2 1 pharmacist of middle degree. 6 300 
6 
District 1 2 2 physician assistant 8 363 
4 3 pharmacist of middle degree 
Binh 1 3 2 2 pharmacist of middle degree. 11 416 
Thanh 2 physician assistant. 
1 midwife 
Phu 1 2 1 2 physician assistant 6 140 
Nhuan 
Ph am 13 36 6 3 administrative staff. 58 149 
Ngoc 
Thach 
District 2 3 1 3 physician assistant. 10 177 
1 1 nurse assistant 
District 1 3 2 1 pharmacist 10 456 
8 3 physician assistant 
Tan 1 3 2 1 physician assistant 9 252 
Binh 1 pharmacist of middle degree 
1 nurse assistant 
-----
-_ .. 
Table 2-1: The number of health staff in DTUs participating in the study and the number of patients with new smear positive 
pulmonary TB in 2007 
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2.1.2 Sample size 
It was estimated that approximately 25% of primary isoniazid-resistant cases would 
fail or relapse [317], half of which would be primary MDR-TB; 12.5% of primary 
isoniazid-resistant, non-MDR cases were therefore expected to fail treatment. 
Screening 2,200 patients was expected to yield approximately 550 isoniazid-resistant 
cases. With an anticipated 10% drop-out rate [37] [318], there would be follow-up 
data on 500 isoniazid-resistant cases. Approximately 200 (40%) of these patients 
would be infected with Beijing genotype strains. The study would therefore have 90% 
power to detect a 2-fold increase in failure rate among isoniazid-resistant Beijing 
genotype isolates. 
2.1.3 Recruitment 
From December 2008 to June 2011, all adult patients presenting to the units (districts 
6, 4, Phu Nhuan, Binh Thanh and PNT Hospital out-patient department) who were 
newly positive smear pulmonary TB cases, were asked to participate in a screening 
study. From November 2009 to June 2011 we sped up the recruitment by including 4 
further districts (district 1,8,3 and Tan Binh) in the study. All patients presenting to 
these units were evaluated for inclusion in the screening study and invited to 
participate if eligible. If the patients agreed, one sputum sample for MODS and a 
sample of blood were taken and the blood sample was stored for host genetics study. 
The patients with INH resistant TB based on MODS were asked to participate in the 
INH study. No other tests were conducted on patients with INH sensitive T8. These 
patients proceeded with standard NTP treatment procedures and were not followed up 
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beyond 8 months. Standard outcome data (WHO criteria) were collected on all 2,200 
patients screened. If the INH resistant TB patients agreed to participate in the INH 
study, they followed the INH study protocol. Recruitment took two years, followed 
by 2 years follow-up. Results of treatment completion (8 months) only are reported in 
this thesis. 
Patient information sheets and informed consents (Appendix A and B) in Vietnamese 
language for both screening and INH study were given to patients. The aims of the 
study, study method, duration of the study, benefits and discomfort, confidentiality 
and responsibility were explained in detail to the patients and/or their families. 
Patients had the right to refuse to participate in the studies or withdraw from the study 
at any time they wanted without affecting medical care. 
2.1.3.1 Inclusion criteria for screening 
1. Negative HIV test. 
2. Written informed consent. 
3. Smear positive pulmonary TB. 
2.1.3.2 Exclusion criteria for screening 
1. Withhold/unable to consent. 
2. Previous TB treatment. 
3. HIV infected. 
4. Pregnancy. 
5. Under 18 years of age. 
6. Would receive DOTS outside study centers. 
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2.1.3.3 Post-screening inclusion criteria 
I. Negative HIV test. 
2. Written informed consent. 
3. Smear positive pulmonary TB. 
4. Isoniazid resistant. 
2.1.3.4 Post-screening exclusion criteria 
I. Withhold/unable to consent. 
2. Previous TB treatment. 
3. HIV infected. 
4. Pregnancy. 
5. Under 18 years of age. 
6. Would recieve DOTS outside study centers. 
7. Isoniazid susceptible. 
2.2 Ethics 
The INH study protocol was approved by the Institutional Review Board (lRB) at 
Pham Ngoc Thach Hospital and then by the HCM City Health Services Department. 
Two individual informed consents (screening study and INH study), which were also 
approved by IRB of PNT Hospital, were signed by patients enrolled into the 
respective studies. The study was also approved by the Oxford Tropical Research 
Ethics Committee (OXTREC) with the code ofOXTREC 030 07. 
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2.3 Case Record File (CRF) (Appendix C) 
For screening CRF, data were recorded including study code, study unit, date 
presenting at admission centre, and date of screening. Other demographic data were 
obtained such as patient name, age, gender, ethnicity, body weight, occupation, 
address, duration of illness, date of X ray and X ray result, date of start of treatment, 
date of initial sputum examination, regimen for treatment, and date of sputum 
examination after 2 months, after 5 months and after 8 months (completion of 
treatment) . After 8 months, outcome of completion of treatment was recorded 
according to NTP guideline (as cured or completed treatment or died or failed or 
defaulted outcome) . At the screening stage, 2 mls blood for host genetics (for a 
genome wide-association study, not reported in this thesis) and 2 mls blood for HIV 
testing were drawn. One sputum sample for MODS testing was sent to PNT Hospital. 
For patients recruited to the second stage (INH study), the following information was 
also recorded: symptoms {cough, hemoptysis, fever, :;weating, weight loss (over 10% 
of body weight), chest pain and malaise}, TB contact history, past medical history, 
social history, medication history, hepatitis evaluation (as risk factors for hepatitis, 
examination findings) . Any additional drugs taken by patients other than standard 
DOTS therapy were also recorded during the 8-month treatment regimen. Hepatitis 
evaluation such as symptoms and liver function tests, and side effects were recorded 
at month 1, month 2, and at month 3. At month 5 and 8, body weight and symptoms 
were evaluated. 
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Sputum culture testing at month I, month 2, month 5 and month 8 were conducted 
and the results were recorded in the files. The results of treatment after 8 months were 
evaluated. Patients were followed up for 16 months more (total for treatment and 
follow-up is 24 months). At month 12, 18 and 24, patients were invited to come to 
centres for examination. Body weight and symptoms were recorded, chest 
radiography and sputum culture tests were conducted. Patients were classified as 
relapsed based on the criteria from NTP guideline (patient has a bacteriologically 
confirmed TB disease after he or she was successfully treated during an 8-month 
previous episode). DOTS administration record, with body weight, types of 
medication, and doses of medications, were completed in by DTU staff. 
In INH study, at month 0, 14 mls blood for examination were taken: 2mls for 
International Normalized Ratio (INR), 2 mls for urea, electrolytes, creatinine and liver 
function test (AL T, AST , bilirubin , alkaline phosphate, protein levels and 
albumin/globulin ratio ), 4 mls for serology, 4 mls for viral load and 2 mls for NAT-2 
testing. At month 1, month 2 and month 3, only 12 mls blood as mentioned above 
were taken (because 2 mls blood for NAT-2 were not taken). All results of blood tests 
were recorded in the file. 
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Study outline (figure 2.2): 
1. Recruit 2200 consecutive HIV negative, primary smear-positive 
pulmonary TB patients presenting to PNT TB hospital out-patient 
department and 7 DTUs. Consent for HIV test and isoniazid resistance 
screening. Consent for genetics study (N=2200) and 2 ml blood stored. 
2. Smear positive sputum screened for isoniazid resistance by MODS 
testing conducted at PNT hospital. We estimated 550 patients with 
isoniazid resistant TB will be recruited into the study. 
3. Enrol isoniazid resistant patients with written informed consent. 
4. DNAs were extracted from all isoniazid resistant isolates enrolled into 
the study and transferred to OVCRU. 
5. Isoniazid resistant isolates will be screened for molecular genetic 
mutation at katG 315 or inhA-15 by MAS PCR and sequencing at 
OUCRU. Positive cultures will be genotyped by large sequence 
polymorphism typing. Minimum inhibitory concentration (MIC) 
testing for INH at 6 drug concentrations on Lowenstein-Jensen media 
will be performed at PNT. 
6. Obtain 14ml blood sample for host genetic NA T2 testing (OUCRU), 
liver function test, hepatitis Band C screening and to confirm HIV 
status (PNT). An aliquot of blood will be stored for hepatitis Band C 
viral load testing, if serology is positive. 
7. Evaluate for hepatotoxicity at month 1,2 and 3. 
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8. Record data on: age, gender, HIV status, hepatitis risk factors in 
addition to socioeconomic and demographic data. 
9. Patients will be followed-up through their DTUs or PNT. 
10. Patients presenting with symptomatic hepatotoxicity at any time will 
be managed according to Vietnamese NTP guidelines. Retrospective 
viral load testing will be done on stored samples from these patients 
(OUCRU). 
11. At 1 month 12 mls blood LFT (additional) (PNT), culture 
( additional)(PNT). 
12. At 2 months 12 mls blood LFT (additional besides routine tests), 
sputum smear (routine), culture (additional test on routine sample) 
(PNT). 
13. At 3 months 12 mls blood LFT (additional) (PNT). 
14. At 5 months, sputum smear (routine), culture (additional test on routine 
sample). 
15. At 8 months, sputum smear (routine), culture (additional test on routine 
sample). This thesis reports data only to this timepoint. 
16. At 12 months: symptomatic evaluation for relapse/failure, sputum 
smear plus culture if sputum produced. 
17. At 18 months symptomatic evaluation for relapse/failure, sputum 
smear plus culture if sputum produced. 
18. At 24 months symptomatic evaluation for relapse/failure, sputum 
smear plus culture if sputum produced. 
139 
INH study recruitment flow chart 
Patient presents to OTU/PNT OPO 
Patient identified as smear positive 
D 
Routine NTP 
practice 
Patient asked for consent to screening when informed smear positive. if consent given 
sputum sample taken and sent to PNT for MODS testing 
D 
I -MODst;s~1 
Store isolate I \==lI INH sensitive 
D 
Patient follows normal NTP 
process. Eight month 
outcome data collected. 
INH resistant Ie=> 
D 
Store isolate and 
conduct conventional 
OST. ONA>OUCRU. 
Patient asked for consent to 
study. If consent given collect 
blood for LFT and follow study 
protocol. Follow-up for 2 years 
Figure 2-2 : INH study recruitment flow chart 
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2.4 Smear 
The standard operating procedures for smear perforn1ed at PNT Hospital and DTUs 
are based on international guidelines from WHO and CDC USA [65, 69, 319]. 
Patients with symptoms suggestive of pulmonary TB were requested to provide 
sputum samples. The patients were asked to inhale deeply 2-3 times, then cough up 
and spit sputum in the sputum containers which were labeled with the laboratory 
serial numbers written on it. The sputum should be of good quality with thick, 
purulent materials and sufficient volumes (about 2-3 ml). The sputum was kept in 
containers with tightly secure lids and kept away from the sun and heat. The sputum 
specimens were transported to the laboratory as soon as possible (daily on weekdays 
and not over 3-4 days from collection). 
Slide for smear should be new, unscratched and labeled with laboratory serial number. 
Smears were made from purulent portion of the sputum using bamboo stick. Sputum 
was spread on the slide about 2 cm x 3cm in size with good density (not too thick and 
not too thin). The smear was dried for 15-30 minutes and passed over the flame 3-5 
times for 3-4 seconds each time. The smear was then stained by Ziehl Neelsen method 
(stained with Fuchsin-phenol 0.3%, removed with alcohol-hydrochloric acid 3%, and 
stained with methylene blue 0.3%). 
Microscopy smears were graded and results were recorded in laboratory form and 
laboratory register book as per Table 2-2 below: 
141 
Table 2-2 : Smear microscopy standardized quantitation scale 
IVA TLD. Technical Guide: sputum examination for tuberculosis by direct 
microscopy in low income countries. Fifth edition. 2000 [320] 
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2.5 HIV testing 
All patients were tested for antibodies to human immunodeficiency virus (HIV) in 
routine practice. A sample of 3 mls blood from each patient at DTUs was taken and 
transferred to PNT laboratory for HIV testing according to standard protocols. 
Samples were tested by ELISA and positive results were confirmed by rapid test and a 
second ELISA. The results were available after 1 week. There are three tests in 
routine use including Elisa Genscreen HIV 112, rapid test (Biorad, USA) Determine 
HIV 112 (Abott, Japan) and Murex Ag/Ab combination (Murex Diagnostics, USA) to 
confirm HIV infection. The HIV testing in HCM City is sponsored by the CDC USA. 
2.6 MODS 
Equipment requirements for MODS are a level 2 Biological Safety Cabinet, inverse 
light microscope, tissue culture plate, consumables and incubator. MODS is a 
technique for the rapid detection of Mtb. MODS testing was performed by 
technicians, who were not aware of the clinical diagnosis, at PNT hospital. One 
sputum sample from smear positive or another sputum sample from each new 
pulmonary TB patient at units was transferred to laboratory at PNT Hospital for 
MODS screening. Sputum samples were homogenized and decontaminated by 
Sputaprep (NaOH-N-Acetyl-L-Ccystein 2%). The processed samples were aliquoted 
for identification of Mtb and DST by MODS. 
The MODS method was performed as described in Park et al. [321] using the minor 
modification described by Caws et al. [87]. For each processed sample, 2 drug-free 
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wells (control wells), 1 INH-containing well and 1 RiF-containing well were set up. 
MODS medium was prepared with 5.9 g Middlebrook 7H9 broth (Difco, Sparks, 
MD), 3.1 ml glycerol and 1.25 g Bacto casitione (Difco, USA) in 880 ml distilled 
water. This medium was autoclaved, filtered and stored in 4.5 ml tubes at 4°C. Each 
new batch of medium was tested for sterility by incubating one aliquot at 37°C for 1 
week. Before use, 0.5 ml OADC (oleicacid, albumin, dextrose and catalase), 0.5 ml 
processed sample and 100 III PANTA (antibiotic medium supplement) were added 
into each 4.5 ml tube. Nine hundred microlitres of the suspension was then transferred 
to each of four wells in a 48 well-plate as described above. Next, 100 III distilled 
water was added into the control wells. Finally, 100 III INH 4 Ilg/ml (Sigma) or 100 
III RiF 10 Ilg/ml (Sigma) was added to the INH-containing well and RiF-containing 
well, respectively. The final concentrations ofOADC and PANTA in each well were 
10% and 20 11 11m I. The drug concentrations in each well were 0.4 flg/ml for INH and 
1 flg/ml for RiF. One susceptible isolate (H37Rv), one INH-resistant clinical isolate 
and one RiF-resistant clinical isolate were inoculated to the first plate each day. 
Resistant control isolates are well-characterised clinical isolates from Ph am Ngoc 
Thach laboratory used as routine controls for all DST procedures. A McFarland 0.5 
(approximately 104 CFU/ml) suspension of each isolate was made and diluted 100-
fold (l02CFU/ml). A 0.5 ml volume of the final suspension was used as the inoculum. 
The plate was incubated at 37°C, and the results were recorded on alternate days from 
day 5 to day 15 and twice a week from day 16 to 1 month. Any cord formation in at 
least one control well was recorded as a positive MODS culture. If there was any cord 
formation in both control wells, the drug containing wells were read. If cords were 
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detected in only one control well, MODS-DST was recorded as un interpretable for 
technical analysis. Any isolate with growth in both the control and drug-containing 
wells was recorded as resistant. If any isolate with growth was observed in control 
wells but not in the drug-containing wells, a susceptible result was recorded for the 
relevant drug. Contamination was recorded if there was any growth or turbidity in any 
negative control well. 
Mello et af. showed that if INH 0.1 Jlg/ml was used for the MODS assay, the 
sensitivity of DST-MODS for detection of INH resistant isolates increased to 96.7% 
[322]. In this study, INH 0.4 Jlg/ml was used until September, 2010 when the 
concentration of INH was reduced to 0.1 Jlg/ml to increase detection of INH resistant 
cases. 
2.7 Culture, identification and drug susceptibility testing 
2.7.1 Culture 
All cultures positive by MODS (control wells) were subcultured on LJ medium m 
duplicate and incubated at 37°C for several weeks. These isolates were then subjected 
to standard biochemical identification tests, DNA extraction [323] and archiving. 
For culture on Lowenstein-Jensen medium performed according to International 
guidelines [76, 319], the neutralized deposit from MODS were inoculated onto 2 
tubes of LJ medium. The LJ tubes were incubated for 72 hours at 36°C_37°C in a 
horizontal position with the caps loosened. Then, LJ tubes continued to be incubated 
at 37°C for 8 weeks. The growth of bacteria was noted weekly. The result was 
released at week 4 and then week 8 (if the results were negative at week 4). The 
growth of typical TB strains is 'rough, tough and buff'. 
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2.7.2 Identification 
The identification of Mtb cultures was performed according to WHO guidelines 
based on a combination of observed colony morphology and results of biochemical 
tests including niacin, catalase and nitrate reductase [77]. 
2.7.3 Drug susceptibility testing 
Proportional 1 % phenotypic DST method using Lowenstein-Jensen medium was 
performed at the reference TB laboratory at Pham Ngoc Thach Hospital, which is 
accredited by the Supranational TB Reference Laboratory Network of Western 
Pacific Region (Adelaide, Australia) following international and national guidelines 
[319]. This method determines the resistant proportion of Mlb to each drug by 
comparison of growth rate of Aftb on drug-free with drug-containing media. A pure 
culture of tubercle bacilli in the active phase of growth at 4 weeks was used for the 
indirect method. A fully susceptible culture of Mlb strain H37Rv was used as control 
strain. 
For all four drugs lNH, RiF, SM and EMB, the critical concentrations are 0.2 ~g/ml, 
40 ~g/ml, 4 ~glml and 2 ~g/ml respectively with the critical proportion of 1 %. The 
first reading of drug susceptible testing result was done at 28 days of incubation. If the 
result was negative, the cultures were incubated for a further two weeks and read 
again at 42 days. 
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2.8 MIC 
INH antibiotic powder (Sigma, Germany) was used for determination of the INH MIC 
concentration. 20 Ilg INH powder was dissolved in 10 ml sterile water (solution I). I 
ml solution 1 was added to 9 ml sterile water (solution 2). The following were INH 
concentrations for MIC: 0.2 Ilg/ml (I ml solution 2), I Ilg/ml (0.5 ml solution I), 2 
Ilg/ml (I ml solution I), 4 Ilg/ml (2ml solution 1), 8 ).lg/ml (4 ml solution 1) and 16 
).lg/ml (8ml solution 1). 
Using the critical concentrations of INH at 0.2 Ilg/ml, I ).lg/ml, 2 Ilg/ml, 4 Ilg/ml, 8 
Ilg/ml and 16 ).l/ml and with the critical proportion of 1 %, the strain was classified as 
susceptible at each concentration if the proportion of resistant bacilli was below 1%, 
and resistant if above 1 % . 
2.9 DNA extraction 
DNA extraction was performed using the CT AB (cetyl trimethylammoniulTI 
bromide)1 chloroform method after culture on LJ [323]. The purified DNA was 
dissolved in Tris-EDTA (ethylenediaminetertraacetic acid) buffer, quantified, diluted 
to the final 15 ng/).ll concentration and stored at -20°C. 
2.10.1 Multiplex Allele Specific PCR (MAS PCR) to detect katG and ;1l"A gene 
mutations 
Multiplex allele-specific PCR (MAS-PCR) is an inexpensive method that was 
developed as an in-house rapid drug resistant assay. MAS-PCR was performed to 
detect mutations in kalG (S315T) and inhA (C- I 5T) genes for INH resistance. MAS-
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PCR cannot be used to rule out true resistance because approximately 20% of INH 
resistant isolates will not have mutations in the targeted gene sites. 
A MAS-PCR was designed with three primer pairs by Dau Quang Tho [324]. One 
pair targets Hsp65 which is specific to Mtb and serves as control. A second primer 
pair targets the inhA promoter region, with the reverse primer designed to detect 
mutation C-15T in this region. The third primer pair is located inside the katG gene 
where forward primer will yield a PCR product if the isolate is of the wild type. 
Each PCR reaction contained 1 U Taq DNA polymerase (Bioline London, UK), 0.2 
mM each of dNTP (Roche, Lewes, East Sussex, UK) and 150-250 nM of primers and 
2 mM MgCb. As serial dilution of genomic DNA showed that 15 ng of genomic 
DNA was required to obtain reliable identification of the mutations, 15 ng genomic 
DNA was added. 
All samples were amplified under the same thermocycling conditions: the initial 
denaturation step at 95°C for 2 minutes, followed by 35 cycles at 95°C for 20 s, 62°C 
for 20-60 s (60 s for the first 10 cycles, 20 s for the latter 25 cycles), nOc for 40 sand 
a final step at nOc for 5 minutes to complete all reactions. The PCR reactions yielded 
two bands for wild type isolates, a single band for katG315 mutants and three bands 
for isolates mutated at inhA C-15T, visualized by 2% agarose gel electrophoresis (20-
40 minutes at 140V). The largest band of 656 bp represents the Hsp65 gene of Mtb. 
The second band of 329 bp represents the katG315 wild-type; the isolates without this 
band have a mutation at katG315 and are therefore INH-resistant. The smallest band 
of 174 bp represents isolates carrying the C-15T mutation in the inhA promoter, and 
are thus INH-resistant. 
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All primers were designed using Primer Express version 2.0 software (Applied 
Biosystems Inc., Foster City, CA, USA). The specificity of the primers to Mrb was 
tested in silico and in vitro with Enterobacteriacae Klebsiella spp., K.oxytoca, K. 
pneumoniae, Escherichia coli, Enterobacter cloacae, Citrobacter freundii, Pantoca 
spp, and atypical mycobacteria M. avium and M.kansasii. 
2.11 Genotype (Large Sequence Polymorphism) 
Isolates were typed for large sequence polymorphisms (LSP) at RD105 (East Asian 
lineage including the Beijing genotype) and RD239 (Indo-Oceanic lineage) to assign 
major geographical clades. Isolates with neither deletion were assigned to the Euro-
American clade on the basis ofspoligotyping patterns [128,325]. 
RDlO5: PCR mix was made based on the following components: ELGA water, buffer 
(w/o MgCh, EHF), dNTPs, MgCh, RDI05F, RDI05R, EHF Taq, DNA template. 
These components create a volume of 15 Jll. PCR programme was set up as follows: 3 
minutes denaturation at 95°C, followed by 25 cycles of 30 seconds at 95°C, 15 
seconds at 64°C and 4 minutes at nOc, and a final 6 minutes extension at nOc. 
Subsequently, the PCR product was subjected to electrophoresis on a 1% agarose gel 
in IX TBE buffer at l20V in 40 minutes. Expected PCR product sizes are positive 
control- H37Rv of 4kb and deleted product of850 bp. 
RD239: PCR mix was made based on the following components: ELGA water, buffer 
(w/o MgCh, EHF), dNTPs, RD239F, RD239R, MgCh, Taq (bioline), DNA template. 
These components create a volume of 15 Jll. PCR programme was set up as follows: 3 
minutes denaturation at 95°C, followed by 25 cycles of 30 seconds at 95°C, 30 
seconds at 64°C and 30 seconds at noc, and a final 6 minutes extension at nOc. 
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Subsequently, the PCR product was subjected to electrophoresis on a 1% agarose gel 
in IX TBE buffer at 120V in 40 minutes. Expected PCR product sizes are positive 
control- H37Rv of 1.8kb and deleted product of900 bp. 
RDISO: PCR mix was made based on the following components: ELGA water, EHF 
buffer with MgCI2 (Roche), dNTPs (Roche), RDI50F, RDI50R, EHF Taq (Roche), 
DNA template. These components create a volume of IS J.d. PCR programme was set 
up as follows: 2 minutes denaturation at 94°C, followed by 30 cycles of IS seconds at 
94°C, 30 seconds at 64°C and 2 minutes and IS seconds at 68°C, and a final 7 minutes 
extension at nOc. Subsequently, the PCR product was subjected to electrophoresis on 
a 1 % agarose gel in IX TBE buffer at I20V in 40 minutes. Expected PCR product 
sizes are positive control- H37Rv of3266 bp and deleted product of 779 bp. 
2.12 Host genetics (NAT2) 
II1ustra ™ DNA Extraction Kit BACC2, (GE Healthcare UK Limited, UK) was used 
to extract genomic DNA from peripheral blood samples following the manufracturer's 
protocol. The procedure includes cell lysis, deproteinisation, DNA extraction, DNA 
precipitation and DNA washing. The NAT-2 genotype was determined by polymerase 
chain reaction and sequencing PCR of NAT -2. PCR was performed using the primers 
TGGGCTT AGAGGCTATTT and GAGTTGGGTGA T ACA T ACAC in a final 
volume of 2S JlI at the following setting: 4 minutes denaturation at 95°C, followed by 
30 cycles of 30 seconds at 9SoC, 30 seconds at 58°C and 30 seconds at noc, and a 
final 2 minutes extension at nOc. Subsequently, the PCR product was sequenced for 
NAT-2. 
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The human NAT -2 gene contains 870 nucleotides encoding a protein with 290 amino 
acids. Nine point mutations have been identified: NAT2-191, NAT2-282, NAT2-34 I , 
NAT2-434, NAT2-481, NAT2-590, NAT2-803, NAT2-845, NAT2-857. Recently, a 
new mutation NA T2-759 was found in a slow acetylator. These mutations occur alone 
or in combination to yield 14 mutant alleles including NAT2*5A, 58, 5C, 6A, 68, 
7A, 78, 12A, 128, 13, 14A, 148, 17, 18. The wild-type allele is NAT2*4 and 
NAT2*5A,58,5C,6A,6B,7A,7B,14A,148 alleles encode enzymes with lower 
acetylation activities [326]. 
A consensus nomenclature for arylamine N-acetyItransferases was set up in 1995. 
Since that time, many new arylamine N-acetyltransferase alleles have been detected. 
The first International Workshop for Arylamine N-acetyltransferases was held in 1998 
to discuss arylamine N-acetyltransferase gene nomenclature. In this workshop, NAT 
was designated as the official gene symbol of arylamine N-acetyltransferase. The 
current nomenclature that is available to the international scientific community can be 
found at http://nat.mbg.duth.gr 
Phenotypes were predicted from genotypes as determined in a study correlating 
caffeine metabolites with NA T2 genotypes in a healthy volunteer cohort from 
OUCRU staff (Figure 2.3, thesis of Dau Quang Tho). Polymorph isms at nucleotide 
number T341 C, G590A and G857 A were found to define the acetylator phenotype in 
Vietnamese individuals. Individuals with homozygous mutations in one of these loci 
or heterozygote at 2 or more loci were slow acetylators. 
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Figure 2-3: Acetylator status from the AAMU/(AAMU+1 X+1 U) ratio and the 
corresponding genotypes deduced from polymorphism at NAT2 allele in 37 healthy 
Vietnamese volunteers 
Bars in the plots show mean and 95% CI of the ratio associated with each genotype. 
Differences between the ratio for each NAT2 genotype were calculated pairwise by two-
way AN OVA and showed statistical significance, p<O.OOl). 
Reproduced from the thesis of Dau Quang Tho. 
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2.13 Blood tests 
2.13.1 International Normalized Ratio (INR) 
Two mls blood sample was drawn into a test tube containing liquid sodium citrate as 
an anticoagulant. The test was done within 4 hours of taking the blood. The volume 
and the quality of the blood sample were checked. The blood was centrifuged at a 
speed of 2,000-3,000 cycles for 10 minutes to separate blood cell from plasma. The 
standardized volume of plasma was taken into Stant4 machine from Japan for this 
procedure, which yields results in about 5 to 10 minutes. 
2.13.2 Urea, creatinine, ALT, AST, bilirubin, alkaline phosphate, protein, A/G, 
electrolytes 
Two mls blood sample was drawn into a test tube containing liquid lithium heparin. 
For urea, creatinine, AL T, AST, bilirubine, alkaline phosphate, protein and A/G, the 
volume and quality of the blood sample were checked. The blood was centrifuged at a 
speed of 2,000-3,000 cycles for 10 minutes to separate blood cells from plasma. The 
standardized volume of plasma for each test was introduced into a Hitachi911 
autoanalyser (Boehringer Mannheim, USA) for this procedure, which yields results in 
about 5-10 minutes. For electrolytes, the plasma volume was put into A VL9181 for 
this procedure, which yields results in about 2-5 minutes. 
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2.13.3 HBV and anti HeV serology 
Four mls blood was drawn into aa anti-coagulant tube. The volume and the quality 
of the blood sample were checked. The blood was centrifuged at a speed of 2,000-
3,000 cycles for 10 minutes to separate blood cells from plasma. Rapid tests for HCV 
(Aeon Laboratories, USA) and for HBV (Determine HBsAg Alere, USA) were 
conducted, yielding results in about 5 to 10 minutes. 
2.14 Statistics 
Demographic characteristics were analysed by calculating mean and range for 
normally distributed continuous variables and median and interquartile range (IQR) 
for other continuous variables. Categorical variables were described by frequency. 
Treatment results were categorized according to the WHO classification scheme as 
well as Vietnamese NTP guidelines as cured, treatment completed, died, treatment 
failure, lost to follow-up or not evaluated. For further analysis treatment outcomes 
were reclassified into favourable (cured and treatment completed) or unfavourable 
(died, treatment failure, lost to follow-up or not evaluated). Variables associated with 
unfavourable outcome were assessed by univariate or multivariate logistic regression 
analysis. 
The cumulative incidence (risk) and incidence rate of drug induced hepatotoxicity 
were calculated. The risk factors for ATDIH were also assessed by univariate and 
multivariate logistic regression. The correlation between HBV DNA and AL T values 
was calculated using Pearson's correlation. All analyses were done by using R 
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software. The odds ratio with 95% confidence interval (CI) was used to assess the 
strength of associations with p<O.OS. 
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Chapter 3 
Isoniazid resistant tuberculosis and treatment outcomes 
3.1 Aims 
1) To evaluate treatment outcomes in patients treated according to Vietnam National 
Tuberculosis Programme guidelines. 
2) To compare treatment outcomes of two standardised regimens (2SRHZ/6HE and 
2RHZE/6HE) used in routine practice. 
3) To investigate the demographic, clinical, paraclinical characteristics and treatment 
outcomes of patients with INH resistance confirmed by LJ cuture and OST results: 
3.2 Introduction 
While there is a pressing need to prevent multidrug resistance (MDR) the most 
effective regimen for the treatment of isoniazid-resistant TB is not known" 
(WHO Treatment of tuberculosis Guidelines 4th Edition, 2009) [265] 
According to the WHO, drug-resistant TB exists in all countries in the world and is a 
major concern in several countries. Globally, WHO estimated 3.7% (95% CI 2.1-
5.2%) ofTB cases were MOR-TB in 2011. In Vietnam, the percentage ofMOR TB 
among new TB cases was estimated to be 2.7% (95% CI 2.0-3.6%) in 2011 [327]. 
Among drug-resistant TB strains worldwide, isoniazid resistant TB is the most 
common. In Vietnam, streptomycin resistance is the most common, followed by INH 
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resistance. Data reported to the World Health Organization from 1994 to 2009 
showed the percentage of INH resistant (INHR) among new TB cases was very high in 
the Eastern European region (33.5%, 95% CI: 24.8%- 42.2%). Meanwhile, Vietnam 
and other countries including China, the Dominican Republic and parts of India 
reported an INHR TB rate between 15% and 20% [328] (figure 3.1). There have been 
few studies on INHR TB which is not MDR. INH resistance in M.tb will reduce the 
success rate of TB treatment, fuel the generation of new MDR-TB strains and reduce 
the effectiveness of INH prophylaxis. 
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Figure 3-1 : World map showing the percentage of incident TB cases with 
isoniazid resistance (INH-R) from the most recent survey in each setting in three 
time periods: (a) 1994-1999, (b) 2000-2004, (c) 2005-2009. 
Reproduced from Jenkins et ai., PLos ONE 2011 [328]. 
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Currently, due to a lack of laboratory capacity in high burden settings, most cases of 
drug resistant TB in newly presenting patients are unidentified and are treated with 
the standard first line regimen (2HRZE/4HR). Outcomes using this regimen for 
patients infected with undiagnosed MOR TB are extremely poor [329]. For cases 
which are isoniazid resistant but remain sensitive to rifampicin, outcomes are also 
known to be worse than for fully sensitive TB although estimates of the relative risk 
in meta-analyses are imprecise due to inconsistencies in treatment regimens, drug 
susceptibility testing (OST) methodology and reporting ofresuIts across studies [330]. 
A study conducted in the Western Cape Province, South Africa showed 16% of 
patients with INHR TB had poor outcomes among whom 61% developed MOR-TB 
[331]. In contrast, other studies reported that there were no differences in treatment 
outcomes in these two groups. The later studies showed no differences because INH 
resistance was detected early and modified regimens were used. INHR TB should be 
quantified and detected early because treatment outcome will be improved when the 
duration of treatment is prolonged and the TB treatment regimen is adjusted [332, 
333]. 
In Ho Chi Minh City, 25% of primary patients and 54% of retreatment patients were 
found to have isoniazid (INH) resistant TB in 2006 [318]. The key drug in the first 
days of therapy, INH kills the largest population of Mtb bacteria in log-phase growth 
within the first 2-3 days of therapy. 
Isoniazid resistance is associated with a poor outcome and the development of MOR 
TB on treatment in Vietnam [318]. Within the NTP framework all new patients 
receive a DOTS regimen of 2 months streptomycin (SM). izoniazid (INH), rifampicin 
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(RiF) and pyrazinamide (PZA) followed by 6 months of isoniazid and ethambutol 
(EM B) (2SHRZ/6HE). Since October 2009, SM has been replaced by EMB in the 
regimen for newly diagnosed pulmonary TB patients in Ho Chi Minh City. The 
standard regimen for these patients is now 2RHZE/6HE. Upon treatment failure or 
relapse, drug susceptibility testing is begun and a retreatment regimen with the same 
drugs is commenced (2 months SHRZE, 1 month HRZE and 5 months IhR3E3). This 
regimen showed just 33% successful sputum smear conversion among MDR cases in 
a retrospective analysis [318]. The subsequent relapse rate was not determined. Green 
light committee procured second line drugs have been available in a limited number 
of NTP centres since 2010 through the programmatic management of MDR-TB 
(PMDT). 
Also within the framework of the NTP, all TB patients are tested for HIV and 
evaluated for sputum smear positivity at 2 months, 5 months and 8 months 
(completion of treatment). Currently, a smear-positive result at 2 months does not lead 
to a change in drug therapy. Patients in the INHR study were also additionally 
evaluated for culture positivity by LJ at months 5 and 8 and followed for relapse at 
12, 18 months and 24 months by sputum smear microscopy and culture. Treatment 
outcomes were evaluated according to Vietnam NTP for all patients in the screening 
study. Treatment outcomes for patients with INHR and MDR TB diagnosed by LJ 
DST (gold standard) were evaluated. The additional failure case detection with the 
addition of culture to the definition was also determined. 
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3.3 Results 
3.3.1 Demographic characteristics of patients in screening study 
During the study period between 1 December 2008 and 30 June 2011, at eight district 
TB units (including districts 1, 4, 6 and 8, Phu Nhuan, Binh Thanh and Tan Binh 
districts and PNT out- patient department), there were 5,036 cases diagnosed as new 
smear positive pulmonary TB including HIV infected individuals. 2,190 (43.5%) of 
these cases met eligibility criteria and agreed to enter the screening study. District 3 
(with 9 cases) withdrew from the study due to low recruitment. Seventy- nine further 
cases were diagnosed with HIV infection post-recruitment and 11 cases were aged < 
18 years old (from 13 to 17 years old) including 7 males and 4 females (1 case each 
from district 1, district 6, Tan Binh district, 2 cases from district 4, 3 cases each from 
district 8 and Phu Nhuan district) and were therefore excluded. Finally, there were 
2,091 cases eligible and included in the screening study. The recruitment flow-chart is 
shown in Figure 3-2. The demographic characteristics for these patients are presented 
in Table 3-1 and occupation distribution in Figure 3-3. 
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jNHs+ RIFr 
5,036 cases diagnosed newly smear 
posItive pulmonary TB 
I---~) 2,846 ineligible or 
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2,190 cases eligde and agree to 
partICipate in the screenmg study 
9 cases withdrew from 
District 3 
I--_~ 79 cases HIV infected 
2,091 cases 
For MODS screening 
study 
1 
11 case~ aged under 18 years 
~ 202 cases with MODS negative 
~ 85 cases MODS undetermined 
1 
324 cases 68 cases 
INHr+ RIFs INHr+ RIFr 
~ / 
1 
1,407 cases 
INHs + RIFs 
---7) 45 cases declined to enter the INH study 
341 cases eligible to participate in the INH study 
Figure 3-2 : Recruitment flowchart for INH study 
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Characteristics Summary measures n (%) 
Age (years) Median 39 [range 18-92] 
Male gender 1541 (73.7%) 
Duration of illness 30 days [1-365] 
(day)* 
Median [range] 
Districts 
Pham Ngoc Thach 127 (6.0%) 
Phu Nhuan 334 (16.0%) 
District 6 502 (24.0%) 
District 4 155 (7.4%) 
Binh Thanh 278 (13.3%) 
District I 231 (11.0%) 
District 8 259 (12.4%) 
Tan Binh 205 (9.8%) 
Total 2091 (lOOIVO) 
Ethnicity 
Kinh 1968 (94.1 %) 
Chinese 108 (5.1 %) 
Other 15 (0.8%) 
Total 2091 (100%) 
Occupation 
Manual labour 1457 (69.7 %) 
Professional/administrative 224 (10.7%) 
Retired/housewife 362 (17.3%) 
No employment 48 (2.3%) 
Total 2091 (100%) 
* 10 patients did not recall the duratIOn of symptoms since onset of Illness 
Table 3-1 : Demographic characteristics of patients for INH screening study 
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Figure 3-3 : Occupation of a ll patients in the screenin g study 
Ninety percent of patients with new smear positi ve pulmonary TB were under 58 
years of age. Table 3-2 and Figure 3-4 shows the age groups and gender among the 
screening patients. 
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Age group No. of cases n (%) Male n (%) Female n (%) 
(years) 
18 - 27 5 11 (24.4) 340 (22 .1 ) 171 (3 1.1 ) 
28 - 37 463 (22 .1 ) 3 18 (20.6) 145 (26.4) 
38 - 47 500 (23 .9) 4 19 (27.2) 81 ( 14.7) 
48 - 57 427 (20.4) 325 ( 15.5) 102 ( 18.5) 
58 - 67 11 5 (5.5) 90 (4.3) 25 (4 .5) 
68 -77 54 (2.6) 37 ( 1.8) 17 (3. 1) 
:::: 78 2 1 ( 1.0) 12 (0 .5) 9 ( 1.6) 
Total 209 1 ( 100) 154 1 ( \00) 550( 100) 
Table 3-2 : Newly smea r pos itive pulmonary TB patients by age and gcndcr in 
screenin g study 
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Figure 3-4 : Newly diagnosed smear positive pulmonary TB patients by age and 
gender in the screening study 
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3.3.2 MODS results 
Sputum samples from 2,091 new smear positive pulmonary TB patients were sent for 
MODS testing. Susceptibility to RiF and INH by MODS was determined. MODS 
cultures were positive for mycobacteria growth in 1,804 cases. Of these, 1,407 cases 
(67.3%) were susceptible to both drugs, 324 cases (15.5%) were resistant to INH and 
susceptible to RiF, 5 cases (0.2%) were susceptible to INH and resistant to RiF, 68 
cases (3.3%) were resistant to both INH and RiF (MDR) (Figure 3-5). There were 
202 cases (9.7 %) which had a negative MODS culture and 85 cases (4.1 %) that were 
indeterminate. The indeterminate category included isolates for which there was a 
negative result in the MODS control well and/or contamination of the control or 
sample well. 
The median time to culture positivity for MODS was 10 days (range 4-60 days). The 
critical concentration for INH susceptibility testing from the beginning of the study 
(December 2008) to 31 August 2010 was 0.4 ~g/ml and from the 1 sl of September 
2010 to the end of the study (June 2011), the concentration was changed to 0.1 ~g/ml. 
In a systematic review and meta-analysis of the MODS assay, with a 0.4 Jlg/ml cutoff, 
sensitivity for INHR was 90.0% (84.5-93.7) compared to LJ DST. With a 0.1 Jlg/ml 
critical concentration, sensitivity for INHR compared to LJ DST increased to 97.7% 
(94.4-99.1) [84]. In the present study, the change of INH critical concentration 
increased the percentage of isolates determined as INHR by MODS from 17.4% to 
21.2%. The overall MODS results are presented in Table 3-3 and Figure 3-5. 
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The percentage of iso lates res istant to IN H by MODS which were confirmed by L.J 
DST decreased signi fica ntly following the concentrat ion change (89.7%, n=234/26 I ) 
for O.4 l1 g/ml and 81. 75 % (n= I 12/ 137) for O. ll1 g/ml. P=O.026. 
RIFRRifampi cin resistant, 
INHR: Isoniazid res istant 
IN Hs: Isoniazid susceptibile 
INHSRlfS 
n=1,407 
RIFs: Ri fa mpicin susceptible 
INHR RIFf! (MDR) 
n=68 
Figure 3-5: Drug Resistance profil e of 1,804 isolates positive by MODS 
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MODS result Susceptibility Number of 
pattern cases 
n (%) 
Positive MODS culture 
INHR+ RIFR 68 (3.3) 
INHR+ RIFs 324 (15.5) 
INHs + RIFs 1,407 (67.3) 
INHs + RIFR 5 (0.2) 
Total 1,804 (86.3) 
Negative MODS culture 202 (9.7) 
Undetermined MODS 85 (4.1) 
Total 2,091 (100%) 
RiFR:Rifampicin resistant, 
INHR: Isoniazid resistant 
INHs: Isoniazid susceptibile 
RiFs: Rifampicin susceptible 
Table 3-3 : MODS culture results of2,091 patients in screening study 
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There were 392 cases with INHR by MODS (324 cases which were INHR + RIFs and 
68 cases which were MDR: INHR + RIFR). Of 392 cases with INH resistant TB (+1_ 
RIF resistance) by MODS, 45 (11.5%) cases declined to participate in the INH study. 
Finally, 347 cases were eligible to enter the INH study. The verbally reported reasons 
for not participating in the study were unstable residence, old age, concomitant 
illnesses such as diabetes or hypertension, a fear of giving blood, transfer to private 
clinics for treatment, being busy, work place far from DTUs, and long follow-up time 
(24 months) . 
Finally, 347 cases were eligible and consented to enter the INH main study with the 
numbers recruited in each district shown in Table 3-4: 
District Number of cases ( %) 
District 1 48 (13.8%) 
District 4 28 (8.l %) 
District 6 73 (21.0%) 
District 8 39 (11.2%) 
Phu Nhuan 53 (15.3%) 
Binh Thanh 58 (16.7%) 
Tan Binh 27 (7.8%) 
Pham Ngoc Thach 21 (6.1%) 
Total 347 cases (100%) 
Table 3-4 : The number of participants with INHR (+1- RIFR) by MODS in each 
district participating in the INH resistant TB study 
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3.3.3 LJ Culture and DST results 
347 samples from 347 patients with INH resistance (+1- RiF resistance) by MODS 
were sent for Drug Susceptibility Testing on Lowenstein Jensen media. Seven 
samples were irretrievable. Susceptibility was determined for INH, RiF, SM, EMB 
and PZA. 
Overall, 315/340 (92.6%) isolates INH resistant by MODS were confirmed INH 
resistant by LJ DST. Fifty-two cases (15.3%) were INH monoresistant and 184 cases 
(54.1 %) were INH and SM resistant and 24 (7.1 %) cases with other patterns of INH 
polyresistance (figure 3.6). 
There were 55 MDR cases with additional resistance to other drugs. There were no 
cases with only INH and RiF resistance (Table 3-5 and Figure 3-7). Further analysis 
ofINH-resistant TB and MDR TB cases was based upon those confirmed by LJ DST. 
170 
/ 
5 cases SMr . 
5 cases no resistance 
15 cases no growth ' 
. 340 cases INHr by MODS 
. .. 
1 UDST ~ 
260 cases INHr 55 cases INHr+RIFr . 
- . 
. _1 
/ j 
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RIFR= rifampicin resistant 
Figure 3-6: LJ DST results of 340 cases with INH Il by MODS 
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Resistance profile by LJ DST The number of casesn (%) 
INH 52 (15.3) 
INH,SM 184 (54.1) 
INH,PZA 2 (0.6) 
INH,SM,EMB 4 (1.2) 
INH,SM,PZA 17 (5.0) 
INH, SM, EMB, PZA, RIF 7(2.1) 
INH, SM, RIF, EMB 17 (5.0) 
INH, SM,RIF 22 (6.5) 
INH,SM, PZA, RIF 9 (2.6) 
SM 5 (1.5) 
SM, INH, EMB,PZA 1 (0.3) 
no resistance 5 (1.5) 
no growth or contamination 15 (4.4) 
Total 340 (100) 
Table 3-5: Drug resistant profile by LJ DST of340 cases detected as INHR by MODS 
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Figure 3-7: Distribution of drug suscepti bili ty p rofil es for 315 isolates res istant to INH 
by LJ DST 
3.3.4 Demographic risk fac tors for INH resistant T B and MDR TB 
Demographic ri sk factors age. gender and di trict were analysed for as ociation with 
both INH res istant (non-MDR) TB or MDR TB. Results are shown in Table 3-6. 
There were no significant associations of gender or di strict with either INH-resistant 
or MDR TB. Age 26-35 years was signifi cantly assoc iated with MDR TB in 
compari son with 18-25 yea r olds as base line (OR=2.98 [95% CI 1.26-7.03]. P=O.O 13). 
There was no significant associati on between age and INH R TB. 
173 
MDRTB INH RESISTANT TB 
OR 95%Cl P-value OR 95% Cl P-value 
Male sex 1.00 0.54- 0.993 1.05 0.80-1.38 0.710 
1.85 
Kinh ethnicity 1.10 0.34- 0.870 1.35 0.78-2.35 0.282 
3.59 
Age category 
1: 18-25 years BASELINE 
2: 26-35 years 2.98 1.26- 0.013 1.11 0.77-1.59 0.584 
7.03 
3: 36-45 years 1.38 0.54- 0.499 1.07 0.75-1.53 0.715 
3.55 
4: 46-55 years- 1.26 0.47-
3.33 
0.648 0.79 0.54-1.16 0.229 
5: :::56 years 0.74 0.19- 0.665 0.77 0.48-1.21 0.255 
2.89 
District 
Pham Ngoc BASELINE 
Thach 
Phu Nhuan 1.06 0.28- 0.936 0.94 0.53-1.68 0.838 
4.06 
District 6 0.81 0.21- 0.751 0.82 0.47-1.43 0.492 
3.03 
District 4 0.81 0.16- 0.803 1.18 0.63-2.25 0.598 
4.11 
Binh Thanh 1.76 0.48- 0.393 1.39 0.79-2.46 0.259 
6.44 
District 1 1.97 0.53- 0.309 1.33 O. 0.348 
7.33 
District 8 1.42 0.37- 0,611 0.82 0.44-1.50 0.511 
5.45 
Tan Binh 0.60 0.12- 0,535 0.76 0.40-1.45 0.405 
3.02 
Table 3-6: Demographic risk factors for MDR and INH resistant TB 
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3.3.5 Treatment outcomes in screening patients 
One patient CRF was irretrievable and therefore 2,090 new pulmonary IB patients 
were evaluated by sputum smear microscopy after 5 and 8 months according to WHO 
guidelines followed by Vietnam NIP. Ihe majority of patients (95.1 %, n=1987/2090) 
received the daily regimen recommended by the Vietnam NIP. Prior to October 2009 
this regimen was SM, RiF, INH and PZA for the first two months (intensive phase) 
followed by 6 months with INH and EMB (continuation phase) (2SRHZ/6HE). In 
October 2009 there was a change to the standard national treatment regimen; SM was 
replaced by EMB (2RHZE/6HE) which enabled us to compare treatment outcomes on 
the two regimens. 
In total, 547 patients recieved 2SRHZ/6HE and 1,440 patients recieved 2RHZE/6HE. 
The remaining 103 patients received alternative individualized regimens, such as 
2SRHZ/RHZ/5HE, 2SRHZEIRHZE/5RHE, 3RHZE/5HE, 3RHZE/3RH, 2SRHZ/4RH 
and 2RHZE/4RH. 
Patients treated at PNI out-patient department were much more likely to receive 
individualized treatment regimens than those treated at the district IB units. Of those 
receiving individualized regimens, 951103 (92.2%) were treated at PNI out-patient 
department. 
Table 3-7 and Figure 3-8 show the overall WHO defined treatment outcomes of the 
patients in the screening study. 1,858 (88.9%) patients were cured and 6 (0.3%) 
patients were classified as 'treatment completed' and so 1,864 (6+ 1858) patients 
(89.2%) were classified as having a favorable outcome. 16 patients died (0.8%), 121 
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(5.8%) treatment failed, 82 were lost to follow up (3.9%) and 7 (0.3%) were not 
evaluated. Therefore, a total of 226/2,090 patients (10.8%) were classified as having 
an unfavourable outcome by WHO criteria. 
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Trea tment ou tcomes N umbcr of cases n (%) 
Favourable 
Cured 1858 (88 .9) 
Treatment completed 6 (0.3) 
Unfavourable 
Died 16 (0.8) 
Treatment failed 12 1 (5.8) 
La t to foll ow-up 82 (3.9) 
at eva luated 7 (0.3) 
Total 2,090 (tOO) 
Table 3-7: Trea tm ent outcomes of patients in the screening study by WHO definitions 
including smea r results only 
3.90% 0.30% 
• cu rcd 
• trcJ tment completed 
• Died 
• Treatment failed 
• Lost to fol low-up 
• Not evaluated 
Figure 3-8 : Treatment ou tcomes in pa tients for sc rcninng study by WHO 
d efi nition includin g s mea r rcsults only_ 
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3.3.6 Comparision of treatment outcomes of two standardized treatment 
regimens (2SRHZl6HE and 2RHZE/6HE) 
Treatment outcomes were compared between the two standardized regimens 
(2SRHZ/6HE and 2RHZE/6HE) in patients within the screening study (Table 3-8). 
The crude OR for unfavourable outcome was 0.97 [95% CI 0.70-1.34], P=0.871 for 
patients receiving 2RHZE/6HE compared to those receiving 2SRHZ/6HE. Adjusting 
for diagnosed drug resistance did not change the OR; adjusted OR= 0.98 [95% CI 
0.67- 1.42], P=O.912 (Table 3-9). 
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Outcome Regimen 
2SRHZl6HE 2RHZE/6HE 
n (%) n (%) 
Cured 491 (90.1) 1287 (89.4) 
Treatment 0 2 (0.1) 
completed 
Died 4 (0.7) 11 (0.7) 
Treatment failed 27 (4.5) 88 (6.0) 
Lost to follow-up 24 (4.3) 46(3.1) 
Not evaluated 1 (0.1) 6 (0.4) 
Total 547 cases (100%) 1,440 cases (100%) 
Table 3-8: Treatment outcomes in screening patients with two main regimens 
Favourable Unfavourable 
outcome outcome 
n (%) n (%) 
2SRHZl6HE 491 (89.8) 56 (10.2) 
(0=547) 
Regimen 1289 (89.5) 151 (l0.5) 
2RHZE/6HE 
(0=1,440) 
Total 1780 207 
(N=1987) 
.. 
*univariate and multivarIate logistic regression 
"adjusted for MDR, SM and INH resistance 
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Crude OR Adjusted OR 
[95%CI] and 195%CI] 
p value* p value** 
Baseline 
0.97 0.98 
[ 0.70-1.34] [ 0.67- 1.42], 
P=0.871 P=0.912 
Table 3-9: Comparison of treatment outcomes by treatment regimen adjusted for drug 
resistance 
3.3.7 Risk of unfavourable WHO outcome by drug resistance pattern 
Overall, patients with INH resistant TB confirmed by LJ DST did not have a higher 
risk of unfavourable WHO outcome on standard treatment regimens (OR= 1.13 [95% 
CI 0.73-1.77], P=0.582). Patients with MDR TB had a much greater risk of 
unfavourable outcome (OR=I1.61 [95% CI 6.58-20.6], P<O.OOI) (Table 3-10). 
Resistance Unfavourable OR 95% CI P-value 
outcomes 
nlN (%) 
INH +RiF 154/1690 (9.1%) BASELINE 
susceptible 
INH resistant 25/245 (l0.2%) 1.13 0.73-1.77 0.582 
MDR 28/52 (53.8%) 11.64 6.58-20.6 <0.0001 
Excluding patients receiving individualized regimens. 
Table 3-10: Unfavourable WHO treatment outcomes by drug resistance profile group 
3.3.8 Demographic, clinical, and paraclinical characteristics of patients with INH 
resistant TB 
Of347 cases resistant to INH by MODS (+/- resistance to RiF), LJ DST for INH, RiF, 
SM PZA and EMB was performed for 340 cases (7 cases were irretrievable for LJ 
, 
culture and DST). 
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The results showed 5 cases with SM monoresistance, 5 cases susceptible to all drugs 
tested and 15 cases with no growth on LJ. The remaining 315 cases included 55 cases 
with both INH and RiF resistance (MDR TB +/- resistance to other drugs). One MDR 
isolate was identified as Non Tuberculosis Mycobacteria (NTM) and therefore the 
case was excluded. Fifty-four cases were therefore classified as MDR TB cases for 
further analyses. The remaining 260 cases were resistant to INH and susceptible to 
RiF but +/-resistance to other drugs (SM, PZA and EM B) by LJ. These cases were 
classified as INH-resistant (non MDR) group for further analyses. These 260 cases 
included 52 cases with INH monoresistance, 184 cases with INHR and SMR, and 24 
cases with other susceptibility patterns including INHR (Figure 3-6). 
Demographic chacteristics were therefore analysed for 314 cases (Table 3-11). The 
median age was 38 years (range 18-91),230 (73.2%) were male. The median duration 
of illness was 30 days (lQR: 14-60). Three quarters of the patients were manual 
labourers (72.6%, n=228/314) (Table 3-11 ). 
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Characteristic n (%) 
Age median: 38, [range 18-91 years] 
Male gender 230 (73.2%) 
Occupation 
Manual labour 228 (72.6%) 
Professional/administrative 30 (9.6%) 
Retiredlhousewife 47 (15.0%) 
No employment 9 (2.9%) 
Total 314 (100%) 
Duration of illness median: 30 days, range [2-365 days] 
Table 3-11: Demographic characteristics of 314 cases with INHr (+1- RlFr) confirmed by 
LJ culture 
Table 3.12 and Figure 3-9 show the distribution of age group and gender in patients 
with INHR (+1- RiFR) confirmed by LJ DST. 
A total of 260 cases with INHR (not MDR) diagnosed by LJ DST were analysed. 
Baseline demographics for these patients are shown in Table 3-13. Age and gender 
distribution of 260 patients with INHR (not MDR) were showed in Table 3-14 and 
Figure 3-10. 
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Age group (years) Number of Male n (%) Female n 
cases (%) 
n (%) 
18 - 27 80 (25. 5) 48 (20.9) 32 (38. I) 
28 - 37 74 (23.6) 55 (23.9) 19 (22.6) 
38 - ·n 86 (27 A ) 74 (32.2) 12 (14.3) 
-t8 - 57 50( 15.9) 36(15.7) 14 (16.7) 
58 - 67 18 (5.7) 13 (5.7) 5 (6.0) 
68 - 77 4 (1.3) 3 (1.3) I (1.2) 
>=78 2 (0.6) I (OA) 1 (1.2) 
Total 314 ( 100) 230( 100) 84 (100) 
Table 3-12: Patients with IN H res istance (+1- RIFr) diagnosed by LJ by age and sex 
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Figure 3-9: Patients with INHR (+1- RIFR) diagnosed by LJ culture by age and 
gender 
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Characteristic n (%)/median [IQR] 
Age 39 years [27-48] 
Male gender 189 (72.7%) 
Occupation 
Manual Labour 183 (70.4% 
Professional/administrative 24 (9.2%) 
Retiredlhousewive 45 (17.3%) 
No employment 8 (3.1%) 
Total 260 (100%) 
Duration of illness 30 days, [14-60] 
Table 3-13: Demographic characteristics of 260 patients with INH' (not MDR) by LJ 
DST 
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Age group Number of cases Male Female 
(years) (%) n (%) n (%) 
18 - 27 70 (26.9) 4 1 (2 1. 7) 29 (40.8) 
28 - 37 - - (? I ?) )) - .- 39 (20.6) 16 (2.3) 
38 - 47 69 (26.5) 61 ( 16.9) 8 ( 11.3) 
48 - 57 44 (16 .9) 32 ( 16.9) 12 (16.9) 
58 - 67 16 (6.2) 12(6.3) 4 (5 .6) 
68 - 77 4 ( 1.5) 3 ( 1. 6) I ( 1. 3) 
>= 78 2 (0.8) I (0.5) I ( 1.3) 
tota l 260 ( 100) 189 (100) 71 (100) 
Table 3-14: Patients with I NHR (not MDR) confirmed by LJ DST by age a nd gcndcr 
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Figure 3-10: Age and gender distribution of260 patients with INHR (not MDR) 
confirmed by LJ DST. 
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For 260 patients with INHR diagnosed by LJ culture, symptoms were assessed. The 
re ults showed 93.4% with cough, 17.8% with haemoptys is ,47.7% with fever, 18.2% 
with night sweat , 26% with weight loss, 29.5% with chest pain and 36% with 
malaise (Figure 3-11). 
VI 
-s:: GJ 
·z 
to 
100% 
80% 
60% 
0. 40% 
-o 
GJ 
CI.O 
to 
-~ 20% 
u 
... 
GJ 
0. 
0% ~~===-.------,-------r------.-------r-~==~---===~ 
Symptoms 
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culture. 
In 260 cases with INHR diagnosed by LJ cuture, blood biochemistry was assessed in 
252 cases for JNR, PT, urea, electrolytes (Na, K. Ca, CI), creatinine, AL T, AST, total 
bilirubin, direct bilirubin, indirect bilirubin, AP, protein and albumin/globumin ratio. 
The results are shown in Table 3- 15. 
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Blood tests normal number mean range 
values evaluated (SD) (lowest-
higest) 
INR 2-3 238 1.2 0.8-5.6 
(0.5) 
PT 70-100% 126 83.8 21-100 
(14.5) 
Urea <8.3mmol/l 252 4.2 1-11.5 
(1.6) 
Na 135-145 252 138.6 143-150 
mmolll (7.1) 
K 3.5-5.1 252 3.9 2.7-10.3 
mmol/l (0.9) 
Ca 2.2-2.5 252 2.2 1.2-2.9 
mmolll (0.2) 
CI 95-110 252 100.9 90-110 
mmolll (3.4) 
Creatinine 55-110 252 85.9 58-778 
~molll (45.5) 
AST 9-48 U/I 252 30.4 6-501 (39.4) 
ALT 5-45 U/l 252 30.3 5-521 
(48.8) 
Total Bilirubin ~19~mol/l 252 14.4 1.1-52.6 
(6) 
Direct Bilirubin ~5.II·unol!1 252 7.5 0.7-801 
(50.2) 
Indirect ~13.9~mol!1 252 10.1 1-41.8 
Bilirubin (4.4) 
AP <258 Ull 252 182.1 93-451 
(60.4) 
Protein 60-80gll 252 87.3 70-908 (52.4) 
albumin/globulin 1.3-1.8 252 1.2 0.3-2.4 
ratio (0.3) 
Table 3-15: Blood biochemistry in patients with INHR confirmed by LJ DST 
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3.3.9 Treatment outcomes of patients with INH resistant TB and MDR TB 
Two groups were defined by LJ DST: MDR and INHR (non MDR) TB. 
MDR TB, INHR + RiFR (group 1) including 54 patients, excluding one NTM isolate. 
There were 54 MDR TB patients who were evaluated at month 8 (treatment 
completion). Based on WHO criteria the treatment results were: 25 cases (46.3%) 
cured, 27 cases (50%) treatment failed, 1 case (1.9%) lost to follow-up and 1 case 
(1.9%) was not evaluated. 
Patients with INHR, not MDR TB (group 2) included 260 cases that were evaluated at 
month 8. There were 231 cases (89%) classified as cured, 2 cases (1 %) died, 21 cases 
(8%) were classified as treatment failed and 6 cases (2%) were lost to follow-up. 
The treatment outcomes of INHR + RiFR (MDR TB, group one) were 25 cases 
(46.3%) with favourable outcome and 29 cases (53.7%) with unfavourable outcome 
by WHO definitions. For INHR (not MDR) patients, there was a favourable outcome 
for 231 cases (88.8%) and an unfavourable outcome for 29 cases (11.2%). 
3.3.10 Effect of culture in addition to smear on unfavourable outcome detection 
rates 
For patients with INHR TB by MODS, enhanced surveillance for treatment failure was 
conducted, with sputum culture at months 5 and 8 in addition to sputum smear. 
Patients with a positive Mtb culture at month 5 or month 8, were additionally 
classified as failure cases. 
The treatment outcomes in the two resistance groups confirmed by LJ DST (MDR 
group and INHR group) were compared using WHO guidelines (smear only) and 
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based on culture at month 5 and 8 addition to smear to detennine the additional 
number of failure cases detected by culture. 
If culture was included in the criteria for evaluation of treatment outcomes, the 
unfavourable outcome detection rate for MDR cases increased from 53.7% (n=29/54) 
to 68.5% (n=37/54). Among INHR (non MDR) cases the unfavourable outcome 
detection rate increased from 11.2% (n=29/260) to 19.2% (n=50/260). The details are 
presented in the Table 3-16 and Table 3-17. Eight additional unfavourable outcomes 
were detected among MDR TB cases by using culture in addition to smear. This 
difference was not significant (P=0.114). 
260 cases with INHR (not MDR) by LJ DST were evaluated. The results are presented 
in Table 3-17. Twenty one additional unfavourable outcomes were detected among 
INHR (non MDR) cases using culture in addition to smear. This difference was 
statistically significant (p = 0.01). 
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Outcome Based on smear Based on smear and 
only culture 
n (%) n (%) 
Favourable 
Cured 25 (46.3) 17 (31.5) 
Treatment 0 0 
completed 
Died 0 0 
Total 25 (46.3) 17 (31.5) 
Unfavourable 
Treatment 27 (50.0) 35 (64.8) 
failed 
Lost to follow- 1 (1.9) 1 (1.9) 
up 
Not evaluated 1 (1.9) 1 (1.9) 
Total 29 (53.7) 37 (68.5) 
Total 54 cases 54 cases 
(100%) (100%1) 
Table 3-16: Treatment outcomes for MDR TB cases using culture in addition to 
smear 
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Outcome Outcome Based on smear Based on smear and 
category only culture 
cases cases 
n(%) n(%) 
Favourable 
Cured 231 (88.8) 210 (80.8) 
Treatment 0 0 
completed 
Total 231 (88.8) 210 (80.8) 
Unfavourable 
Died 2 (0.8) 2 (0.8) 
Treatment 21 (8.1) 42 (16.2) 
failed 
Lost to follow- 6 (2.3) 6 (2.3) 
up 
Not evaluated 0 0 
Total 29 (11.2) 50 (19.2) 
Total 260 cases (100%) 260 cases (100%) 
Table 3-17: Treatment results based on smear only and smear+culture in 
INHRnot MDR (group 2) cases 
3.3.11 Comparison oftreatment outcomes between patients with MDR TB and 
INHR (non-MDR) TB 
Treatment outcomes based on smear and culture of MDR cases (group 1) and INHR 
(group 2) were compared with each other. Patients with MDR IB were more likely to 
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have unfavourable outcome compared to patients with INHR (not MDR) (OR= 9.41, 
95%CI: 4.84-18.29, p< 0.001) (Table 3-18 and Figure 3-12). 
Unfavourable Favourable Total OR [9S%CI),p value* 
outcome outcome 
[cases, n (%)] [cases, n (%») 
INHR n=247 46 (18.7) %) 201(81.4) %) 247 BASELINE 
(100%) 
MDRn=S2 35 (67.3%) 17 (32.7%) 52 9.41 [4.84-18.29], P < 0.00 I 
(100%) 
*excluding patients receiving individualized regimens. 
Table 3-18: Treatment outcomes in MDR group (group 1) and INHR group (group 2) 
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3.4 Discussion 
3.4.1 Impact of INHR on treatment outcomes 
Overall, the WHO classified treatment outcomes for all patients in this study were 
consistent with those reported by the NTP, with 10.8% patients having an 
unfavourable outcome by WHO criteria, exceeding the WHO target of 85% treatment 
success. However, intensified surveillance for treatment failure/relapse among INHR 
(non-MDR) cases detected almost twice as many unfavourable outcomes (11.2% vs. 
19.2%). As intensified surveliance for treatment failure was not conducted among all 
patients due to resource limitations, it is unclear if this additional failure/relapse is 
limited to INHR cases; it seems likely that additional failure/relapse cases would be 
detected among patients with drug susceptible isolates but the number of additional 
cases would be few. 
The number of additional failure/relapse cases detected among INHR (non-MDR) 
cases is cause for grave concern in the Vietnamese National TB control strategy. It is 
clear from this data that under the WHO recommended smear-only monitoring for 
treatment outcome, a substantial number of INHR cases will be declared cured at 
treatment completion, only to relapse at a later date due to failure to eradicate the 
infection. This may be a significant contributing factor to the lack of observed decline 
in TB notification rates in Vietnam, despite a comprehensive NTP and control 
strategy for over 15 years [37]. Several other explanations have been proposed for the 
lack of impact such as the emergence of the HIV epidemic [38], rapid urbanization 
[334] and the role of Mtb Beijing genotype [335]. International TB guidelines 
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recommend the use of microscopic examination (direct smear) of at least two sputum 
specimens for acid fast bacilli to diagnose TB and follow-up to evaluate the treatment 
outcomes at month 5 and month 8 in high burden countries with financial constrains 
[164]. Vietnam National TB guidelines follow this recommendation, using three 
sputum smear according to old guidelines. A patient whose smear is positive at month 
5 or later, month 8 is classified as treatment failure. However, the use of smear for 
evaluation ofTB treatment is clearly insufficient to detect all treatment failures. 
It would not be possible to provide culture follow-up to every patient within the NTP 
with current resources and case-burden, even within HCMC where the reference 
laboratory for southern Vietnam is located. There is limited capacity for Mtb culture 
and culture of approximately 16,000 new TB patients within the city at treatment 
completion would be an unrealistic goal. Alternative methods for treatment 
monitoring are urgently required; the role of GeneXpert MTBIRIF testing in treatment 
monitoring has yet to be established and is not currently recommended. While PCR-
based tests detect both viable and dead bacilli and are therefore considered to be of 
limited use in treatment monitoring at month 2/3, the use of Genexpert at month 8 
may have value and should be evaluated. The GeneXpert MTB/RIF test may have an 
advantage over other NAAT in this regard due to the capture of intact bacilli from the 
sample within the cartridge, prior to DNA extraction and amplification, which will 
reduce positive follow-up results due to extracellular DNA within the sputum. A two-
pronged strategy in which patients with INHR TB are identified at diagnosis for 
alternative treatment and more intensive outcome monitoring may be more cost-
effective. Currently available methods for rapid identification of INHR TB are 
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phenotypic methods such as the MODS assay used here, or genotypic approaches 
such as the Line Probe Assay [91, 95]. The major disadvatages of MODS are labour 
requirements and biosafety, while HAIN test has significant costs, quality control 
(QC) and training requirements. A novel Xpert cartridge which detects INH and RiF 
resistance may become available in the future but current strategies in high burden 
settings focus on TB case detection with Xpert and therefore target Xpert testing to 
HIV and MDR suspects only, the resource implementations of screening all TB 
suspects with Xpert would be prohibitive [336]. Modelling of cost-effectiveness of 
alternative approaches should provide insights into the optimal strategy to use and the 
long term cost: benefit ratio. 
WHO has recommended a 4HRE treatment continuation phase' in areas of high INH 
resistance' and this is currently being piloted in the Vietnamese NTP [129]. It is 
unclear if this regimen will have significantly improved outcomes in those patients 
with INHR TB as the regimen is based on expert opinion rather than trial evidence. 
Overall the favourable outcome rates were not different between the 2 regimens 
(2SRHZ/6HE and 2RHZE/6HE). 
Outcomes for patients on MDR TB were extrememly poor. For treatment outcomes 
based on definition of WHO and also Vietnam NTP, the favourable treatment 
outcomes of patients with MDR TB by LJ DST was just 46.3% (25/54 cases). If 
culture were included for evaluation of treatment outcomes, the cured rate decreased 
from 46.3% to just 31.5% in MDR patients at 8 months and it is likely that many of 
these would go on to relapse if not yet enrolled into appropriate treatment. Patients 
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with MDR TB were more likely to have unfavourable outcome compared to INHR 
patients (OR= 9.41, 95%CI: 4.84-18.29, p<O.OOI). 
Patients in this study with MDR TB had additional resistance and therefore received 
only one or .two drugs to which the isolate was susceptible when given the 
standardised regimens 2SRHZl6HE or 2RHZE/6HE. This clearly generates further 
resistance to the remaining first-line drugs to which the isolate is susceptible. During 
the study, patients diagnosed with MDR by MODS were not eligible for the MDR 
treatment programme in HeMe and were referred for HAIN testing if smear positive 
at month 5, consistent with NTP guidelines. At initiation of the programmatic 
management of MDR TB in HeMe, a limited number of treatment courses were 
available and patients were often not able to receive immediate registration for MDR 
treatment. Successful outcomes from the initial PMDRTB cohorts has led to an 
expansion of the treatment programme and improved access for patients, including 
eligibility based upon a positive GeneXpert test for RiF resistance at any treatment 
stage. This is a significant advance in the management of MDR TB within HeMe 
and should lead to significantly improved outcomes for individual patients in addition 
to reduced MDR TB transmission over time, but other research studies wiII be needed 
to establish the true impact of the PMDRTB on the DR TB epidemic in Vietnam. 
3.4.2 Demographics of TB patients 
The majority of patients (90%) were under 60 years of age and male (73.7%). This is 
consistent with data from other settings where TB is more common in men than 
women, usually with a ratio of between two and three to one [337]. The reasons for 
this are unknown but have been hypothesized as due to higher smoking rates or pre-
197 
existing lung damage in men, different patterns of social mixing and immune 
response variation [337]. For occupations, 69.7% ofTB patients are manual labourers 
. Low socioeconomic status has been repeatedly associated with risk of TB disease , 
probably due to factors such as malnutrition, over-crowding, co-morbidities and 
access to healthcare [338] but in this study was probably over-estimated due to 
recruitment of patients only through the public sector. In this study, gender and age 
were not an associated with treatment outcome although in other studies from Asia, 
association has been found between male gender [339] or young age [340] and poor 
treatment outcome. 
No association was seen in this study between gender and age and risk of INHR TB 
but MDR TB was significantly associated with young age, as in other studies from 
Vietnam. As all patients in this study were new smear positive TB patients, not having 
received any previous TB treatment, this suggests there is active community 
transmission of MDR TB among young adults and contact tracing of MDR TB 
patients via social networks should be intensified. 
3.4.3 MODS for detection of INHR TB 
Based on MODS, we detected 392 cases (18.6%) with INH resistant TB (+1- RiF 
resistance). However, from the beginning of September 20 I 0, we decreased the 
concentration of INH from 0.4 to 0.1 Ilglml, the number of INH resistant TB 
increased from 17.4% to 21.2%, but the percentage of these confirmed by LJ DST as 
the gold standard decreased from 89.7% to 81.75%. Due to resource limitations we 
were not able to test all cultures by LJ DST to confirm the accuracy of MODS for 
INHR detection or to determine how many INHR isolates were undiagnosed, before 
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and after the change in critical concentration. The sensitivity will be increased with 
the use of the 0.1 J.lg/ml isoniazid cutoff but conversely the specificity will be 
compromised compared to 0.4 Jlg/ml cutoff [322]. The median time for detection of 
Mtb by MODS was 10 days (mean: 10 days, range: 4-60 days). This is substantially 
faster than the 4-6 weeks required for conventional culture and DST. Moreover, this 
test is useful to diagnose HIV -infected patients with TB. According to a systematic 
review and meta-analysis, the MODS assay had wide variability with isoniazid for 
sensitivity (82-100%) and specificity (78- 100%) [341]. Another limitation of MODS 
is the inability to differentiate A1.tb and NTM which has been addressed by the 
addition of P-nitrobenzoic acid (PNB) to a well [85], biohazard risk, labour 
requirements for plate-reading, and a lack bf established External quality assessment 
(EQA) procedures. However, WHO has recommended the MODS assay as an interim 
solution, especially in resource constrained settings [91]. The investment in training, 
infrastructure, EQA policy and modification of national algorithms will need to be 
weighed carefully in considering implementation of any new diagnostic as an 
'interim' measure. 
The MDR rate detected was 2.6% (n=54/2090). There were no cases of RiF 
monoresistance detected in this study; RiF resistance always occured in strains that 
were also resistant to other drugs such as INH, SM, EMB and PZA. This is consistent 
with global data showing rifampin resistance can be considered as a marker for MDR 
TB and confirms that use of the GeneXpert MTB/RIF test for diagnosis of MDR TB 
is appropriate in Vietnam [342]. GeneXpert MTBIRIF and Line Probe assays which 
are rapid, reliable and easy to interpret, can both be effectively applied for early 
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detection of MDR TB because these molecular techniques correlate very highly with 
solid or liquid medium culture and DST which is a gold standard for TB diagnosis 
[343]. However, molecular testing also has limitations, principally failure to detect all 
phenotypically resistant cases, and the need for traditional culture and DST is not 
removed [344]. Further, line probe assays can only be used effectively in smear 
positive cases. WHO issued a policy statement recommending LPA for rapid 
screening of patients suspected with MDR TB in 2008 [345]. In 2010, WHO also 
approved the Xpert MTBIRIF test [96]. Technical and operational practical 
considerations for using Xpert MTBIRIF have also been presented and published by 
WHO in 2011 [336] . The global community has since undertaken huge scale up 
implementation of Xpert MTBIRIF testing in high-burden settings and data on the 
true impact of this implementation on TB epidemics is likely to emerge first from 
South Africa, which has undertaken country-wide implementation [346, 347]. 
3.4.4 Treatment options for INHR TB 
For INHR TB which is susceptible to rifampicin, the unfavourable outcome rate was 
19.2%. Patients with INHR received the standard regimen according to NTP 
guidelines; 2SRHZ/6HE or 2RHZE/6HE. These patients effectively received 
2SRZ/6E or 2RZE/6E, although there is evidence from MDR series that taking INH 
retains some benefit in INHR cases [222]. 
Resistance to isoniazid is likely to increase as countries implement the WHO 
recommended strategy of 'the 31's', including isoniazid preventative therapy (lPT) 
provision in HIV-infected individuals on a large scale [348]. Theoretical studies 
suggest there may be an impact of large-scale IPT on INH-resistance rates in 
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Mtuberculosis [349] but this has not yet been observed in practice probably due to 
the time required for any impact to become apparent [350]. In addition, studies have 
consistently demonstrated an increased risk of drug resistance amplification, and 
MDR development, in patients with undiagnosed INH-resistant TB at commencement 
of standardized drug regimens [330]. A recent WHO review of existing data 
concluded "Patients with pretreatment isoniazid resistance (but susceptibility to 
rifampicin and streptomycin) were 22 times more likely to acquire drug resistance 
than patients who started treatment with drug-susceptible disease" [265, 330]. 
Determining and applying an optimized regimen for INH-resistant, RiF sensitive TB 
will 'tum off the tap' for MDR TB and substantially reduce the emergence of new 
MDR strains [351]. The WHO currently recommends the addition of ethambutol to 
the continuation phase programmatically 'in regions of high prevalence of INH 
resistance', but the threshold for 'high' is undefined: "In populations with known or 
suspected high levels of isoniazid resistance, new TB patients may receive HRE as 
therapy in the continuation phase as an acceptable alternative to HR 
(weak/insufficient evidence, expert opinion)" [129]. Vietnam is a country with high 
INHR rate [352] so since May, 2013 the regimen of 2RHZE/4RHE for new smear 
positive pulmonary TB has been implemented in HCM City. The effectiveness of this 
regimen should be evaluated and the data will help to determine if implementation of 
this regimen is of benefit. 
For patients with confirmed INH resistance a regimen of 6-9 months RZE with the 
addition of a FQ to strengthen the regimen in 'extensive' disease is recommended 
[234]. The British National Institute for Clinical Excellence (NICE) guidelines 
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recommend a 7 month continuation phase of RE [353] and the American Thoracic 
Society guidelines suggest a fluoroquinolone (FQ) is added in cases of "extensive 
disease" [354]. The programmatic addition of ethambutol to the regimen for all 
patients must be considered carefully against the risk of ocular toxicity with the 
potential for permanent blindness in patients who are receiving ethambutol 
unnecessarily. Further, it is not actually known if the addition of ethambutol has any 
impact on outcome or the risk of drug resistance amplification due to the lack of 
evidence from randomised controlled trials. The evidence base for all 
recommendations is acknowledged to be extremely weak and no randomized 
controlled trials have been conducted for the treatment ofINH-resistant, RiF sensitive 
TB. 
3.4.5 Study limitations 
There was considerable recruitment bias in this study due to two principle factors. 
Firstly, in Ho Chi Minh City, the percentage of TB patients managed within the 
private sector may be as high as 30% to 40% and is increasing with economic 
development of the country, which achieved middle income status in 20 I 0 [355]. 
These patients were not captured within the study. Furthermore, many patients were 
ineligible or declined to participate in the research. Socio-economic characteristics are 
likely to differ substantially between patients accessing the private and public sectors 
and this is likely to influence outcomes through various factors. Although patients in 
the private sector are likely to have better health care access, nutrition and opportunity 
to convalesce they may also receive inadequate treatment within the private sector. 
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Adherence to treatment was recorded during the study in the patient CRF but was not 
incorporated in the analysis because treatment adherence was recorded as 100% for 
all patients which is unlikely to be accurate, therefore we were probably unable to 
capture adherence. Alternative methods such as fingerprint monitoring would have 
more acurrately captured adherence and enabled us to separate the impact of primary 
drug resistance and poor adherence on treatment outcomes. 
MODS was used for screening INHR and a change in critical concentration was made 
during the study due to new recommendations. LJ DST showed that the specificity of 
MODS for detection of INHR TB was relatively low: 89.7% for O.4Jlg/ml cut-off and 
81. 75% for 0.1 Jlg/ml. We were unable to determine the sensitivity of MODS for 
INHR detection due to resource limitations which prevented us conducting LJ DST on 
all patients in the screening study, therefore some cases of INHR TB may have been 
mis-classified as susceptible, particularly with a 0.4 Jlg/m I cut-off and the 
concentration change will have resulted in uneven distribution of mis-classification 
during the study. 
It was also not possible to conduct culture monitoring for treatment failure in all 
screening patients which would have enable comparison of enhanced surveillance for 
treatment outcomes between all groups. The high unfavourable outcome rate in INHR 
TB detected by culture at month 8 should be compared with drug susceptible TB to 
determine the true impact of INHR on treatment outcome. Further surveillance of 
patients up to 2 years post-treatment will also allow determination of relapse rates. 
Finally, patients who died during TB treatment, were classified as unfavourable 
outcome (all-cause mortality). This would not be totally accurate because some 
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patients may have improved clinical situations and they may die from another causes 
such as accident. The causes of death in this study were not investigated 
systematically; at least one patient died due to knife fight rather than tuberculosis. 
3.4.6 Conclusion 
In conculsion, an unfavourable outcome rate of 19% by treatment completion is 
unacceptably high, and is likely to be further augmented by relapse over the 
subsequent 1-2 years. It is clear there is an urgent need to evaluate screening 
strategies for INHR TB and to determine the optimal programmatic treatment regimen 
through randomized controlled trials. 
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Chapter 4 
Bacterial factors associated with treatment failure for Isoniazid 
Resistant Tuberculosis 
4.1 Aims 
1) Determine the association between lineage of Mtb and drug resistance. 
2) Determine the association between mutations conferring INH resistance, 
MIC level, bacterial lineage and outcome. 
3) Investigate the relationship between MIC for isoniazid and unfavourable 
outcome in cases of INH-resistant TB susceptible to rifampicin. 
4) Determine the impact of resistance to additional drugs on outcome. 
5) Compare treatment outcomes on two standardized treatment regimens for 
patients infected with different patterns ofINH polyresistance. 
4.2 Introduction 
While the majority of patients with INH resistant TB are successfully cured on 
standard regimens, the failure/relapse rate is known to be higher than for drug 
susceptible strains. The purpose of this chapter was to investigate three bacterial 
factors as risk-factors for treatment failure and relapse, namely bacterial lineage, INH 
MIC, and mutation responsible for INH resistance. 
The kltb Beijing genotype, which was first described in 1995 from the Beijing region 
of China is one of the most prevalent clades worldwide [124,356]. Beijing genotype 
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represents the predominant genotype in some regions, particularly Asia, and has been 
estimated to account for 13% of AI.tb strains circulating globally [124]. The 
prevalence of this strain is high in Asia, intermediate in the USA and Cuba and low in 
parts of Africa, Latin America, Western Europe, Eastern Europe and in the Middle 
East. The Beijing genotype has been associated with drug resistance and MDR in 
some studies but not in others [357, 358]. This variation may be due to different and 
undistinguished sublineages of the Beijing lineage but further studies are required to 
detennine the underlying reasons for these observed differences. In 2004, Beijing 
genotype strains were defined as those which hybridized by spoJigotyping to at least 
three of the spacer 35-43 in the genomic direct-repeat region, and lack spacers 1-34 
[359]. Further sub-division of the clade has been defined by several techniques 
including second-generation spoligotyping, IS6110 typing and Mycobacterial 
Interspersed repetitive units (MIRU) also known as variable number tandem repeat 
(VNTR). In early studies of the phylogeny the Beijing clade was divided into two 
principal groups named typical and atypical Beijing strains [359]. Based on large-
sequence polymorph isms, the Beijing lineage has been divided into four subgroups on 
the basis of large phylogenetic deletions known as regional difference (RD): RD I 05, 
RD181, RDI50 and RDI42 [360]. Beijing genotype strains have been considered to 
be an emerging in some regions based on evidence such as the increase in the Beijing 
genotype strains over more than 3 years in some Western European countries, strong 
correlation between this strain and young age, and the increased presence in archived 
samples conducted in South Africa [358, 361]. The emergence of Beijing genotype 
strains has been hypothesized to be due to an 'escape mutant' of BCG vaccination but 
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there is limited evidence to support this theory [358, 362, 363]. An alternative theory 
is a fitness advantage under selective drug pressure. However, the comparative 
virulence of this strain has been also investigated in terms of transmission , 
progression from latent to active TB, acquisition of drug resistance and chronicity of 
the TB disease [364]. It is possible that the Beijing lineage represents an adaptation to 
urbanization of human populations into high density populations which favours a 
higher transmission over latency. There is a significant association between this strain 
and young age in some regions which is a surrogate marker of active transmission in 
communities [365]. In a study from Vietnam, during 2003-2006, all patients with new 
sputum smear-positive pulmonary tuberculosis in 3 rural districts in Tien Giang 
Province situated in Mekong River Delta in Southern Vietnam were genotyped. 
Beijing genotype was more frequent in younger patients (15-24 years of age, 
compared to other patients (53% vs. 31 %, p<O.OO I) and associated with MDR [335]. 
The increase of Case Notification Rates was larger with the Beijing genotype than 
other genotypes but this difference was not statistically significant [335]. 
The association between Beijing genotype and specific resistance-conferring 
mutations has also been investigated. An association between Beijing genotype and 
katG315 mutations for isoniazid resistance has been demonstrated but no clear 
association is evident between this strain and any specific mutation site in the rpoB 
gene [366, 367]. This may reflect the fact that the common c1inicallpoB mutations do 
not vary substantially in the level of resistance they confer, whereas those for INH do. 
Research from Vietnam has shown that katG315 mutations, were also associated with 
unfavorable treatment outcomes compared to inhA mutations but this study found no 
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association between !wIG mutation and Beijing genotype [368]. A study from Russia 
found that Beijing strains were more likely to have mutations in the embB306 gene. 
High level fluoroquinolone and streptomycin resistance conferring genes in gyrA and 
rpsL were also found to be associated with Beijing genotype among resistant isolates 
in Vietnam [369, 370]. The underlying factors responsible for increased drug 
resistance in Beijing strains have been hypothesized to be a higher mutation 
frequency, the specific cell wall structures leading to intracellular inadequate TB drug 
concentration, efflux mechanisms or compensatory mutations which allow lower 
fitness cost of specific resistance mutations [358]. 
Mtb Beijing genotype strains may have an ability to subvert the immune response and 
alter c1in ical disease progression [371]. Patients infected with the Beij ing genotype 
strains were more likely to progress to disease in one study [119]. Many clinical 
features have been compared between patients infected with the Beijing lineage 
strains and those infected with other lineages but the results have been conflicting. In 
a study from Vietnam, patients with HIV and TBM caused by the Beijing genotype 
strains had a shorter duration of illness and a lower cerebrospinal fluid leucocyte 
count compared to other strains [372]. 
In summary, the Beijing lineage of Mtb appears to be increasing in global prevalence 
and to be associated with drug resistance. More research is required to understand the 
molecular epidemiology, potential variation in vaccine efficacy and mechanisms of 
drug resistance [358]. 
It is known that INH resistant strains of Aftb have different MICs, in particular the 
two commonest INH-resistance conferring mutations katG315 and inhA -15C_ T 
208 
mutations have high (~Sug/ml), and low MIC's (:51 ug/ml), respectively [178]. The 
clinical relevance of this is not known but serum isoniazid concentrations fall within 
this range, with 3 J..lg/ml at 2 hours after dosing being generally considered the lower 
limit of normal. It is therefore probable that patients with inhA -ISC-T isolates have 
a better chance of successful treatment with standard regimens. The katG315 mutation 
is also associated with the development of MDR and transmission, an effect not seen 
with inhA -ISC-T mutation [178]. In addition, isolates with a katG mutation are 
more likely to develop ethambutol resistance [373] which would further decrease the 
chances of successful treatment in 8 month INH/ethambutol continuation phase 
regimens. 
While many patients are successfully treated on the standard 8-month regimen, 
primary isoniazid resistance is strongly associated with failure or relapse. It is likely 
that isolates with a high MIC to isoniazid carry a higher risk of failure than those with 
a low MIC. It is possible that molecular screening of isolates for katG31S mutations 
would help to identify those at risk of treatment failure and acquiring MDR on 
treatment with standard regimens. 
Greater understanding of risk factors for treatment failure/relapse in patients with 
INHR TB will potentially help us to design screening which will target interventions 
to those at high risk of failure and avoid unnecessary increased drug administration to 
all patients. 
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4.3 Results 
4.3.1 Association of bacterial lineage with demographic characteristics and drug 
resistance 
Overall, among 2,090 isolates from patients included in the screening study LSP 
genotyping data was available for 1,780 (85.2%) cases. Beijing genotype was 
identified by LSP typing in 1,063 (59.7%) cases, Indo-Oceanic in 421 (23.6%), Euro-
American in 192 (10.8%) and 104 (5.8%) isolates had indeterminate genotype. 
LSP genotyping results were available for 241 patients with INH resistance confirmed 
by LJ DST. The results showed 162 cases (67.2%) were infected with the Beijing 
lineage, 33 cases (13.7%) with Indo Oceanic lineage, 35 cases (14.5%) with Euro 
American lineage and for II cases (4.6%) the lineage was undetermined (mixed 
infection or failed peR) (Figure 4-1). 
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A 
• Beijing 
. lndo~Oc@II"1c 
• [uro-Amerlcan 
• Indeterminate 
B 
• Beijing 
• Indo-Oceanic 
• Euro-American 
• Indeterminate 
Figure 4-1: Distribution of M.tb lineages identifed in (A) all patients and (8) patients 
infected with INHR (non MDR) M.tb confirmed by LJ DST 
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Overall, when demographic factors associated with bacterial lineage were analysed 
Beijing lineage was independently associated with young age «35 years of age) 
(OR=1.29 [95% CI 1.06-1.57], P=O.OII) and male sex (OR =1.29 [95% CI 1.03-
1.62], P=0.024). Indo-Oceanic lineage was significantly associated with older age 
(OR=0.71 [95% CI 0.57-0.90], P=0.04) . No lineage showed an association with Kinh 
ethnicity (Table 4-1). 
Analysis of drug resistance patterns showed that Beijing genotype was significantly 
associated with both INH resistance (OR= 1.63 [95% CI 1.26-2.12], P=<O.OO 1) and 
MDR (OR=4.01 [95% CI 1.88-8.55], P=<O.OOl). Conversely, Indo-Oceanic strains 
were significantly less likely to be either INH resistant (OR=0.36 [95% CI 0.25-0.52], 
P=<O.OOl) or MDR (OR=O.l2 [95% CI 0.29-0.49], P=0.003). Euro-American strains 
showed no association with drug resistance (Table 4-2). 
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Lineage Factor Crude OR 
OR 95%CI 
Beijing 
Young 1.33 1.09-1.61 
Age «35 
yrs) 
Sex 1.35 1.08-1.68 
Kinh 0.89 0.60-1.32 
ethnicity 
Indo-Oceanic 
Young 0.69 0.55-0.87 
age «35 
yrs) 
Male sex 0.74 0.57-0.97 
Kinh 0.90 0.58-1.41 
ethnicity 
Euro-American 
Young 0.84 0.62-1.14 
Age «35 
yrs) 
Male sex 0.91 0.64-1.29 
Kinh 0.98 0.53-1.81 
ethnicity 
Comparison for each lineage agamst all other strams 
* Adjusted for age, gender, etbnicity 
Adjusted OR 
P-value OR* 95%CI 
0.004 1.29 1.06-1.57 
0.008 1.29 1.03-1.62 
0.558 0.89 0.59-1.33 
<0.001 0.71 0.57-0.90 
0.027 0.78 0.60-1.02 
0.647 0.90 0.58-1.41 
0.271 0.85 0.62-1.16 
0.603 0.94 0.66-1.34 
0.938 0.97 0.52-1.81 
Table 4-1: Association between demographic factors and lineage of infecting 
M.th strain 
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P-
value 
0.011 
0.024 
0.565 
0.04 
0.659 
0.659 
0.297 
0.736 
0.938 
Lineage Drug Crude 95%CI 
resistance OR 
pattern 
Beijing 
INH 1.65 1.27-
resistant 2.14 
MDR 4.11 1.93-
8.76 
Indo-Oceanic 
INH 0.36 0.025-
resistant 0.51 
MDR 0.12 0.028-
0.48 
Eu ro-American 
INH 1.30 0.90-
resistant 1.88 
MDR 0.30 0.74-
1.26 
• Adjusted for young age «35 years of age) and sex 
Comparison for each lineage against all other strains 
P-value Adjusted 95% 
OR* CI 
<0.001 1.63 1.26-
2.12 
<0.001 4.01 1.88-
8.55 
<0.001 0.36 0.25-
0.52 
0.03 0.12 0.29-
0.49 
0.161 1.32 0.75-
1.29 
0.100 1.32 0.91-
1.91 
Table 4-2: Association between drug resistance and bacterial lineage. 
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P-
value 
<0.001 
<0.001 
<0.001 
0.003 
0.108 
0.141 
4.3.2 Impact oflNH MIC on outcome for patients with INH resistant (not MDR) 
TB 
Six of 260 isolates (2.3%) were lost or culture failed for MIC. The remaining 254 
isolates with INHR diagnosed by LJ DST were tested for MIC of INH using the 
critical concentrations of INH at 0.2 Ilg/ml, 1 Ilg/ml, 2 Ilg/ml, 4 Ilg/ml, 8 Ilg/ml and 
16 11 g/m 1. The results showed 127 isolates (50%) ofINHR strains with MIC 0.2 Ilg/ml 
~ MIC < 2 Jlg/ml and 127 cases (50%) with INHR strains with MIC ~ 2Jlg/ml. The 
detailed results are shown in Table 4-3. 
Concentration ~ 0.2 ~1 ~2 ~4 ;::8 ;:: 16 total 
(Ilg!ml) 
n (0/0) 32 95 113 9 2 3 254 
(12.6%) (37.4%) (44.5%) (3.5%) (0.8%) (1.2%) (100%) 
Table 4-3: The distribution of INH MIC among 254 INHr cases 
Treatment outomes (smear+culture) were evaluated by INH MIC level for 254 INHR 
cases (non MOR) diagnosed by LJ OST. The results are shown in the Table 4-4. 
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Concentration Outcomes Total 
blg/ml) /outcomes 
Cured Treatment Died Lost to Treatment Not Total 
n (%) completed n (%) follow- failed evaluated n (%) 
n (%) up n (%) n (%) 
n (%) 
2:0.2 25 0 0 0 7 0 32 
(12.0%) (18.4%) (12.6%) 
2:1 77 0 1 2 15 0 95 
(37.0%) (50%) (33%) (39.5%) (37.4%) 
2:2 93 0 I 4 15 0 113 
(44.7%) (50%) (67%) (39.4%) (44.5%) 
2:4 8 0 0 0 1 0 9 
(3.8%) (2.6%) (3.5%) 
2:8 2 0 0 0 0 0 2 
(9.6%) (0.8%) 
2:16 3 0 0 
0 0 0 3 
(1.4%) (1.2%) 
Total 208 0 2 6 38 0 254 
(100%) (100%) (100%) (100%) (100%) 
Table 4-4: Treatment outcomes by INH MIC level 
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MIC to INH was categorized into high «~ 1 Ilg/ml) and low «lllg/ml) for further 
analysis. Treatment outcomes were categorized as favourable (cured and treatment 
completed) or unfavourable (death, lost to follow-up, treatment failed and not 
evaluated). 
There was no association between unfavourable outcome and high MIC (OR=0.83 
[95%CI 0.38-2.06], P=0.69. Further, there was no association between high MIC and 
bacterial lineage (ANOV A, P=0.289) (Table 4-5). 
MIC / outcome Unfavourable Favourable Total OR,l95%CIJ. 
outcome outcome n (%) p-value* 
n (%) n (%) 
High MIC 39 (17.6) 183 (82.4) 222 (100) BASELINE 
(> 1 p.g/ml) 
Low MIC 7 (21.9) 25 (78.1) 32 (100) OR-0.83 
«1 p.g/ml) [95% CI 0.38-2.06] 
P=0.69. 
Total 45 (17.7) 209 (82.3) 254 (100) 
Table 4-5: Association between MIC category and and unfavourable treatment 
outcome 
4.3.3 Mutations identified by MAS_INH PCR among INHR isolates 
MAS-INH PCR demonstrated that 197 cases (77.3 %) were infected with isolates 
with a kalG mutation, 21 cases (8.2 %) had inhA promoter mutation and 37 cases 
(14.5 %) showed WT isolates (Figure 4-2). 
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• kJ tG 
. inhA 
Fig ure 4-2 : Distribution of mutations identified by MAS PCR in patients with 
INHR (not MDR) by LJ culture 
.t.3A Association between INH-resistance mutation and MIC for iso niazid 
M IC and mutation data was availab le on 299 IN H res istant iso lates. including MDR 
stra ins. MIC was categorized into high (~ lll g/ml ) and low MIC « I Il g/111 I). KOIG 
mutated isolates were signifi cantly more likely to have hi gh MI C to INH (OR= II .73 
r95 % C I 5.25-26.2]. P=O.OO I ) while inhA mutants and wild-type strain s were 
significantly less likely to have a high MIC to INH (OR=O.05 [95%CI 0. 19-13 .01. 
P<O.OO I ). Table 4-6 shows the association between mutati ons and MIC in 299 ca cs 
wi th I HI{ diagnosed by LJ DST in this study. 
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INHMIC KatG II (%) ill/,A ,,(%) Wildtype n(%) Total n(%) 
Low 
0.2 10 (4.3) 14 (60.9) 10 (21.7) 34 (11.4) 
Total 
Higb 
1 100 (43.5) 2 (8.7) 19 (41.3) 121 (40.5) 
2 107 (46.5) 3 (13.0) 15 (34.9) 125 (41.8) 
4 12 (5.2) 0 0 12 (4.0) 
8 0 1 (4.3) 1 (2.2) 2 (0.7) 
16 1 (0.4) 3 (13.0) 1 (2.2) 5 (1.7) 
Total 230 (100) 23 (100) 46 (100) 299 (100) 
I 
-- --
Table 4-6: Distribution of INH MIC among isolates with different mutations conferring INH resistance 
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4.3.5 Association between Bacterial lineage and INH resistance mutation 
Beijing lineage was significantly associated with katG mutation among INHR isolates, 
(OR=2.01 [9S% CI 1.23-3.S8], P=0.018), while Indo-Oceanic strains were 
significantly less likely to have a katG mutation (OR=0.34 [9S%CI 0.16-0.70], 
P=0.003). No lineage showed an association with inhA promoter mutation. Indo -
oceanic strains were significantly more likely to be wild type, carrying neither a katG 
nor an inhA promoter mutation (OR=3.79 [1.7S-8.19], P=O.OOI)(Table 4-7). 
Lineage KatG inhA Wild type 
N=295 
OR 9S% P- OR 95% P- OR 95% P-
CI value CI value CI value 
Beijing N=218 
2.01 1.23- 0.018 1.07 0.41- 0.888 0.39 0.20- O.OOS 
3.S8 2.81 0.75 
Indo-Oceanic N=36 
0.34 0.16- 0.003 1.01 0.29- 0.989 3.79 1.75- 0.001 
0.70 3.S7 8.19 
Euro-American N=41 
0.95 0.44- 0.891 0.88 0.25- 0.848 1.15 0.47- 0.760 
2.05 3.11 2.78 
Table 4-7: Association between M.tb lineages and mutation conferring INH 
resistance among 295 INHR isolates 
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4.3.6 Association between INH resistance mutation and unfavourable outcome 
The relationship between INHR mutation and treatment outcome was investigated for 
255 cases with INHR (non MDR) diagnosed by LJ DST(table 4.8). There was no 
association between !mtG (P=0.281), inhA (P=O.578) or wild-type (0.395) with 
unfavourable outcome. The results are presented in table 4.9 
Treatment Cured Treatment Treatment Lost to Died Total 
outcomes n (%) completed failed follow-up n (%) n (%) 
n (%) n (%) n (%) 
katG 164 0 27 (13.7) 6 (3.0) 2 (1.0) 197 (100) 
mutation (83.7) 
illltA 17 (81.0) 0 4 (19.0) 0 0 21 (100) 
mutation 
WT 28 (75.7) 0 9 (24.3) 0 37 (100) 
Total 207 40 (15.6) 6 (2.4) 2 (0.8) 255 (100) 
(81.2) 
Table 4-8: Treatment outcomes and mutation types of 255 cases with INHR (non 
MDR) 
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INH Favourable Unfavourable Total OR, [95%CI] and 
resistance outcome outcome n(%) value* 
mutation n(%) n(%) 
kutG 164 (82.2) 35 (17.8) 197(100) 0.68 [0.34-1.37J 0.281 
mutation 
bIllA 17 (81.0) 4(19.0) 21 (100) 1.35 [0.47-3.88J 0.578 
Wild type 28 (75.7) 9 (24.3) 37 (100) 1.43 [0.63-3.27J 0.395 
total 209 (80.8) 46 (19.2) 255 (100) 
Comparison for each mutatIOn type with other pooled mutalOn types. 
Table 4-9: Association between treatment outcomes and INHR mutations among 
255 cases with INHR (non MDR) TB 
4.3.7 Association between unfavourable outcome and M.th lineage 
The final outcomes by Mtb lineage of the infecting strain were assessed in 229 
patients with INHR (non MDR) TB confinned by LJ DST. 
There was no significant association of any Mtb lineage with unfavourable outcome 
(table 4.10). 
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p-
Mtb Outcome Crude OR* Adjusted OR** 
Lineage 
Favourable Unfavourable OR 95%CI P-value OR 95%CI 
n (%) n(%) 
Beijing 126 (78.3) 35 (21.7) 2.08 0.91-4.76 0.08 2.37 0.97-5.83 
n=161 
Indo- 26 (89.7) 3 (10.3) 0.46 1.33-1.60 0.223 0.43 0.12-1.57 
Oceanic 
n=29 
Euro- 34(87.2) 5 (12.8) 0.59 0.22-1.61 0.300 0.55 0.19-1.59 
American 
n=34 
Total 186 (81.2) 43 (18.8) 
n=229 
*OR for unfavourable outcome. Each lineage compared to others combmed. 
**adjusted for resistance to streptomycin, ethambutol and pyrazinamide and 
treatment regimen. 
Patients with MDR TB and receiving individualized regimens excluded. 
Table 4-10: Treatment outcomes in 229 INHR cases (non MDR) by M.th lineage 
of the infecting strain 
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P-value 
0.059 
0.201 
0.273 
4.3.8 Treatment outcomes by drug resistance profile among patients with INH 
resistant TB 
LJ DST was performed for INH, RiF, SM, PZA and EMB for 340 samples with INHR 
by MODS. The results showed 55 cases with MDR (INH and RiF resistance) and 260 
cases with INHR. Among these 260 cases, 52 cases were INH monoresistant, 184 
cases were resistant to INH and SM and 24 cases were INH polyresistant with other 
DST profiles (not MDR). 260 cases with INHR (not MDR) were followed up to 
evaluate their treatment outcomes. Discrepencies in treatment outcome between INH 
monoresistant cases and INH polyresistant cases (excluding MDR) were investigated 
(Table 4-11). 
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DST profile Treatment outcomes 
Cured Treatment Died Lost to Treatment 
completed foil ow- failed 
up 
INHR 41 (78.8) 0 0 0 11 (21.2) 
SMK+INHK 159 0 I (0.5) 5 (2.7) 20 (10.9) 
(85.9) 
INHR + PZAK 0 0 0 0 2 (l00) 
SM/\ + INHR + 1 (25.0) 0 0 1 (25.0) 2 (50.0) 
EMBR 
SM" + INHK + 13 (76.5) 0 0 0 4 (23.5) 
PZAR 
SMK + INHK + 0 1 0 0 
EMBR+PZAR (100) 
Total 213 (81.9) 0 2 (0.8) 6 (2.3) 39 (15.0) 
Table 4-11: Treatment outcome in patients with INH resistant TB (excluding 
MDR) by drug resistance profile 
Total 
52 (I 00) 
184 (100) 
2 (100) 
4 (100) 
17 (l00) 
I (100) 
260 (l00) 
Treatment outomes (smear + culture) were compared for patients infected with INHR 
+/_ SM R with those infected with strains with additional drug resistance (lNH 
polyresistance). For those patients receiving the regimen of2RHZE/6HE, SMR should 
have no impact on outcome. Patients with INH po\yresistance (not MDR) were more 
likely to have unfavourable outcome compared to patients with INHR +/- SMR (the 
regimens for these patients were 2SHRZ/6HE and 2RHZE/6HE) (OR=3.84, 95%Cl: 
1.59-9.30, p=O.003) (Table 4-12 and Figure 4-3). 
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Unfavourable Favou ra ble Total OR, [95%C Ij, 
outcome outcome n(%) p-value* 
n (%) n (%» 
INH 10(4 1. 7%) 14 (58 .3%) 24 (100%) OR=3.84 
poly res istance [ 1.59-9.30] 
p=0.003 
INHH +/- SM1( 37 ( \5.7%) 199 (84.3%) 236 BASELINE 
Tota l 46 2 14 260 
* Iog lstl c regressIOn 
Table 4-12: Association between treatment outcomes a nd DST profile for 260 
patients with INHR TB 
OJ 
tlO 
ro 
+-' 
c 
OJ 
u 
~ 
OJ 
a. 
100% ---
80% 
60% 
40% 
20% 
0% 
INHR+/-SMR 
N=236 
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*Polyresistance= additional res istance to ethambutol and/or py razinamide. 
Figure 4-3 : Association between INH resistance profiles and treatment outcomes 
in 260 INHR cases 
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4.3.9 Multivaraite analysis of bacterial factors associated with unfavourable 
treatment outcome 
Association of Beijing lineage, katG mutation, treatment with streptomycin 
(2SRHZ/6HE), streptomycin resistance and ethambutol resistance was analysed for 
association with unfavourable outcome (including culture) additionally adjusted for 
MODS concentration (table 4.13). Among 225 cases with all variables available, 
excluding those receiving individualized regimens, the adjusted OR for association of 
Beijing genotype with unfavourable treatment outcome (including culture) was 2.52 
[95% CI 1.00-6.31], P=0.028. Streptomycin resistance was associated with favourable 
outcome (adjusted OR=0.37 [0.154-0.88], P=0.024). 
Resistance to ethambutol was significantly associated with unfavourable outcome 
(adjusted OR=2 I. 1 [2.00-222.50], P=O.OII). 
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Variable Unfavourable Crude 95% p- Adjusted 95% p-
N=225 outcomes n OR CI value OR CI value 
Beijing 35 2.08 0.91- 0.082 2.52 1.00- 0.049 
lineage 4.76 6.31 
n=161 
/wIG 31 0.81 0.38- 0.600 0.59 0.22- 0.283 
mutation 1.76 1.56 
n=173 
Streptomycin 15 1.96 0.95- 0.067 2.09 0.87- 0.101 
treatment* 4.01 5.06 
N=55 
Streptomycin 30 0.59 0.28- 0.167 0.37 0.154 0.024 
resistance 1.24 0.88 
N=178 
Ethambutol 3 13.88 1041- 0.024 21.1 2.00- 0.011 
resistance 136.85 222.50 
n=4 
MODS 12 0.64 0.31- 0.233 0.78 0.32 0.586 
concentration 1.33 1.92 
N=82 
(O.lllg/ml ) 
*2SRHZ/6HE 
Excluding individuals receiving individualized regimens. 
Table 4-13: The univariate (unadjusted) and multivariate (adjusted) OR, 95% 
CI and p values for the association between risk factors and treatment outcomes 
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4.3.1 0 Comparison of treatment outcomes of 2 regimens (2SRHZl6HE and 
2RHZE/6HE) in patients with INH and SM resistance confirmed by LJ culture 
and DST 
There were 184 cases with INHR and SMR diagnosed by LJ culture. Overall, the 
favourable outcome rate in patients with SM+INH resistance was 86.4 % (159/184). 
From the end of 2009, the regimen 2SRHZ/6HE was replaced by the regimen 
2RHZE/6HE at DTUs according to Vietnam NTP. We compared the treatment 
outcomes of patients treated with these two regimens among patients infected with 
strains resistant to both isoniazid and streptomycin but susceptible to other first line 
drugs (INHR + and SMR). The treatment outcomes by treatment regimen 
(2SRHZ/6HE and 2RHZE/6HE) are shown in the table 4.14. 
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Regimen Treatment outcome 
Cured Treatment Lost to Died Total 
n (%) failed follow-
up 
2SRHZl6HE 33 (76.7) 7 (16.3) 3 (7) 0 43 (100) 
2RHZE/6HE 118 (90.8) 12 (9.2) 0 0 130(100) 
other 7 (66.7) 1 (8.3) 2 (16.7) I (8.3) 11 (100) 
regimens 
Total 158 (86.4) 20(10.9) 5 (2.7) I (0.5) 184(100) 
Table 4-14: Treatment outcomes in patients with SM+INH resistance according 
to different regimens 
In patients with SM and INH resistant TB, if the regimen of 2SRHZ/6HE was used 
the cured rate was 76.7% (n=33/43) and the unfavourable outcome rate was 23.3% 
(n= 1 0/43). In contrast, if the regimen of 2RHZE/6HE was used, the cured rate 
increased to 90.8% (n=118/130) and the unfavourable outcome rate decreased to 
12.0% (n=12/130) (table 4-14). This difference was not statistically significant 
(OR=1.88[95 % CI 0.82-4.28] P=0.134). 
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4.3.11 Treatment outcomes of patients with INH monoresistance confirmed by 
LJ culture and DST 
Fifty two cases with INH monoresistance diagnosed by LJ culture were investigated. 
In 52 patients with INH monoresistance by LJ, 48 cases were treated with the regimen 
of 2RHZE/6HE, 10 cases were treated with the regimen of 2SRHZ/6HE and 4 cases 
were treated with other individualized regimens (2SRHZ/SHE-Oflo/6E-Oflo , 
2SRHZ/RHZ/5RHE, 3RHEZ/5HE and 3RHZE/3RH). Treatment outcomes were 
compared for patients receiving the two standardized regimens in 48 cases with INH 
monoresistant TB. Although the unfavourable outcome rate was doubled with 
2SRHZ/6HE regimen (30.0%) compared to 2RHZE/6HE (15.8%) this difference was 
not statisticaIly significant (P=0.370) among patients with INH monoresistance 
diagnosed by LJ culture (Table 4. I 5) 
Regimen Favourable Unfavourable Total OR, [95%CI] and p 
outcome outcome n(%) value· 
n(%) n(%) 
2RHZE/6HE 32 (84.2) 6(15.8) 38 (100) OR=2.24 [0.29-14.12] 
p=0.370 
2SRHZl6HE 7 (70.0) 3 (30.0) 10 (l00) BASELINE 
total 39 (81.3) 9 (18.8) 48 (100) 
Table 4-15 : Treatment outcomes in INH monoresistant TB patients (diagnosed 
by LJ) with two regimens 
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4.4 Discussion 
4.4.1 Bacterial lineage 
Beijing genotype was associated with young age, male sex, isoniazid resistance and 
MDR in this study. Indo-Oceanic strains were associated with older age and less 
likely to be either isoniazid resistant or MDR. Three major lineages of Aftb are 
circulating in Vietnam, those of the Beijing and Euro-American lineage belong to the 
'modern' lineages as defined by deletion of the TDt region, and the Indo-Oceanic 
linege is an 'ancient' lineage. 
The evidence from this study contributes to the body of evidence that Beijing 
genotype strains are associated with drug resistance and with active transmission 
among young adults in Vietnam. Beijing genotype strains which were resistant to 
isoniazid were also more likely to carry a KatG mutation which confers a higher MIC 
than inM or wild-type isoniazid resistant strains, whereas Indo-Oceanic strains were 
more likely to be wild-type with other unknown resistance mechanisms to isoniazid. 
Overall, Beijing lineage was an independent risk factor for unfavourable outcome. 
The mechanism underlying this is unknown but may increase drug tolerance accross 
the spectrum of drugs used in multi-drug therapy due to an intrinsic mechanism such 
as efflux or permeability. Alternatively, Beijing genotype may subvert the immune 
response to Mtb, resulting in ineffective clearance of bacilli even after treatment is 
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initiated or have a higher tolerance to oxidative stress encountered within the 
phagosome [371]. 
Further research is required to elucidate the underlying mechanisms responsible for 
the increased treatment failure seen among patients infected with the Beijing genotype 
of Mtb. It would not be practical to screen patients for the infecting genotype, nor is it 
clear if alternative treatment regimens would be more effective as this will depend on 
the underlying mechanism responsible for these epidemiologically observed 
associations. 
4.4.2 INH MIC 
There was no association between high MIC to INH and unfavourable treatment 
outcome among patients with INH resistant TB. This suggests that INH MIC above 
0.2 J.1g1ml are resistant to serum levels achieved under standard INH treatment doses 
and the current critical concentration for INH in vitro is appropriate. We were not able 
to evaluate pharmacokinetic levels of INH in patients which would have enabled us to 
examine the relationship between INH MIC and unfavourable outcomes in more 
detail. The influence ofNAT2 acetylator status is investigated in the next chapter. 
4.4.3 INH resistance mutation 
The majority of INH resistant isolates in this study had a mutation in katG responsible 
for INH resistance (77.3%). This is consistent with data from other studies which 
shows a high prevalence of katG mutated isolates among INH resistant isolates from 
Vietnam and Asia [345-348] [349]. 
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KatG mutation was significantly more likely to have high MIC to INH than other 
resistant strains. This is consistent with data from other studies and confirms that the 
kalG mutation confers a high level of INH resistance. A study by Gagneux et af. also 
demonstrated that the backbone genotype of Aflb influences the level of resistance to 
INH conferred by a mutation, with Beijing genotype isolates carrying a kalG mutation 
having a higher MIC to INH than katG mutated isolates of other Iineages[] 77]. Again, 
the underlying mechanisms responsible for this association are unknown and require 
further investigation. 
A recent study in the United States showed that patients with isoniazid resistant Til 
without kalG mutation had a higher rate of sputum culture conversion at month 1 
(aOR=4.4, 95% CI 1.1-23.6,p=0.04), which suggests kalG mutants have a slower 
bacterial clearance in response to treatment [374]. A study conducted in Mumbai, 
India also showed an association between kalG and poor outcome (p=0.037). 
However, in this study the GenoType MTBDRpfus line probe assay was used to 
determine mutations and therefore only katG and inhA mutations were detected, rather 
than phenotypic resistance. Resistance to INH through kalG mutation may also be 
associated with resistance to SM and EMB and this is likely to impact treatment 
outcomes [375] [376]. 
In the present study, there was no association between katG mutation and 
unfavourable treatment outcome in patients with INH resistance (non MDR) 
(aOR=O.59, 95% CI : 0.22-1.56, p =0.283) (Table 4-8 and Table 4-13). In South 
A frica a study also found no evidence of association between treatment outcome and 
specific isoniazid resistance conferring mutation performed by sequencing [331]. The 
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circulating backbone Mtb strains vary in different settings and this may account for 
the different findings. Global studies are required to fully elucidate the relationship 
between mutation, bacterial lineage and treatment outcome. 
4.4.4 Impact of additional drug resistance on outcome 
Patients with INHR monoresistance had an unfavourable outcome of 21.2% compared 
with patients with INHR +SMR (l0.9%), and patients with polyresistance (lNHR plus 
resistance to EMB or PZA, not MDR) (41.7%). Patients with additional drug 
resistance, excluding streptomycin, are likely to require treatment regimens including 
second line drugs, ideally a fluoroquinolone where susceptible. The optimal regimens 
and duration are undetermined and must be guided by patient treatment history, DST 
when available and response to therapy. 
4.4.5 Conclusion 
Beijing genotype was associated with INH resistance, MDR, young age and male sex. 
Among INH resistant isolates, Beijing genotype was also associated with 
unfavourable treatment outcome. No associations were identified between 
unfavourable treatment outcome and INH resistance mutation or MIC and 
unfavourable outcome. Further in vitro and epidemiological studies are required to 
understand the mechanisms responsible for the association of Beijing genotype and 
with treatment failure. These studies will improve understanding of the mechanisms 
responsible for the global emergence of the Beijing genotype and the evolution of 
mechanisms in kftb which combat existing treating strategies and allow the 
emergence and propagation of drug resistant TB, which is a major threat to global TB 
control in the existing landscape of limited effective drug therapies. 
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Chapter 5 
Drug-induced hepatitis and INH resistant TB 
5.1 Aims 
]) Determine the seropreva]ence of hepatitis B surface antigen (HBsAg) and 
hepatitis C anti HCV in patients with INH resistant TB diagnosed by MODS 
2) Characterise the incidence of symptomatic and asymptomatic ATOUI in 
patients with INH resistant pulmonary TB in Ho Chi Minh City 
3) Identify risk factors associated with development of A TDIH. 
4) Examine the effect of A TDIH on the viral dynamics of HBV in infected 
patients. 
5.2 Introduction 
Anti-tuberculous drug induced hepatitis or hepatotoxicity (A TDIH) is a potentially 
serious complication of the treatment of both active and latent tuberculosis with first 
line drugs. This hepatitis can be serious enough to result in death, although 
asymptomatic hepatitis (elevated liver transaminases in the absence of symptoms) is 
commoner. Pyrazinamide is the drug most frequently implicated, but hepatitis is also 
associated with other agents including isoniazid and rifampicin (377]. The risk of 
A TDIH is largely influenced by underlying risk factors and varies from 5 - 33% in 
published reports (378]. Interruption of treatment is often sufficient to resolve the 
hepatotoxicity. A gradual sequential re-introduction of each drug is usually well-
236 
tolerated without recurrence of hepatotoxicity [292]. However, the overall outcome in 
TB is adversely influenced by treatment interruptions - for example, a trial of 
dexamethasone as adjunctive treatment in TB meningitis at our hospital found 
treatment interruption to be one of the most sensitive predictors of a poor outcome, 
after advanced disease stage at diagnosis. Treatment interruption is also associated 
with the development of drug resistance in TB [379]. Interestingly, in the study of 
dexamethasone in TB meningitis by our group there was a marked difference in the 
incidence of ATDIH between the patients receiving dexamethasone and those 
receiving placebo - there were no cases of severe hepatotoxicity in the steroid arm but 
8/274 (2.9%, P=0.004) in the placebo arm, suggesting that the reduction in mortality 
in patients receiving steroids may in part be due to a hepato-protective effect of 
dexamethasone [380]. 
Factors that are implicated in the development of ATDIH include gender, older age, 
concomitant use of other hepatotoxic drugs, malnutrition, heavy alcohol consumption 
and pre-existing liver disease [281, 379, 381-385]. Racial and genetic factors (such as 
acetylator status) are also probably important although there is conflicting evidence 
over their roles [382, 386-388]. The role of factors such as co-infection with 
hepatotrophic viruses such as hepatitis B virus (HBY) and hepatitis C virus (HCY) is 
also unclear [303, 316, 381,389]. Infection with these viruses is common in Yietnam, 
with HBY infection approaching 10% in the general population, and HCY infection 
rare in the general population but approaching 100% in some groups such as 
intravenous drug users [314, 390]. Similarly, the effect of ATDIH on the viral 
dynamics of these infections has not been studied. ATDIH may be associated with 
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increases in viral replication, which theoretically may have adverse consequences, 
since level of viraemia correlates with progression of liver disease. There are no data 
describing the relationship between the level of HBV or HCV viraemia and the 
subsequent risk of ATDIH. An understanding of the prevalence of ATDIH in 
Vietnamese patients and the ability to predict which patients are at risk of ATDIH 
would help in the design of clinical interventions to protect against ATDIH, which 
may have both a mortality benefit and a benefit in reducing the likelihood ofTB drug 
resistance developing. 
The aim of this chapter was to determine the seroprevalence of hepatitis B surface 
antigen (HBsAg) and hepatitis C anti HCV and to characterise the incidence of 
A TOIH in patients with INH resistant pulmonary TB in Ho Chi Minh City diagnosed 
by MODS, and identify risk factors associated with its development. The effect of 
ATOIH on the viral dynamics ofHBV in infected patients was also examined. 
5.3 Results 
5.3.1 Prevalence of Hepatitis B/C infection among patients with INHR TB 
Among 347 patients with INH resistance by MODS who were tested for serum 
HBsAg and antiHCV at month 0, month 1, month 2 and month 3; 34 cases (9.8%) 
were seropositive for HBsAg in which there were 3 cases of seroconversion and 16 
cases (4.6%) were positive for antiHCV with 2 cases of seroconversion. There was 
one case that was positive for both hepatitis B and hepatitis C infection. The total of 
patients with either hepatitis B or hepatitis C infection was 49/347 cases (14.1 %). 
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5.3.2 Liver function tests in patients with viral hepatitis infection 
Alanine aminotransferase (ALT) levels in patients infected with hepatitis B/C were as 
follows: mean 40.73 V/I, SO 75.74, range: 5-521. ALT level was elevated (>200 VI) 
in only 1 case (n=1I49, 2.0%). Mean pretreatment total bilirubin liver function tests in 
patients infected with viral hepatitis was 15.4 ~mol/I (SO: 5.87, range: 2.2 -36). Nine 
patients (n=9/49, 18.4%) had elevated total bilirubin (above 19 ~mol/L). A single case 
of protein level was identified < 60 giL (1149 = 2%). For blood Albumin/Globulin 
ratio (NG), there were 36 cases with NG <1 (36/49 = 73.5%). 
5.3.3 Demographic risk factors for viral hepatitis infection 
Baseline demographic data for 34 patients with positive HBsAg are shown in Table 5-
I. 
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n (%)/ median [IQR] 
Age 38 [28.8-43.5] 
Male sex 29 (85.3%) 
Occupation 
Manual labour 29 (85.3%) 
Professional/administrative 1 (2.9%) 
Retiredlhousewife 2 (5.9%) 
No employment 2 (5.9%) 
Total 34 (100%) 
Duration of illness 30, [15-90 days] 
Districts 
Pham N goe Thach 1 (2.9%) 
Phu Nhuan 3 (8.8%) 
District 6 4 (11.8%) 
District 4 3 (8.8%) 
Binh Thanh 4(11.8%) 
District 1 7 (10.6%) 
District 8 4 (11.8%) 
Tan Binh 8 (23.5%) 
Total 34 (100%) 
Table 5-1: Demographic characteristics of 34 patients with positive HBsAg test 
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Demographic characteristics ofHBV infected and un infected patients are compared in 
Table 5-2. No demographic factors associated with hepatitis B infection were 
identified. 
Characteristics HBsAg (+) HBsAg (-) Crude OR (95% CI) 
n=34 n=313 
Age (median [IQR]) 38 (29 - 44) 39 (28 - 48) 0.99 (0.97 - 1.02) 
Male sex 29 (85%) 224 (72%) 2.30 (0.86 - 6.14) 
Occupation: manual labour 29 (85%) 226 (72%) 2.23 (0.84 - 5.95) 
Treatment centre: PNT* 1 (3%) 14 (4%) 0.65 (0.08 - 5.08) 
*PNT compared with local DTUs 
Table 5-2: Comparison of demographic factors among hepatitis B infected and 
uninfected patients 
A total of 16 cases with positive antiHCV were identified. Baseline demographics for 
these patients are shown in Table 5-3. 
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P value 
0.711 
0.095 
0.108 
0.679 
n (%)/ median [IQR} 
Age 46 [35.0-52.5] 
Male Sex 15 (93.8%) 
Occupation 
Manual labour 9 (56.2%) 
Professional/administrative I (6.3%) 
Retired/housewife 3 (18.8%) 
No employment 3 (18.8%) 
Total 16 (100%) 
Duration of illness 30 [14.0-67.5] 
Treatment centre 
Pham Ngoc Thach 1 (6.3%) 
Phu Nhuan 3 (18.8%) 
District 6 4 (25.0%) 
District 4 I (6.3%) 
Binh Thanh 3 (18.8%) 
District 1 2 (12.5%) 
District 8 1 (6.3%) 
Tan Binh 1 (6.3%) 
Total 16 (100%) 
Table 5-3: Demographic characteristics of 16 patients with positive antiHCV test 
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5.3.4 Comparison of treatment outcomes in patients infected with hepatitis B/C 
and those uninfected 
Of 49 cases positive for HBsAg or antiHCV, 9 cases were diagnosed as MDR and 3 
cases received individualized regimens leaving 37 cases of hepatitis co-infection in 
the treatment outcome analysis. The treatment outcomes of this group were compared 
to patients negative for HBsAg and antiHCV among patients with INHR (not MDR) 
TB. 
Favourable outcome includes cured and treatment completed outcomes and 
unfavourable outcome includes died, lost to follow-up and treatment failed outcomes. 
There was no difference between treatment outcomes (favourable and unfavourable 
outcomes) in those infected with viral hepatitis and those uninfected OR=0.69 [95% 
CI0.25; 1.89], P=0.475.The details are shown in Table 5-4. 
Favourable Unfavourable Total OR,[ 95% elj, 
outcome outcome n (%) p value'" 
n (%) n (%) 
HBsAG/ 181 (80.1) 45 (19.9) 226 (100) BASELINE 
antiHCV 
negative 
HBsAG/ 29 (85.3) 5 (14.7) 34 (100) 0.69 [0.25-1.89], 
antiHCV P=0.475 
positive 
Total 210 (80.8) 50 (19.2) 260 (100) 
Table 5-4 : Association between treatment outcome and viral hepatitis infection 
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5.3.5 Incidence of antituberculous drug induced hepatitis 
According to the diagnostic criteria for ATOIH (serum ALT levels> 3 times ULN 
plus clinical features of hepatitis such as anorexia, nausea and vomiting or serum ALT 
levels > 5 times ULN without symptoms and/or serum total bilirubin of > 32.49 
flmollL (> 1.5-1.7 times ULN with normal level of 19 flmolll) [378], there were 11 
cases with ATOIH. The cumulative incidence risk of DIH was 3.17% (11/347). 
Based on the World Health Organization (WHO) Toxicity Classification Standards 
[140, 391], there was one case with mild DIH (ALT at month 1: 181 U/I) (mild 
ATDIH is defined as ALT elevation of 3-5 times the ULN (121-200 VII), 6 cases 
were considered as moderate DIH (5-10 times the VLN: 201-400 V/l) and no case 
with severe A TDIH (> 10 times the ULN : > 400 VII). There were 4 cases with 
increased serum bilirubin (two cases at month 2 and two cases at month 3). One 
patient developed the increase of AL T at month 1, three cases developed the increase 
of ALT at month 2 and three cases increased ALT levels at month 3. Six cases (3 
cases with positive HBsAg tests and 3 cases with positive antiHCV tests) developed 
A TDIH (the rate for DIH in patients with viral hepatitis BIC was 6/49 = 12.2%). All 
these 4 cases did not have increase in Akaline Phosphatase (ALP) (The nonnal value 
of ALP ranges from 50 to 258 V/I). 
5.3.6 Risk factors for ATDIH 
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No significant differences were observed in tenns of age, gender, serum protein, BMI, 
between patients who had ATDIH and those who did not have ATDIH (Table 5-5). 
Patients with hepatitis B infection were significantly more likely to have ATDIH than 
those without viral hepatitis infection (37.5% vs. 9.3%) OR=5.86 [95% CI 1.33-25.7], 
P=0.019. Patients with hepatits C infection were also at significantly greater risk of 
ATDIH than those without viral hepatitis infection: OR=14.7 [95% CI 3.13-68.6], 
P=O.OO 1. Overall viral hepatitis infection (B/C) was significantly associated with 
ATDIH OR=8.18 [95% CI 2.39-28.0], P=O.OO 1. The details are shown in Table 5-5. 
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Risk factor Crude OR (95% CI) P value 
N=2,090 
Age' (years) 1.02 (0.98, 1.05) 0.378 
male gender n=1524 1.06 [0.28-3.99 0.937 
HBsAg (+) n=34 5.86 [1.33-25.7] 0.019 
HCVAb (+) n=16 14.7 [3.13-68.6J 0.001 
HBsAg (+) L HCVAb (+) n=49 8.18 [2.39-28.0J 0.001 
Serum protein (gIL) 1.0 I [0.91- 1.12] 0.838 
BMI (kglm2) 1.06 [0.84- 1.34] 0.634 
Table 5-5 : Risk factors for ATDIH 
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5.3.7 Treatment outcomes in patients with ATDIH 
Treatment outcomes were compared between patients with and without A TOIH, 
excluding MOR cases and those treated with individualized regimens. 
There was no significant difference in treatment outcomes (unfavourable and 
favourable outcomes) between patients with A TDIH and those without A TDIH for 
patients with INH resistant TB (non-MOR). The number of ATDIH events in the 
study overall was too low to detect a significant difference (Table 5-6). 
Favourable Unfavourable Total n (%) OR, 95%CI, P 
outcome n outcome n value 
(%) (%) 
No ATDllI 204 (80.6) 49(19.4) 253 (100) BASELINE 
ATDIH 6 (85.7) 1 (14.3) 7 (100) 0.69 [0.82; 5.90], 
0.738 
Total 210(80.8) 50 (19.2) 260 (100) 
Excluding MDR and patients receiving individualized regimens. 
Table 5-6: Treatment outcomes among patients with ATDIH and without ATDIH ( 
patients with INHR not MDR) 
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5.3.8 Viral dynamics in patients infected with viral hepatitis 
There were 34 cases with positive HBsAg in which 31 cases (3 cases were not 
measured HBV DNA) HBV DNA was measured at month 0, month 1, month 2 and 
month 3. In one case HBV DNA was not detected at month 0, month 1, month 2 and 
month 3. There were 18 cases in which HBV DNA was detected at month 0, month 
1, month 2 and month 3. In seven cases HBV DNA was detected at 3 times. In two 
cases HBV DNA was detected at 2 times and three cases HBV DNA was detected 
only one time. The values of HBV DNA were transferred to logarithm of 10. 
Figure 5-1 shows HBV DNA viral load counts of 30 patients related to month 0, 
month 1, month 2 and month 3. 
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Figure 5-1: Dynamics ofHBV DNA counts at month 0, 1,2 and 3 in 30 patients 
with positive HBsAg tests 
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The correlation between HBY DNA and AL T values was evaluated by measure of 
association using Pearson ' s correlation and calculating Pearson's correlation 
coefficient. The result showed there was a positive correlation (r = 0.24) between 
HBY DNA and AL T values in patients with positive HBY DNA test (95%CI: 0.04-
0.42, p= 0.02) (Figure 5-2) . 
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Figure 5-2 : Association between HBV DNA and ALT values in patients with 
positive HBV DNA 
250 
5.4 Discussion 
5.4.1 Prevalence of viral hepatitis among Vietnamese INHR TB patients 
Hepatitis B virus infection is common in Southeast Asia and the Western Pacific with 
a prevalence of from 2% to 3 I % [392, 393]. Studies in different regions of Vietnam 
have shown a prevalence of HBsAg of between 4 and 18% in the population[394-
396]. To my knowledge, this is the first study to determine the prevalence of ~msAg 
in TB patients in Vietnam. Although only patients with INH resistant TB diagnosed 
by MODS were tested for HBsAg, the prevalence of HBsAg positivity was 9.8% and 
this result is consistent with the background population prevalence in Vietnam. The 
prevalence of antiHCV among INH study patients was 4.6% which was relatively 
high for an HIV uninfected population; the reason for this is unclear and a larger 
group of TB patients should be evaluated to determine if this high prevalence is 
representative. HCV infection is concentrated in high risk groups in Vietnam as in 
other settings; for example 55.6% for people at high risk such as IDUs, or only 0.5% 
for people at low risk such as voluntary blood donors, soldiers and pregnant women. 
The prevalence also varies geographically [397]. 
Treatment after development of ATDIH was undertaken according to Vietnam NTP 
guidelines, as determined by the treating clinician. When patients exhibited ATDIH, 
all hepatotoxic drugs were withdrawn and nonhepatotoxic drugs such as SM, EMB 
and quinolone were used. After liver function (AL T, bilirubin) returned to normal, the 
hepatotoxic drugs were reintroduced sequentially for each drug at standard doses (RiF 
and INH and PZA), one per week. If symptoms of A TDII-! and/or liver function tests 
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increased during the reintroduction, the offending drug was con finned and then 
withdrawn from the regimen. 
5.4.2 Risk factors for A TDIH in Vietnamese TB patients 
In the current study, patients coinfected with hepatitis B/C were at much greater risk 
of A TDIH compared to patients without Hepatitis B/C infection (OR =8.18 [95% CI 
2.39-28.0], P=O.OOI). HBYIHCV infected patients were not more likely to have 
unfavourable outcomes (OR=0.98 [95% CI 0.41-2.38], P=0.972) possibly due to early 
detection and experienced clinical management. 
There was no significant association between ATDUI and demographic factors of age, 
gender, and BMI in this study. The reasons for lack of observed associations with risk 
factors described in other populations are probably due to the low number of ATDIH 
events, limiting the power to detect associations. 
The risk of A TDIH during treatment of TB patients who are seropositive for the 
hepatitis C virus (HCY) has been investigated. A study from Korea showed that 
A TDIH occurred more commonly in HCV -seropositive patients compared to control 
group, although the difference was borderline statistically significant with p value of 
0.056 [398]. In contrast, a study from Taiwan showed HCY co-infection had a high 
incidence of ATDIH during TB treatment (OR 3.43, [95%CI 1.14-10.35], P = 0.03) 
[315]. This study advised screening for HCY infection before TB treatment in order to 
determine follow-up monitoring. In the present study, HCY infection was also a 
strong risk factor for ATDIH (OR=14.7 [95% CI 3.13-68.6], P=O.OOI) although only 
16 HeV infected patients were identified. The nature of HCY disease may also be a 
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confounding factor because liver function tests (ALT) in patients HCV seropositive 
may be normal or wax and wane over time [316]. 
Chronic hepatitis B infection has been reported as a risk factor for ATDIH elsewhere 
[389]. For HBV carriers, a study from China showed the incidence of abnormal liver 
function tests was higher in HBV carriers (34.9%) on TB therapy compared to HBV 
noncarriers (9.4%) on TB therapy (p<O.O I) and to HBV carriers (8.1 %) not given any 
anti TB drugs (p<O.OI) [303]. The theory suggested that anti TB drugs may have a 
direct effect in hastening HBAg seroconversion [303]. However, there are no studies 
demonstrating a difference in liver damage due to ATDIH and hepatitis B viral 
activity. 
5.4.3 Impact of ATDIH on treatment outcomes 
There was also no difference in treatment outcomes between INHR patients (not 
MDR) with A TDIH and those without A TDIH which may be due to the small number 
of A TDIH events (7 cases with D1H were analysed). A larger study would be required 
to have sufficient power to detect an impact of A TDIH on treatment outcomes. 
5.4.4 Correlation of HBV viral load and liver function 
Higher HBV DNA values correlated with increased AL T values with correlation 
coefficient of 0.24 [95%CI: 0.04-0.42], p= 0.02). This result demonstrates the 
underlying association between higher viral load and A TDIH in patients with TB and 
on TB treatment. 
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5.4.5 Study limitations 
The study had some limitations. The criterion for hyperbilirubinemia was a bilirubin 
level> 1.7 times the ULN. In patients with this criterion, hyperbilirubinemia may be 
due to adaption or a transient increase and so it is possible that some patients without 
true A TDIH were included. The number of ATDIH cases occurring during the study 
was low (11 cases) and it was not possible to examine Hepatitis B/C infection and 
A TDIH incidence in all patients included in the screening study due to resource 
limitations, which would have given greater power to detect risk factors for both 
Hepatitis B/C infection and A TDIH. 
5.4.6 Conclusion 
In summary, the study showed that in patients with INH resistant TB diagnosed by 
MODS, the prevalence of HBsAg positivity was 9.8% and antiHCV positivity was 
4.6%. The cumulative incidence risk of A TDIH was 3. I 7%. Viral hepatitis infection 
was strongly associated with A TDIH (OR=8. I 8, [95%CI 2.39-28.0], p= 0.00 I) but 
not with unfavourable outcomes. Ideally, Hepatitis B vaccination programmes should 
be applied to reduce the prevalence of hepatitis B infection in the population. In the 
meantime, this data emphazises the need for screening of hepatitis B/C infection 
among TB patients prior to initiation ofTB therapy to identify patients at high risk for 
ATDIH and requiring more intensive monitoring for liver function, especially in 
populations with a high prevalence of viral hepatitis. Resource limitations may 
necessitate targeted Hepatitis B/C screening and further study is required to identify 
the population-based risk factors for Hepatitis B/C infection in the Vietnamese 
population. 
254 
Chapter 6 
N-acetyltransferase-2 (NAT2) genotype and treatment outcomes of 
INH resistant TB 
6.1 Aims 
1) Determine the prevalence of predicted fast acetylator phenotype in 
Vietnamese TB patients by NA T2 genotype sequencing. 
2) Determine the impact of predicted fast acetylator phenotype on treatment 
outcomes in patients with INH-resistant TB by INH MIC level. 
6.2 Introduction 
Isoniazid is eliminated by the N-acetyItransferase-2 (NAT2) enzyme system. 
Individuals are either homozygous rapid acetylators (FF), heterozygous (FS), or 
homozygous slow acetylators (SS) [237]. It is known that NA T2 genotype affects the 
serum concentration of isoniazid, influencing the Early Bactericidal Activity (EBA) 
of isoniazid which is optimal in patients with fully sensitive isolates at 2-3~g/ml 
serum concentration [237, 243]. The NAT2 genotype therefore may also impact on 
the efficacy of isoniazid therapy in patients infected with isolates with a slightly 
raised MIC. The Vietnamese are likely to be predominantly fast acetylators as 
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Chinese, Japanese and Thai ethnic groups are predominantly fast acetylators, in 
contrast to Caucasian and African populations, where the majority are slow [248, 249] 
We therefore determined the acetylator genotype assigned on the basis of 6 known 
SNP's in the NAT2 gene (C190T, GI9IA, T34IC, C48IT, G590A and G857A) in the 
Vietnamese population and evaluated the role of predicted NA T2 fast acetylator 
phenotype on TB treatment outcomes in patients infected with Mtb with high or low 
level resistance to isoniazid. 
6.3 Results 
6.3.1 Distribution of acetyIator phenotypes predicted by genotype among 
patients with INH-resistant TB 
260 cases with INHR (not MDR) were sequenced to determine the acetylator 
genotype. The results showed 58 cases (22%) were predicted to be homozygous rapid 
acetylators (FF), 126 cases (49%) were heterozygous (FS) and 74 cases (29%) were 
homozygous slow acetylators (SS). One case was determined as unknown acetylator 
genotype and one case was missing for NA T2 genotype (Figure 6- I). 
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FF= fast acetylator 
FS=Intennediate acetylator 
SS= slow acetylator 
Figure 6-1 : The distribution of different acetylator genotypes in 258 cases with 
INHR (not MDR) 
6.3.2 Treatment outcomes by predicted acetylator phenotype among patients 
with INH-resistant (non MDR) TB 
The treatment outcomes determined by culture in addition to smear, categorized as 
favourable or unfavourable, of 260 patients with INHR (not MDR) were analyzed by 
predicted acetylator phenotype. Two cases were excluded from the analysis because 
of missing or indeterminate genotype. The predicted acetylator phenotypes were 
divided into 2 groups including 184 cases (71.3%) with fast acetylator (FF and FS) 
and 74 cases (28.7%) of slow acetylator (SS) phenotype. The results of treatment 
outcomes are presented in the Table 6-1. Overall, there was no significant difference 
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between the treatment outcomes by predicted acetylator phenotype (P=I.OO). Indeed 
the proportion of unfavourable outcomes was 17% in both acetylator groups. 
Unfavourable Favourable Total n OR, [95%CI), 
outcome n (%) outcome n (%) value* 
(%) 
Fast 32 (17.4) 152 (82.6) 184 (100) 0.99 [0.47-2.20]. 
acetylator p = 1.00 
Slow 13 (17.6) 61 (82.4) 74 (100) BASELINE 
acetylator 
Table 6-1 : Treatment outcomes in INHR patients (not MDR) with fast and slow 
acetylator5 
6.3.3 Treatment outcomes in fast acetylator patients infected with M.tb with low-
level INH- resistance 
The association between predicted acetylator phenotypes (fast and slow) and 
treatment outcome in patients infected with isolates with high MIC to INH ( MIC 2:1 
Jig/ml ) versus low MIC (0.2 Jig/ml S MIC < 1 Jlg/ml) was further investigated. 
Patients who were MDR (n=54) or received individualized regimens (n=16) were 
excluded, leaving 239 patients in the analysis. There were 154 cases (64.4%) who 
were fast acetylators infected with isolates with high MIC, 55 cases (23.0%) who 
were slow acetylator and high MIC, 19 cases (8.0%) with fast acetylator and low 
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MIC, and]] cases (4.9%) with slow acetylator and low MIC. In theory, patients who 
are fast acetylators and infected with isolates with low MIC might have unfavourable 
outcomes compared with slow acetylator patients infected with isolates with a low 
MIC. We compared the treatment outcomes in these groups. The results are shown in 
Table 6.2. 
NAT2 MIC Favourable Unfavourable Total 
outcome outcome 
n (%) 
n (%) n (%) 
Fast Low 15 (79.0) 4 (21.1) 19 (100) 
Slow Low 9 (82.8) 2(18.2) ]1 (100) 
Slow High 46 (83.6) 9 (16.4) 55(100) 
Fast High ]26 (81.8) 28(18.2) 154 (100) 
Total 196 (82.0) 43 (18.0) 239 (100) 
MDR and patients receiving individualized regimens excluded 
Table 6-2 : Treatment outcomes by acetylator status and INH MIC level among 
patients with INHR TB 
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NAT2 MIC Crude OR Adjusted OR * 
OR 95% p. OR 95%CI P-value 
CI value 
Fast Low BASELINE 
Slow Low 0.83 0.13- 0.850 0.78 0.11- 0.797 
5.50 5.29 
Slow High 0.73 0.20- 0.644 0.72 0.18- 0.638 
2.73 2.85 
Fast high 0.83 0.26- 0.761 0.82 0.25- 0.753 
2.73 2.77 
All groupS 0.81 0.25- 0.718 0.80 0.24- 0.709 
compared to 2.57 2.63 
baseline 
* Adjusted for streptomycin, ethambutol and pyrazinamide resistance and treatment 
regimen. 
MDR and patients receiving individualized regimens excluded. 
Table 6-3: Risk of unfavourable outcome by acetylator status and INH MIC 
There was no significant difference between unfavourable treatment outcomes among 
patients with fast acetylator status infected with low MIC isolates compared with 
thers (OR=0.80 [95% CI 0.24-2.63], P=0.709) (Table 6-3). 
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6.3.4 Impact of acetylator phenotype on ATDIH risk 
Patients with a predicted slow acetylator phenotype were significantly more likely to 
develop ATDIH (OR=4.62 [95% CI 1.17-18.3], P=O.029). This remained true when 
adjusted for viral hepatitis infection (OR= 6.23 [95% CI 1.46-26.49, P=O.O 13) (Table 
6-4). 
NAT2 No ATDIH Crude OR Adjusted OR. 
ATDIH 
OR 95% P- OR 95% p-
CI value CI value 
Slow 93 7 4.62 1.17- 0.029 6.23 1.46- 0.013 
18.3 26.49 
Fast 184 3 BASELINE 
... 
• Adj usted for vIral hepatItIs mfectIon. 
Table 6-4: Impact of acetylator status on risk of ATDIH in patients with INH resistant 
tuberculosis. 
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6.4 Discussion 
This study confirmed there is a predominance of fast acetylators (71.3%) for isoniazid 
among the Vietnamese population. During the first 2 to 5 days of TB treatment, INII 
drives the bactericidal activity of the regimen. PZA is effective against slow growing 
TB bacilli and RiF is effective against nonreplicating TB bacilli. EBA of isoniazid is 
influenced by the NAT2 genotype. A study conducted in South Africa found that , 
heterozygous fast (FS) and homozygous fast (FF) acetylators had a lower EBA 
compared to homozygous slow (SS) acetylators with a standard isoniazid dose [131]. 
A maximum EBA of INH was reached with a serum concentration of INH of 2-3 
flg/ml 2 hours post-dose. Therefore, increasing the dose of INH would increase the 
INH concentration but would not increase the EBA. For rapid and slow acetylator. the 
mean elimination half-lives of INH are 80 mintutes and 180 minutes, respectively. 
There was no detected association of acetylator status with unfavourable outcome for 
patients with isoniazid resistant TB in the study reported here and this was also true 
when patients were stratified by MIC to INH of the infecting isolate. Data presented 
in chapter 4 showed that INH MIC alone was not a significant risk factor for 
unfavourable outcome and the data presented here suggests that this is not influenced 
by acetylator status of the patient, although the study may have been too small to 
detect an association. We were not able to examine isoniazid serum pharmacokinetics 
in this study which would have confirmed the predicted acetylator phenotype of 
patients and provided more reliable data on the serum INH levels achieved, which can 
be influenced by many factors including nutrition and co-morbidities. However, this 
data Suggests that programmatic screening for acetylator phenotype alone among 
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patients with INH resistant TB would not be useful in determining which patients may 
benefit from increased INH dose or be at risk of treatment failure on standard 
regimens. 
A larger study of acetylator phenotypes among TB patients would establish if there is 
any association with unfavourable outcome among patients with drug susceptible TH. 
Compared to rapid acetylators, slow acetylators have been reported to be more likely 
to develop polyneuropathy and drug-induced hepatotoxicity (ATDIH) [399, 400]. 
[401, 402]. Among Vietnamese TB patients, slow acetylators were also significantly 
more likely to develop ATDIH in this study (OR=6.23 [1.46-26.49]) which suggests a 
rapid test for determination of acetylator status may have clinical value. No such 
commercial test currently exists. Alternative strategies could be used to develop such 
a test, including determination of INH serum level at 2 hours post-dose or rapid 
genotyping using pyrosequencing or PCR-RFLP. Low plasma isoniazid concentration 
in rapid acetylators is considered one of many reasons for failure in TB treatment with 
the standard regimen (5 mg/kg of isoniazid) [403, 404]. However, in general, with 
standard daily isoniazid treatment, both rapid and slow acetylators have the same 
treatment efficacy [405, 406]. 
Analysis of pharmacokinetics of isoniazid among 18 Caucasian healthy volunteers in 
Germany showed substantial variation in isoniazid exposure which was largely 
explained by NAT2 variation. The authors recommended adjustment of the dose of 
isoniazid to 2.5 mg/kg, 5.0 mg/kg and 7.5 mg/kg for patients with none, one and two 
rapid NAT2 alleles, respectively [246]. A clinical trial from Japan randomized 172 
patients to either standard or NAT2-guided INH dose. Low, medium or high dose 
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INH were used for slow, intennediate or fast acetylators repectively. The trial showed 
that the incidence of A TDIH was substantially lower in slow acteylators given a low 
dose (2.5mglkg) of INH compared to those receiveing a standard dose (Smg/kg) 78% 
vs. 0% without apparent impainnent of treatment efficacy. On the other hand, rapid 
acetylators, who received high dose of isoniazid (7.5mglkg), achieved a lower rate of 
early clinical failure (I5 vs. 38%) compared to the patients who were on standard 
treatment [407] . This trial supports systematic screening for NA T2 genotype and 
tailored INH dosage. However, at the present time this approach is not feasible in 
developing world settings and would require development of a rapid inexpensive 
point-of-care test. Further research would be needed to demonstrate a consistent 
benefit of treatment stratification across all ethnicities to justify the implementation of 
such an approach programmatically. 
264 
Chapter 7 
Discussion 
Globally, the prevalence of INH resitance among Af.tb is increasing which presents a 
serious challenge to the target ofTB elimination by 2050. Isoniazid is one of only six 
truly effective drugs for the treatment of TB, alongside rifampicin, streptomycin, 
ethambutol, pyrazinamide and fluoroqinolones. Each TB drug has a different 
spectrum of activity and INH is the key drug in rapidly reducing bacterial load and 
therefore infectiousness in the first days of treatment. Rifampicin is active against 
non-replicating bacilli and is the key companion drug in clearing lNH resistant or 
tolerant persisters. Pyrazinamide has a unique spectrum of activity at low pH and is 
active against bacteria with low metabolic activity and therefore plays the crucial role 
in sterilizing persistent bacilli. Ethambutol and streptomycin are weaker anti-
tuberculous agents and their principal role in multi-drug therapy is to guard against 
the emergence of resistance to the stronger agents and to maintain treatment efficacy 
in patients with undiagnosed resistance to other drugs within the regimen. The later 
generation fluoroquinolones (Ievofloxacin, moxifloxacin and gatitloxacin) have an 
EBA similar to that of isoniazid but it is unclear if regimens which substitute a FQ for 
INH will have similar efficacy. Treatment trials are underway which are testing if FQ 
can allow shorter TB treatment regimens of four months rather than six OFLOTUB 
NCT00216385[408], REMOX TB NCT00864383. However, widescale use of FQ in 
programmatic standardised regimens would likely lead to an increased prevalence of 
,L,VJ 
FQ resistance and reduce the potential of FQs to treat INH and MDR resistant TB. 
The approval of bedaquiline for MDR TB [22]was a landmark in the development of 
antituberculous drugs but the pipeline remains extremely weak and new regimens 
containing multiple novel drugs are urgently required in order to address the epidemic 
of drug-resistant TB. A major challenge to global TB control programmes in the next 
decade wiII be to balance the need for individual access to life-saving regimens while 
preserving efficacy for communities. By developing and approving fixed-dose 
combination regimens of novel agents, there is an opportunity to develop a model for 
implementation of new drugs for infectious diseases which enables access while 
preserving susceptibility, but this remains a daunting challenge. 
7.1 Impact ofINH resistance on treatment outcomes 
The unfavourable treatment outcome rate of INH resistant TB (19% at treatment 
completion) shown in this study coupled with the high prevalence of INH resistant TB 
in Vietnam, underlines the urgent need for trials determining the optimal treatment 
strategy for INH resistant TB. While systematic review data suggests additional drugs 
and/or prolongation of treatment are effective strategies for achieving high treatment 
success rates, all guidelines are based on expert opinion and no high-quality trial data 
exists to guide National TB Programmes in deriving standardized recommendations. 
While the implementation of drug susceptibility testing for every TB patient remains 
an impractical ideal, national TB programmes in countries with a high prevalence of 
INH resistant TB must consider implementation of standardized regimens which have 
improved efficacy for undiagnosed INH resistant TB while not increasing toxicity to 
unacceptable levels for those who are receiving additional unnecessary drugs. The 
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current WHO recommendation of an HRE continuation phase remains untested and 
data from Vietnam will be crucial in determining the effectiveness of this strategy 
[129]. 
7.2 Bacterial risk factors for unfavourable outcome among patients with 
INH resistant TB 
This thesis addressed a number of potential risk factors for poor treatment outcome 
among patients with INH resistant TB to determine if a screening strategy could assist 
in detecting those at high risk of treatment failure on standardized regimens and to 
prioritise these patients for alternative interventions which may present an alternative 
to changing the standardized regimen for all patients. Bacterial mutation responsible 
for INH resistance was not a risk factor for unfavourable outcome although kalG 
mutations were associated with higher MIC to INH. This indicates that the molecular 
line probe assays which determine the mutation responsible for INH resistance cannot 
be used to identify those at higher risk of unfavourable outcome. 
Beijing genotype is independently associated with unfavourable outcome among 
patients with INH resistant TB and this finding requires further investigation to 
identify the underlying mechanism responsible. There is a growing body of evidence 
that Beijing genotype is associated with increased drug resistance and, given the 
epidemic emergence of the Beijing genotype in some regions, a greater understanding 
of this phenomenon is needed to avert the further propagation of MDR and XDR 
strains of Tll. It is important to note that studies in several regions have failed to find 
any association of Beijing genotype with drug resistance and this may be due to 
differences in the circulating background strains to which Beijing genotype is 
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compared, sub-lineages of the Beijing genotype which have a propensity to develop 
resistance rather than the whole clade, programmatic differences in the management 
ofTB, or to differences in the host genetics of the population which may influence the 
ability of Beij ing genotype to subvert the immune response. Whole genome sequence 
analysis, host susceptibility studies coupled with bacterial sequencing, in vitro and in 
vivo immune studies and novel bacterial resistance models will all help to elucidate 
the mechanisms which Beijing genotype has evolved to evade drug therapy. 
7.3 Patient risk factors for unfavourable outcome from INH resistant TB 
Acetylator status and co-infection with viral hepatitis were investigated for 
association with unfavourable outcome among patients with INH resistant TB. No 
association was found. Although patients with viral hepatitis (B/C) were at strongly 
increased risk of drug induced hepatotoxicity, these patients did not have a higher risk 
of unfavourable outcome. This suggests that, despite the high prevalence of viral 
hepatitis among Vietnamese TB patients, the existing protocols for management of 
A TDIH are adequate but this should be interpreted with caution due to the low 
number of events. This may vary from other settings where there is a lower 
prevalence of viral hepatitis and less experience in the management of ATDIH. 
Pharmacokinetics and EBA studies have shown that acetylator status is important in 
detennining serum isoniazid levels achieved on standard INH doses but it is unclear 
the extent to which this affects treatment outcomes and if acetylator status 
detennination would be of value in programmatic management of TB. This thesis 
investigated outcomes only among INH resistant TB patients and acetylator status 
be an important determinant of outcome for patients infected with fully 
may 
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susceptible isolates, but these patients generally achieve very high treatment success 
rates on standardized therapy and the cost of acetylator status screening is unlikely to 
be justified. The data presented in this thesis indicates that acetylator status screening 
will not assist in identifying those at increased risk of treatment failure among patients 
with INH resistant TB. 
7.4 Recommendations for further research 
1) Determination of all L~ resistance mechanisms in ft1.1b 
Resistance to INH in jyf.tb is not fully understood, more than fifty years after 
its discovery. While the proportion of Mtb isolates carrying known INH 
resistance mechanisms varies geographically, it is clear that the resistance 
mechanism is undetermined in 10-20% of phenotypically resistant Af.lb 
isolates. Whole genome sequencing projects have provided clues to 
alternative mechanisms of resistance but these are yet to be conclusively 
validated and it is likely that efflux pump or other mechanisms also playa 
role, particularly in low-level but clinically important resistance. The lack of 
comprehensive knowledge of INH resistance mechanisms means that 
genotypic tests for the detection of INH resistant TB have limited sensitivity 
and in vitro research is required both to confirm postulated mechanisms of 
resistance and determine the role of novel mechanisms. 
2) Development of a point-of-care test for INH resistant TB 
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There has been a huge global investment in the development of point-of-care 
tests for TB in the last decade, with a focus on TB detection and MDR 
detection. While this has yielded some impressive advances, most notably 
with the development and application of the Xpert MTBIRIF assay. an ideal 
point-of-care test which can be applied at TB clinics remains elusive. 
Phenotypic methods for the detection of TB and drug resistance. such as 
MODS. have been evaluated and endorsed by WHO. but are challenging for 
programmatic application due to the resource and biosafety requirements. 
Similarly. line-probe assays which can detect INH resistant TB have 
prohibitive costs which prevent application to all TB patients. 
The global increase in INH resistant TB. the important role of INH resistant 
TB in fuelling the development of MDR TB and the evidence. including that 
in this thesis. that INH resistant TB has unacceptable treatment outcomes 
using current strategies. all underline the urgent need for a point-of-care test 
for INH resistant TB which can be applied programmatically. The current 
development pipeline for novel TB diagnostics does not include any tests for 
INH resistant TB which is likely to be scaleable to all TB patients. 
3) Randomised controlled trials to determine optimal treatment for INH 
resistant TB 
WHO has recognized the limited evidence base to inform the treatment of INH 
resistant TB and currently recommends countries with a 'high' prevalence of 
270 
JNH resistant TB implement a HRE continuation phase, based on expert 
opinion. Alternative strategies would be to use a fluoroquinolone in addition 
to or to replace INH in these settings, or to prolong treatment. The widespread 
use of a fluoroquinolone in standardized regimens would carry a high risk of 
propagating fluoroquinolone resistant strains. Fluoroquinolones remain the 
most effective drug in the treatment of MDR TB and therefore the 
consequences of increased fluoroquinolone resistance are grave in the absence 
of alternative regimens for MDR TB. High quality randomized controlled 
trials are required to determine if the HRE continuation phase is effective for 
JNH resistant TB and if the use of this regimen in all patients increases the 
incidence of ocular toxicity. Comparative trials of alternative treatment 
regimens would determine the most effective standardized regimen for INH 
TB. These should include assessment of adverse events and health economics 
modeling to determine which regimens should be applied in national TB 
programs. 
4) Evaluation of cost-effectiveness of screening and treatment strategies for 
INH resistant TB 
Modelling of the long-term cost-effectiveness of alternative screening and 
treatment strategies for INH TB are required to help National TB programmes 
determine the true costs of both implementation and neglect of INH resistant 
TB. The failure to address the increasing prevalence of INH resistant TB 
globally is creating a reservoir of drug resistant TB which, when ineffectively 
treated under current strategies, leads to the development and propagation of 
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MDR Tll. While detection and treatment of MDR TB is being scaled up 
globally, there is no evidence-based strategy to address INH resistant Tll. The 
increased application of INH prophylaxis, particularly in regions of high HIV 
prevalence, is likely to lead to increase in INH resistant TB in areas which 
currently have relatively low rates. While the costs of any screening strategy 
for INH resistant TB are likely to be substantive, improved data on true 
treatment failure rates for INH resistant TB and the impact on MDR TB rates 
will allow in silica models to more accurately determine the potential impact 
of screening and treatment strategies on the epidemic and the potential 
contribution towards the ultimate goal ofTB elimination by 2050. 
5) Elucidation of the underlying mechanisms responsible for the association 
of Beijing genotype with drug resistance and unfavourable treatment 
outcome 
It has become clear in the last decade that there are substantive differences in 
!vftb genotypes, which were previously thought to be highly clonal, largely 
due to the focus of research in the last century on strains from Europe and 
America. The increased application of advanced research techniques to global 
collections of clinical Af.lb strains has revealed the global population structure 
of J.flb but we have yet to understand the forces driving Mtb evolution and 
how these variations affect transmission and clinical disease. It is now clear 
that the long co-evolution of Af.lb with human host populations of different 
ethnicities has resulted in local co-adaptation and there consequently exists 
variation in the interaction between different Af.lb lineages and human host 
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immune responses. Human host susceptibility to kf.tb infection has been 
studied in isolation from the variation in l\f.tb strains and the field of research 
into host pathogen interaction in TB has gained momentum only in recent 
years. It has been hypothesized that rapid urbanization of human populations 
has driven modern ;.\f.tb lineages such as the Beijing genotype towards a 
phenotype which favours active disease rather than latency. Further research is 
required to prove this hypothesis. Variations in immune interaction may have 
important implications for vaccine development, as a vaccine that is effective 
in one region may be less effective in regions with a predominace of different 
Mtb lineages or different ethnic human populations. It is therefore important 
to conduct both epidemiological and in vitro research into the mechanisms 
responsible for the association of Beijing genotype with treatment failure. 
The association of Beijing genotype with drug resistance also requires further 
investigation to elucidate the underlying mechanisms. It is important to 
understand if the Beijing genotype has an intrinsic propensity for resistance 
which will apply to novel agents as they become available, or if the 
mechanism is specific to certain drugs. Proposed mechanisms of resistance 
include increased mutational frequency or compensatory mechanisms which 
aI10w the Beijing genotype to tolerate resistance mutations with a lower fitness 
cost. In vitro evidence has been found for both strategies but remains to be 
confirmed in larger studies. Whole genome sequencing projects of global M.tb 
collections of both drug resistant and drug sensitive strains will also contribute 
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to the understanding of mechanisms of drug resistance in J.{tb and the isolates 
collected in this study are being sequenced. 
The momentum of the millennium development goals has led to impressive advances 
in TB research after decades of stagnation. The pace of progress must be maintained, 
and indeed, increased, if we are to achieve the goal of TB eradication by 2050. In 
order to stem the surge of MDR TB it is crucial to understand the fundamental 
mechanisms of INH resistance in Xltb, develop rapid point-of-care diagnostics and 
optimized regimens for the treatment of INHR strains. The need for multi-drug therapy 
in TB and the extremely long time required from drug discovery to approval will 
ensure that INH remains the most essential antituberculous drug, alongside 
rifampicin, for the foreseeable future. The work described in this thesis underlines the 
urgent need for greater research efforts to preserve the efficacy of INH for future 
generations. 
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Appendix A 
PATIENT INFORMATION SHEET 
OXTREC 030 07 
Testing for inclusion in study on drug resistant tuberculosis 
(Screening for inclusion in Predictors of outcome in isoniazid resistant tuberculosis) 
You are being considered for inclusion in a research study of drug resistant tuberculosis 
because you might have this condition. Please read this information sheet carefully or have 
someone read it to you. You will be given a copy of this form to keep. 
What is the reason for screening? 
We are looking for people who have tuberculosis that is resistant to the drug isoniazid and 
whO do not have HIV infection to take part in a research study. You have already been 
diagnosed with tuberculosis and we would like to test your bacteria for resistance to isoniazid 
to see if you eligible for the study. 
What will happen if I take part in the screening? 
If yOU agree, we will test you for HIV infection and test your bacteria for resistance to 
isoniazid. If you fit the criteria for the study, we will invite you to join the study. You will be 
given more information about the study and you can decide whether to participate or not. 
There is no obligation to join the study if you fit the criteria. You will be given standard 
treatment for your condition, whether or not you decide to take part in the screening or the 
studY. At any stage in the study you are completely free to withdraw your consent from the 
studY. This will not affect the care you receive. 
What tests will be done? 
We will test you for: 
1. HIV infection. If you are found to be HIV positive you can be referred to a clinic for 
HIV treatment if you wish. 
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2. If you agree we will also study your genes to try and understand why some people 
suffer from TB. This will involve studying the DNA from your cells. The DNA will 
be stored in a freezer for future studies of the genetic susceptibility to TB. 
We will test your bacteria for: 
1. resistance to isoniazid. 
Your doctor will be given the results of these tests and will discuss them with you. 
If you do not fit the criteria or if you decide not to participate in the study we will not store 
your samples. 
What are the risks? 
Having a blood test can be uncomfortable and may cause a bruise. Some people feel faint. 
confidentiality 
Infonnation about you will be kept confidential and will not be made available to anyone who 
is not connected with the study without your consent. All samples will be labeled with a study 
number rather than your name, to protect your identity. 
costs 
you will not have to pay for anything other than the normal costs of routine care. All tests 
related to the study will be paid for. 
Choosing or refusing to participate 
you may refuse to be in any parts of the screening or the study. You can choose to consent to 
the screening study and not the genetics study if you want to. If you do not want to be 
screened that decision will not in any way interfere with your medical care or your ability to 
receive proper medical care or attention in the future. 
Questions 
If yOU have any other questions about the study please contact: 
Doctor'S name: Dr Phan Vuong Khach Thai 
Telephone number: 
303 
PATIENT CONSENT FORM 
OXTRECXXX 
Testing for inclusion in study on drug resistant tuberculosis 
(Screening for inclusion in Predictors of outcome in isoniazid resistant tuberculosis) 
Consent from patient for isoniazid study screening 
o I have been fully informed of the possible risks and benefits of taking part in this 
screening and agree that I will take part. 
o I know who to contact if I need more information. I understand that all information 
about me will be kept confidential. I understand that I am free to withdraw from the 
study at any time without affecting the care I will receive. 
Name Signature: _________ _ 
Date:_---------
Consent from patient for isoniazid study screening and the genetics study 
o I have been fully informed ofthe possible risks and benefits of taking part in this 
screening and agree that I will take part. 
o I agree that the samples may be stored and further tests undertaken (including 
genetic tests) in the future to further the understanding of this disease 
o I know who to contact if I need more information. I understand that all information 
about me will be kept confidential. I understand that I am free to withdraw from the 
study at any time without affecting the care I will receive. 
NaJ11e Signature: ________ _ 
Date:_---------
Investigator's statement 
1 tbe undersigned, have defined and explained to the volunteer in a language he/she 
~ derstands, the procedures of this study, its aims and the risks and benefits associated 
un . l" 
witb hislber participation. I have IDJormed the volunteer that confidentiality will be 
reserved, that he/she is free to withdraw from the trial at any time without affecting 
Pbe care he/she will receh'e at the clinic. Following my definitions and explanations the 
!olunteer agrees to participate in this study. 
-Date Name of investigator who gave the infonnation about the study 
Signature: ----------------
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Appendix B 
PATIENT INFORMATION SHEET 
OXTRECXXX 
Study number: 
Results of treatment in tuberculosis resistant to the drug isoniazid 
(Predictors of outcome in isoniazid resistant tuberculosis) 
You are being being invited to take part in a research study of tuberculosis resistant to the 
drug isoniazid because you have this condition. Please read this information sheet carefully or 
have someone read it to you. You will be given a copy of this form to keep. 
What is the reason for doing the study? 
A lot of people in Viet Nam have tuberculosis that is resistant to the drug isoniazid. Although 
Isoniazid is a very important drug in the treatment of tuberculosis most people are 
successfully cured with normal tuberculosis treatment. We want to look at how resistance to 
isoniazid affects the success of tuberculosis treatment. 
What will happen if I take part in the study? 
you will be given standard treatment for your condition, whether or not you decide to take 
part in the screening or the study. At any stage in the study you are completely free to 
withdraw your consent from the study. This will not affect the care you receive. 
What tests will be done? 
During your visits to the clinic we will take some blood to test if you are infected with the 
virus hepatitis B or C and to see if you have any liver problems. These results will be given to 
your doctor and he can use the information to treat you for this condition if you have it. In 
addition to the routine hospital blood tests this study will involve taking an extra 14 mls blood 
(about 4 spoonfuls) on your first clinic visit and an extra 12mls at your 1 and 2 month visits. 
We will also test your DNA for mutations in genes that may affect the way your body 
processes isoniazid. 
samples will be tested and stored indefinitely in a freezer at the Hospital for Tropical 
Diseases (HeMC). If you develop liver problems during your TB treatment we will do some 
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extra tests on the sample. Further tests may be done on stored samples in the future to 
improve our understanding of tuberculosis and hepatitis. The researcher doing these tests will 
not know your name, only your study code. 
We wiIl ask you to come to the clinic 3 times after you have finished your treatment for the 
doctor to see if your treatment was completely successful. You will be reimbursed for your 
travel for these visits so it will not cost you anything. 
What are the risks? 
Having a blood test can be uncomfortable and may cause a bruise. Some people feel faint. 
Confidentiality 
Information about you will be kept private and will not be made available to anyone who is 
not connected with the study without your consent. All samples will be labeled with a study 
number rather than your name, to protect your identity. 
costs 
you will not have to pay for anything other than the normal costs of routine care. All tests 
related to the study will be paid for. 
Cboosing or refusing to participate 
you may refuse to be in any parts of the study. If you do not want to take part that 
decision wiII not in any way interfere with your medical care or your ability to receive 
proper medical care or attention in the future. 
Questions 
If yOU have any other questions about the study please contact: 
Doctor's name: Dr Phan Vuong Khach Thai 
Telephone number: 
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PATIENT CONSENT FORM 
OXTRECXXX 
Testing for inclusion in study on drug resistant tuberculosis 
(Screening for inclusion in Predictors of outcome in isoniazid resistant tuberculosis) 
Consent from patient 
o 
o 
I have been fully informed ofthe possible risks and benefits of taking part in this 
study and agree that I will take part. 
I know who to contact if I need more information. I understand that all information 
about me will be kept confidential. I understand that I am free to withdraw from the 
study at any time without affecting the care I will receive. 
Name __ ----------- Signature: ---------
Date ___ --------
Investigator's statement 
I tbe undersigned, have defined and explained to the volunteer in a language he/she 
~ derstands, the procedures of this study, its aims and the risks and benefits associated 
U~tb his/her participation. I have informed the volunteer that confidentiality will be 
W eserved, that he/she is free to withdraw from the trial at any time without affecting 
Pbr care he/she will receive at the clinic. Following my definitions and explanations the 
t e . . . th' t d 
"olunteer agrees to participate ID IS S U y. 
--Date 
Name of investigator who gave the information about the study 
Signature: ----------------
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Action Timepoint 
presentation enrolment 1 2 3 5 8 12 18 24 
written consent to routine HI V test x 
written consent to isoniazid resistance x 
screening 
written consent to genetics study x 
complete screening form for genetics x 
2ml blood for genetics study x 
written consent for full study x 
complete enrolment form x 
14mls blood x 
hepatitis evaluation x x x x 
12 mls blood x x x 
3 x sputum sample x x x x x (if indicated) x (if indicated) x (if indicated) 
document any adverse reactions x x x x x 
document any treatment interruptions x x x x x 
Document any additional medications x x x x x 
TB symptomatic evaluation x x x 
I 
--
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SCREENING GENETICS 
STUDY ENTRY FORM 
PREDICTORS OF OUTCOME IN ISONIAZID RESIST ANT TUBERCULOSIS 
ENTRY DETAILS 
1 SCREENING STUDY NUMBER XXX 
2 ADMISSION CENTRE PNT 0 
Phu Nhuan [] 
District 2 0 
District 4 0 
Binh Thanh [-l 
3 DATE PRESENTED AT ADMISSION '_I_-
CENTRE 
4 DATE OF SCREENING _' __ I 
ENTRY CRITERIA 
1 HIV test positive 0 negative 0 
unknown 0 
Patient cannot enter if HIV infected 
2 sputum smear result positive 0 negative 0 
unknown 0 
Patient cannot enter if smear negative 
3 Has the patient had previous Tb positive 0 negative 0 
treatment 
unknown 0 
Patient cannot enter if previously treatedIor TB 
4 Is patient ~ 18 years of age yes 0 no 0 
patient cannot enter if < 18 J'ears old 
5 Is patient pregnant? yes 0 no 0 
Patient cannot enter ifpregnant 
1-"6. Will patient receive DOTS at this yes 0 no 0 
centre? 
Patient mu.~t intend to receive DOTS at study centre 
7 Has written informed consent been yes 0 no 0 
obtained? 
SIGNED CONSENT MUST BE OBTAINED BEFORE ENTRY INTO THE 
STUDY 
....-
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Appendix C 
SCREENING GENETICS 
SCREENING GENETICS ENTRY QUESTIONAIRE 
Demographic Details 
Full name, ______________ _ 
Age, ______ _ 
Sex Male 0 Female o 
Ethnic Group _________ _ 
occupation ______ _ 
Address, ______________________ _ 
Days of illness ____ _ 
Radiology Date ofX-ray _____ _ 
X-ray result abnormal 
consistent with active pulmonary TB 
indeterm inate 
pleural effusion 
pleural thickening 
pneumothorax 
miliaryTB 
pericardial involvement 
Yes [J 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
NoD 
NoD 
NoD 
NoD 
NoD 
Noll 
NoD 
NoD 
Any other e\'idence of extrapulmonary disease? Yes 0 NoD 
(eg lymphadenopathy, neck stiffness, headache, cranial nerve lesions) 
Please take sample in accordance with the study schedule: 
1. Genetics -2mls -EDTA tube 
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ENROLl\tENT 
STUDY ENTRY FORM 
PREDICTORS OF OUTCOME IN ISONIAZID RESITANT TUBERCULOSIS 
ENTRY DETAILS 
1 INH RES STUDY ~'UMBER XXX 
2 ADMISSION CENTRE PNT 0 
Phu Nhuan 0 
District 2 0 
District 4 0 
Binh Thanh D 
3 DATE PRESENTED AT ADMISSION 
, , 
-----
CENTRE 
4 DATE ENROLLED TO STUDY _' __ I 
ENTRY CRITERIA 
1 HIV test positive 0 negative 0 
unknown 0 
Patient cannot enter if HIV infected 
2 sputum smear result positive 0 negative 0 
unknown 0 
-Patient cannot enter if smear neI!ative 
-3 Has the patient had previous Tb positive 0 negative 0 
treatment 
unknown 0 
Patient cannot enter if prel'ioll!liv treated for TB 
t-4 Is patient ~ 18 years of age yes 0 no 0 
patient cannot enter if < 18 l'ears old 
~ Is patient pregnant? yes 0 no 0 
-Patient cannot enter if preI!nant 
6. Will patient receh'e DOTS at this yes 0 no 0 
centre? 
-Patient nlll!.t intend to receive DOTS at study centre 
-7 Has written informed consent been yes 0 no 0 
obtained? 
SIGNED CONSENT MUST BE OBTAINED BEFORE ENTRY INTO THE 
STUDY 
-
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AppendixC 
ENROLMENT 
ENTRY QUESTIONAIRE 
Demographic Details 
Full name, ______________ _ 
Age, __ ----
S Male 0 ex Female 
Ethnic Group ________ _ 
occupation ______ _ 
o 
Address._---------------------
Telephone number for follow-up. ______________ _ 
symptom E"aluation 
Days of illness ____ _ 
Cough 
Haemoptysis 
Fever 
Nightsweats 
Weightloss (>10% bodyweight) 
Chest pain 
Malaise 
Radiology 
X-ray result No abnormalities 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
Yes 0 
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NoD 
No 0 
No 0 
No 0 
No 0 
No 0 
No 0 
Consistent with TB 0 Indetemlinate 0 
Appendix C 
ENROLl\IENT 
TB Contact History 
Known contact with IB patient Yes 0 No 0 
If yes, is it: 
Family member Yes 0 No 0 
Colleague Yes 0 NoO 
Neighbour Yes 0 NoO 
Other Yes 0 No 0 
Past Medical History 
Previous IB Yes 0 No 0 
If yes state site: Pulmonary 0 
Extra-pulmonary 0 
BCG Vaccination Yes 0 No 0 
BCG scar Yes 0 No 0 
Jaundice Yes 0 No 0 
Known Hepatitis infection Yes 0 No 0 
HepA 0 HepB C HepC L HepD 0 HepE o unknown 0 
Renal Disease Yes 0 No 0 
Diabetes Yes 0 No 0 
Other illness Yes 0 No 0 
Jfyes please specify 
Social History 
Smoker Yes 0 No 0 
Drinks Alcohol Yes 0 No 0 
If Yes state average weekly consumption Units/week 
(I beer = 1.5 units, I glass ,vine = 1.5 units, 1 whiskey = 1.5 units) 
Previous heavy alcohol consumption? Yes 0 No 0 
Medication History 
Please list all current medications on next page 
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Appendix C 
El''ROLMENT 
Hepatitis E,,·aluation 
Risk factors for Hepatitis 
Tattoos Yes 0 No D 
IV drug use Yes 0 No D 
Commercial sex worker Yes 0 No D 
Man who has sex with men Yes D No D 
Alcoholic Yes D No D 
Health care worker Yes 0 No 0 
Previous Blood Transfusion Yes 0 No D 
Haemophiliac Yes 0 NoD 
Examination Findings 
Height cm Weight Kg 
Cachexia Yes D NoD 
Lymphadenopathy Yes D No 0 
Anaemia Yes D No 0 
Signs of liver disease: 
Jaundice Yes 0 No D 
Palmar el)1hema Yes D No D 
Clubbing Yes 0 No D 
Spider Naevi Yes 0 No D 
Bruising Yes D NoD 
Gynaecomastia Yes 0 NoD 
Hepatomegaly Yes D NoD 
Splenomegaly Yes D No D 
Caput Medusae Yes D No D 
Ascites Yes D NoD 
Peripheral Oedema Yes D No D 
If the patient has hepatitis has there been any confusion or loss of consciousness? 
Yes ::J No 0 
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ENROLMENT 
Please take samples in accordance with the study schedule: 
1. JNR - 2mls - Citrate tube (green) 
2. Urea, electrol)1eS, creatinine & LFT's - 2mls - Lithium Heparin tube (black) 
3. Serology - 4mls - Plain tube (red) 
4. Viral load - EDT A - 4mls - EDTA tube (blue) 
5. NAT2 testing -2mls -EDTA tube 
DRUGS TAKEN BY PATIENT OTHER THAN STANDARD DOTS THERAPY 
Please document any drugs taken by the patient other than standard DOTS 'herapy. 
DRUG REASON DOSE/24HRS ROUTE START STOP 
DATE DATE 
r-
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Appendix C 
Week 4 evaluation 
Has the patient been diagnosed with hepatitis in the last 4 weeks? 
Yes 0 No D 
Does the patient have any symptoms suggestive of hepatitis? 
Eg Nausea Yes 0 
Vomiting Yes 0 
Abdominal pain Yes D 
Anorexia Yes 0 
Jaundice Yes 0 
Does the patient have any signs of hepatitis? 
Jaundice Yes 0 
Palmar ef)1hema Yes D 
Spider Naevi Yes D 
Bruising Yes 0 
Hepatomegaly Yes 0 
Ascites Yes 0 
Peripheral Oedema Yes D 
List all medication taken in the last 4 weeks 
-
Has the patient drunk alcohol in the past 4 weeks? 
Yes D No 0 
No D 
No D 
No 0 
No D 
No D 
No D 
No D 
No D 
No D 
No D 
No D 
No D 
(fYes state average weekly consumption Units/week 
(1 beer = 1.5 units, 1 glass wine = l.5 units, 1 whiskey = l.5 units) 
Please take samples in accordance with the study schedule: 
t. INR - 2m Is - Citrate tube 
2. Urea, electrol)1eS, creatinine & LFT's - 2mls - Lithium Heparin tube 
3. Serology - 4mls - Plain tube 
4. Viral load - EDT A - 4mls - EDTA tube 
5.3 x sputum smear 
6. 3 x U culture 
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Appendix C 
Week 4 evaluation 
ADVERSE EVENTS SHEET 
Please complete if an adverse event has been noted at any time. 
Describe ennt. ego date Was date of drugs restarted 
bepatitis/nausea/bleeding of treatment interuption stopped (Ibit stllrt 
etc onset interupted? (list 1I11 dlltefor 
drugs each 
stopped) individUlll 
druJ!) 
DRUGS TAKEN BY PATIENT OTHER THAN STANDARD DOTS THERAPY 
Please document any drugs taken by the plItient other tltlln standllrd DOTS therapy. 
DRUG REASON DOSE/24HRS ROUTE START STOP 
DATE DATE 
,...-
r--
r--
r-
....... 
-
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Appendix C 
Week 8 evaluation 
Has the patient been diagnosed with hepatitis in the last 4 weeks? 
Yes 0 No D 
Does the patient have any symptoms suggestive of hepatitis? 
Eg Nausea Yes 0 No 0 
Vomiting Yes 0 No 0 
Abdominal pain Yes 0 No 0 
Anorexia Yes 0 No D 
Jaundice Yes 0 No 0 
Does the patient have any signs ofhepatitis? 
Jaundice Yes 0 No 0 
Palmar erythema Yes 0 No 0 
Spider Naevi Yes 0 No 0 
Bruising Yes 0 No 0 
Hepatomegaly Yes D· No 0 
Ascites Yes D No 0 
Peripheral Oedema Yes 0 No 0 
If the patient has hepatitis has there been any confusion or loss of consciousness? 
Yes J No 0 
List all medication taken in the last 4 weeks (excluding TB medication) on next page. 
Has the patient drunk alcohol in the past 4 weeks? Yes 0 No 0 
If Yes state average weekly consumption Units/week 
(1 beer = 1.5 units, 1 glass wine = 1.5 units, 1 whiskey = 1.5 units) 
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Appendix C 
Week 8 evaluation 
Please take samples in accordance with the study schedule: 
1. INR - 2mls - Citrate tube (green) 
2. Urea, electrolytes, creatinine & LFT's - 2mls - Lithium Heparin tube (black) 
3. Serology - 4mls - Plain tube (red) 
4. Virol load - EDTA - 4mls - EDT A tube (blue) 
5.3 x sputum smear 
6. U culture 
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Appendix C 
Week 8 evaluation 
ADVERSE EVENTS SHEET 
Please complete if an adverse event is noted at any time. 
Describe event. ego date Was date of drugs restarted 
hepatitis/nausealbleeding of treatment interuption stopped (Ii.\'t start 
etc onset interupted? (/ist aI/ date/or 
llrug.~ each 
stopped) i mli., it! 11(11 
tlruJ!) 
DRUGS TAKEN BY PATIENT OTHER THAN STANDARD DOTS THERAPY 
Please document any drugs taken by the patient other tlra" standard DOTS tlterapy. 
DRUG REASON DOSE/24HRS ROUTE START STOP 
DATE DATE 
t-
r-
t-
,... 
t-
...-
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Appendix C 
Week 12 evaluation 
Hepatitis evaluation 
Has the patient been diagnosed with hepatitis in the last 4 weeks? 
Yes 0 No D 
Does the patient have any symptoms suggestive of hepatitis? 
Eg Nausea Yes 0 
Vomiting Yes 0 
Abdominal pain Yes 0 
Anorexia Yes 0 
Jaundice Yes 0 
Does the patient have any signs of hepatitis? 
Jaundice Yes 0 
Palmar erythema Yes 0 
No D 
No D 
No 0 
No 0 
No 0 
No 0 
No 0 
Spider Naevi Yes 0 No 0 
Bruising Yes 0 No 0 
Hepatomegaly Yes 0 No 0 
Ascites Yes 0 No 0 
Peripheral Oedema Yes 0 No 0 
If the patient has hepatitis has there been any confusion or loss of consciousness? 
Yes 0 No 0 
List all medication taken in the last 4 weeks on next page. 
Has the patient drunk alcohol in the past 4 weeks? 
Yes 0 No 0 
]fYes state average weekly consumption Units/week 
(1 beer = 1.5 units, 1 glass wine = 1.5 units, 1 whiskey = 1.5 units) 
Please take samples in accordance with the study schedule: 
1. INR - 2mls - Citrate tube (green) 
2. Urea, electrol)1eS, creatinine & LFT's - 2mls - Lithium Heparin tube (black) 
3. Serology - 4mls - Plain tube (red) 
4. Viral load - EOTA -4mls-EOTA tube (blue) 
5.3 x sputum smear (if indicated) 
6. 3 x U culture (if indicated) 
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ADVERSE EVENTS SHEET 
Please complete if an adverse event is noted at any time. 
Describe event. ego date Was date of drugs restarted 
hepatitis/nausealbleeding of treatment interuption stopped (list st(lrt 
etc onset interupted? (/ist (1/1 dllte/or 
drugs e(lch 
stopped) intiil'itlu(li 
drll/:) 
DRUGS TAKEN BY PATIENT OTHER THAN STANDARD DOTS THERAPY 
Please document any drugs taken by the patient other titan standard DOTS theTllpy. 
DRUG REASON DOSE/24HRS ROUTE START STOP 
DATE DATE 
l-
I-
t-
t-
t-
-
-
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20 week evaluation 
Symptom Evaluation 
Weight (kg) 
Cough Yes 0 No 0 
Haemopt),sis Yes 0 No 0 
Fever Yes 0 No D 
Nightsweats Yes 0 No 0 
Weightloss (> 10% bodyweight) Yes 0 No D 
Chest pain Yes 0 No D 
Malaise Yes 0 No 0 
Please take samples in accordance with the study schedule: 
1. 3x sputum smear. 
2. 3 x U culture 
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8 month evaluation 
Symptom Evaluation 
Weight (kg) 
Cough Yes D No D 
Haemoptysis Yes D No D 
Fever Yes D No D 
Nightsweats Yes D No D 
Weightloss (>10% bodyweight) Yes D No 0 
Chest pain Yes D No 0 
Malaise Yes D No D 
If the answer is yes to any of the questions above, please take X-ay and 3x sputum 
for smear and culture 
X-ray result No abnormalities 0 Consistent with TB D Indetenninate r-J 
Has their been any Yes D 
eyidence of hepatitis NoD throughout the course of 
treatment? 
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8 month evaluation 
8 MONTH OUTCOME ON COMPLETION OF TREATMENT 
(by WHO definitions) 
Please tick one at 8 month completion of treatment 
Outcome Definition 
Cured A patient who was initially 
smear positive and who was 
smear negative in the last 
month of treatment and on 
at least one previous 
occasion 
Completed treatment A patient who completed 
treatment but did not meet 
the criteria for cure or 
failure. 
Died A patient who died from 
any cause during treatment 
Failed A patient who was initially 
smear positive and who 
remained smear positive at 
month 5 or later during 
treatment. 
Defaulted A patient who transferred to 
another reporting unit and 
for whom the treatment 
outcome is not known. 
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8 month evaluation 
ADVERSE EVENTS SHEET 
Please complete if an adverse event is noted at any time. 
Describe event. ego date Was date of drugs restarted 
hepatitis!nausealbleeding of treatment interuption stopped (!i.,'t start 
etc onset interupted? (list all dllle/or 
drugs eaclt 
slopped) individual 
druf.l) 
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12 month evaluation 
Symptom Evaluation 
Weight (kg) 
Cough Yes 0 No 0 
Haemoptysis Yes 0 No 0 
Fever Yes 0 No 0 
Nightsweats Yes 0 No 0 
Weightloss (> I 0% bod)''Weight) Yes 0 No 0 
Chest pain Yes 0 No 0 
Malaise Yes 0 No 0 
If the answer is yes to any of the questions above, please take X-ay and 3x sputum 
for smear and culture 
X-ray result No abnonnalities 0 Consistent with TB 0 Indeterminate 0 
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18 month evaluation 
Symptom Evaluation 
Weight (kg) 
Cough Yes D No 0 
Haemopt),sis Yes D No D 
Fever Yes 0 No D 
Nightsweats Yes 0 No D 
Weightloss (>10% bodyweight) Yes D No D 
Chest pain Yes D No D 
Malaise Yes D No 0 
If the answer is yes to any of the questions above, please take X-ay and 3x sputum 
for smear and culture 
X-ray result No abnormalities D Consistent with TB 0 Indeterminate [1 
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24 month evaluation 
Symptom Evaluation 
Weight (kg) 
Cough Yes 0 No 0 
Haemoptysis Yes 0 No 0 
Fever Yes 0 No 0 
Nightsweats Yes 0 No 0 
Weight loss (> 1 0% bodyweight) Yes 0 No 0 
Chest pain Yes 0 No 0 
Malaise Yes 0 No 0 
Iftbe answer is yes to any of the questions above, please take X-ay and 3x sputum 
for smear and culture 
X-ray result No abnormalities 0 Consistent with TB 0 Indeterminate 0 
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Patient name ___ _ 
DTU centre ____ _ DTU telephone _____ _ 
DOTS ADMINISTRATION RECORD 
Please tick each day drugs are taken. Record any missing or incomplete doses Oil page 
x. 
Afonth J + 2 to be completed by DTU staff. Month 3-8 to be completed by patient. 
Month 1. Start date of treatment __ , __ , __ 
Dav 1 2 3 4 5 6 7 
"'eek 
1 
2 
3 
4 
Month 2 Start date __ ,__ , __ _ 
Dav 1 2 3 4 5 6 7 
Week 
1 
2 
3 
4 
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Patient name ___ _ 
DTU centre. ____ _ DTU telephone _____ _ 
Please cross each day that you take your TB medicine. If you forget to take your 
medicine please do not tick the box so that the record is accurate. Please give this 
back to the nurse each time you return for your check-up. 
Month 3 Start date __ ,__ , __ 
Day 1 2 3 4 5 6 7 
Week 
1 
2 
3 
4 
Please go to the D TV at the end of 3 months for your check-up 
Month 4. Start date __ , __ , __ 
Dav 1 2 3 4 5 6 7 
Week 
1 
2 
3 
4 
Month 5. Start date _,_, __ 
Dav 1 2 3 4 5 6 7 
Week 
1 
2 
3 
4 
Please go to the DTV at the end of 5 months for your check-up 
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Patient name ___ _ 
DTU centre, ____ _ DTU telephone _____ _ 
Month 6. Start date __ , __ , __ 
Dav 1 2 3 4 5 6 7 
Week 
1 
2 
3 
" 
Month 7. Start date __ '__ '--
Dav 1 2 3 4 5 6 7 
Week 
1 
2 
3 
" 
Month 8. Start Date __ , __ , __ 
Dav 1 2 3 4 5 6 7 
Week 
1 
2 
3 
" 
Please go to tile D TU at the end of 8 months for your check-up 
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IN"'ESTIGA TION RESULT SHEET 
TB microbiology 
sputum smear timepoint sample date result 
0 
4 weeks 
8 weeks 
20 weeks 
8 months 
12 months 
18 months 
24 months 
LJ culture 0 
4 weeks 
8 weeks 
20 weeks 
8 months 
12 months 
18 months 
24 months 
Biochemistry 
investigation date result units 
Na mmollL 
K mmollL 
Vrea mmollL 
Creatinine J'mollL 
ALT I.U.IL 
AST I.U.IL 
protein 21L 
bilirubin J'mol/L 
INR (if done) 
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Serology 
HBsAg 
HBcAb 
HCVAb 
Positive 
Positive 
Positive 
0 
0 
0 
NegativeD 
NegativeD 
NegativeD 
Hepatits B viral load (if positive) _____ copies/ml 
Hepatitis C Viral load (if positive) _____ copies/ml 
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